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Ziel dieser Arbeit ist die Entwicklung neuer chemischer Sonden zur Überwachung der Aktivität 
von ASM sowohl in vitro als auch in vivo. Darüber hinaus wurde auch die Optimierung der 
angegebenen Sonden (besser: bereits publizierter Sonden) durchgeführt. Im ersten Teil dieser 
Studie wurden zwei Eu-Komplexe ausgehend von handelsüblicher Chelidaminsäure 
synthetisiert und führten zu einer guten Ausbeute mit hoher Reinheit. Die synthetisierten 
Sonden 4-D+ und 5-D+ wurden zum Nachweis verschiedener Phosphate und Carboxylatspezies 
verwendet. Sie wurden zur Überwachung der ASM-Aktivität durch den Nachweis des 
enzymatisch freigesetzten Phosphorylcholins (PC) eingesetzt. Trotz der vielversprechenden 
Abnahme der Lumineszenz von 4-D+ als Reaktion auf das anorganische PC zusätzlich zur 
Simulationsreaktion zur Änderung des SM / PC-Verhältnisses wurde in allen enzymatischen 
homogenen und heterogenen Experimenten ein allgemeiner Löscheffekt beobachtet. Der 5-D+ 
Komplex könnte zur Überwachung des ATP-hydrolysierenden Apyrase-Enzyms in Echtzeit 
verwendet werden. 
Im zweiten Teil dieser Studie wurden verschiedene FRET- und monomarkierte ASM-Sonden 
entworfen und synthetisiert. Eine neuartige FRET-Sonde mit einem besseren 2P-anregbaren 
Cumarinderivat zeigte eine etwa 20% Steigerung der Cumarinintensität im Vergleich zum alten 
Cumarinderivat. Eine neue Generation von ASM-Sonden mit einer quaternären 
Ammoniumgruppe, die das natürliche Substrat nachahmt, wurde ebenfalls entworfen und 
synthetisiert. Alle neuen quaternären Sonden wurden als ASM-Substrate nachgewiesen und 
zeigten unterschiedliche kinetische Parameter. Sie zeigten höhere Umsatz-Kcat-Werte im 
Vergleich zur nicht quaternären Sonde. Die meisten neuen Sonden zeigten auch höhere 
Spezifitätskonstanten gegenüber dem ASM-Enzym. 
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Sphingolipids are a family of bioactive signalling molecules. Besides their role in cellular 
structure, sphingolipids act as key regulators of many cellular functions including cell 
proliferation, differentiation, and apoptosis. The acid sphingomyelinase (ASM) catalyses the 
hydrolysis of sphingomyelin (SM) to ceramide, a metabolic hub of sphingolipid metabolism, 
and phosphoryl choline. Due to the lack of biochemical analytical tools, the molecular details 
of acid sphingomyelinase activity are still not fully discovered, and the development of 
pharmacological inhibitors is also hampered. The scope of this work is to develop new 
chemical probes for monitoring the activity of ASM both in vitro and in vivo.  
In the first part of this study, two Eu complexes 4-D+ and 5-D+ (Figure 1) were synthesized 
starting from commercially available chelidamic acid and resulted in a good yield with high 
purity. The two probes were designed to have a positive charge that promotes binding with 
phosphates. The synthesized probes were used for detecting different phosphates and 
carboxylate species. The response of the two probes toward the studied phosphates was 
dramatically different, confirming the effect of structural and geometrical differences on the 
luminescence response.  
The probes were applied for the monitoring of the ASM 
activity through the detection of the enzymatically 
released phosphocholine (PC).  In the optimization 
steps, the 4-D+ revealed a promising luminescence 
decrease in response to the inorganic PC in addition to 
the SM/PC ratio change simulation reaction. A general 
quenching effect was observed in both of the 
homogeneous and heterogeneous enzymatic 
experiments and this was attributed to the ASM acetate 
buffer. Other trials for the monitoring of neutral 
sphingomyelinase 2 (nSMase 2) could not prove the ability of the probes to monitor the 
phosphates (SM & PC) ratio change in the complex enzymatic reaction media despite the 
obvious ability in the simulation reaction containing the phosphates only. However, the 5-D+ 
complex could be used for the monitoring of the ATP  hydrolyzing Apyrase enzyme in a real-
time pattern and could differentiate between the effect of an 8 fold range of different enzyme 
concentrations. 
Figure 1. Structures of the Eu-
Complexes. 
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In the second part of this study, different FRET and mono-labelled ASM probes were designed 
and synthesized (Figure 2). A novel FRET probe ZP-403  with a better 2P-excitable coumarin 
derivative was synthesized to make use of the 2P excitation advantages in monitoring of ASM 
in biological samples. 
 
Figure 2. Structural elucidation of the ASM probes with a secondary amino group which were 
prepared in this study. 
This probe was confirmed as an ASM substrate with a 10-fold coumarin fluorescence intensity 
turnover and could be used for the detection of ASM inhibitors. The quantification of the 2P 
excitability difference using silica beads labelled with the probe showed about 20% 
enhancement of the coumarin intensity compared to that of TP-366. The reported probes TP-
366 and TP-367 were also resynthesize for high throughput screening and ASM monitoring in 
live cells studies.  
A new generation of ASM probes containing a quaternary ammonium group which mimics the 
natural substrate were also designed and synthesized. A phosphorylation strategy which allows 
the insertion of a quaternary ammonium moiety in addition to a terminal alkyne group was 
applied. Two FRET probes ZQP-407 and ZQ2P-410 were synthesized which can be excited 
in the ultraviolet and visible light range respectively. Another fluorescein mono-labelled probe 
ZQ3P-411 was also synthesized (Figure 3). All three probes were proven as ASM substrates 
and revealed varying kinetics parameters. All novel quaternary probes revealed higher turnover 
Kcat values when compared to the ZP-403 probe. All of the novel probes displayed higher 
specificity constants kcat/KM toward the ASM enzyme except the ZQ2P-410 probe. 
 
Figure 3.  Structure elucidation of the ASM probes with a quaternary ammonium group which 
were prepared in this study. 
List of abbreviations 




List of abbreviations 
2PE Two-photon excitation   
ACN Acetonitrile   
ADP Adenosine diphosphate   
alk-SMase Alkaline sphingomyelinase   
AMP Adenosine monophosphate   
aq. Aqueous   
ar Aromatic   
ASM Acid sphingomyelinase   
ATP Adenosine triphosphate   
Boc tert-Butyloxycarbonyl   
Boc2O di- tert-butyloxycarbonyl   
br. s Broad singlet (NMR)   
BSA Bovine serum albumin   
Calc. Calculated   
CDase Ceramidase   
cDNA Complementary DNA   
Cer Ceramide   
CerS Dihydroceramide synthase   
CERT Ceramide transporter   
conc. Concentrated   
d Doublet (NMR)   
DCC N, N′-dicyclohexylcarbodiimide   
DCC 1,3-Dicyclohexylcarbodiimide   
DCM Dichloromethane   
dd Doublet of doublet (NMR)   
dhCer Dihydroceramides   
DIBAL-H Diisobutylaluminum hydride   
DIPEA N-N‟-Diisopropylethylamine   
DMAP 4-Dimethylaminopyridine   
DMAP 4-dimethylaminopyridine   
DMF N,N‐Dimethylformamide   
DMSO Dimethylsulfoxide   
dt Doublet of trip et (NMR)   
EDTA Ethylenediaminetetraacetic acid   
em Emission   
equiv Equivalent   
ER Endoplasmic reticulum   
et al. et alia   
EtOAc Ethylacetate   
EtOH Ethanol   
Ex Excitation   
FACS Fluorescence activated cell sorting   
FRET Förster resonance energy transfer   
GluCer    Glucosylceramide   
H  Hour (s)   
HeLa      Human cervical cancer cell line   
HOBt              1-Hydroxybenzotriazole hydrate   
HOSu        N-Hydroxysuccinimide   
List of abbreviations 




HPLC     High‐performance liquid chromatography   
HRMS        High‐resolution mass spectrometry   
HTS                    High throughput screening   
J               Coupling constant [Hz]   
kcat                     Catalytic constant   
KM                                  Michaelis constant   
KO      (ASM) knockout   
LLCs                   Luminescent lanthanide (III) complexes   
Ln                        Lanthanide (III)   
L-SMase              Lysosomal sphingomyelinase   
m        Meta   
M       Molarity (mol/L)   
m       Multiplet (NMR)   
m/z         Mass/Charge ratio   
Me        Methyl   
MEF                    Mouse Embryonic Fibroblasts   
MeOH      Methanol   
MHz                     Megahertz   
min     Minutes   
ml        Milliliter   
MOM           Methoxymethyl   
MS        Mass spectrometry   
NaOAc       Sodium acetate   
NBD     7-Nitrobenzo-2-oxa-1,3-diazole amine   
NBD-Cl 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole   
NBS                    N-bromo succinimide   
NMR      Nuclear magnetic resonance   
NPD                    Niemann–Pick disease   
NR         9-Diethylamino-5-oxo-5H-benzo[a]-phenoxazin-2-yl-   
n-SMase             Neutral sphingomyelinase   
OE                        Over expression   
PBS      Phosphate buffered saline   
PC       Phosphorylcholin   
PC     Phosphatidylcholine   
Ph       Phenyl-   
ppm        Parts per million (NMR)   
q       Quartet (NMR)   
quant.     quantitative   
RT      Room temperature   
Rf        Retardation factor   
s           Singlet (NMR)   
S1P                      Sphingosine-1-phosphate   
SAPs                   Sphingolipid activator proteins   
SLs                      Sphingolipids   
SM                      Sphingomyelin   
SMases                Sphingomyelinases   
SMPD1               Sphingomyelin phosphodiesterase 1   
SPT                     Serine palmitoyl transferase   
S-SMase              Secreted  sphingomyelinase   
t        Triplet (NMR)   
List of abbreviations 




TBAF                  Tetrabutylammonium fluoride   
TBDPS                tert-Butyldiphenylsilyl   
TBDPS         tert‐Butyldiphenylsily   
TBLAH               Tri-tert-butoxyaluminumLithium hydride   
tBu      tert-Butyl-   
TFA                    Trifluoroacetic acid   
THF                     Tetrahydrofuran   
TLC        Thin layer chromatography   
Tris       Tris(hydroxymethyl)aminomethane   
Tris-HCl      Tris(hydroxymethyl)aminomethane hydrochloride   
UPLC        Ultra‐performance liquid chromatography   
UV     Ultraviolet   
Vmax                    Maximum catalytic velocity   










1   Introduction 
1.1   Sphingolipids 
Sphingolipids SLs were initially discovered in the 1880s by J. L. W. Thudichum while studying 
the lipid composition of the brain and were named after the Greek mythological creature 
‘Sphinx’ because of their enigmatic nature1. Sphingolipids were considered for a long time to 
be essential only as structural components of the cellular membranes2–4. It is shown by 
calculation that sphingolipid is a major part of the surface monolayer, in addition to protein, 
cholesterol, and phosphatidylcholine5. However, intensive research over the last recent decades 
has established that Sphingolipids are both structural and functional lipids. Alongside playing 
structural functions in cellular membranes, some metabolites, including ceramide (Cer), 
sphingosine, and sphingosine-1-phosphate (S1P), have drawn attention as bioactive signaling 
molecules implicated in the regulation of cell growth, differentiation, senescence, and 
apoptosis6–8. Moreover, SLs have been reported to play a crucial role in infectious diseases 9–
11, Major Depression/Psychiatric disorders12,13, various cancers, immune function, 
cardiovascular disorders, and skin integrity14. 
1.1.1   Structure 
Sphingolipids are various classes of lipids with a varying degree of hydrophobic and 
hydrophilic properties. They contain a sphingoid base, N-linked to a fatty acid, and, in some of 
them, O-linked to a charged group. The Sphingoid base is the hydrophobic backbone of 
sphingolipids and consists of a long chain aminodiol which encompasses a wide array of 2-
amino-1,3-dihydroxyalkanes or -enes with (2S,3R)-erythro stereochemistry15,16. Sphingoid 
bases vary in alkyl chain length, the position and number of double bonds and hydroxyl groups, 
and other features17. 
Sphingosine, sphinganine, and phytosphingosine are the most frequent basic sphingolipids in 
mammalian tissues and found also in yeast and plants. These species can be either with a free 
amino group or with N-acylated variable fatty acids generating a diverse ceramide species. The 
headgroups range in complexity from a simple H in ceramide to highly complex 
glycoconjugates18 (Figure 4). 
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Figure 4.  Structural diversity of SLs Compared to the structurally basic Sphingosine. R = 
different acyl chains19. 
1.1.2   Sphingolipids metabolism 
Sphingolipid metabolism occurs mainly in eukaryotes but is also found in the Sphingomonas 
bacterial genus. The metabolic entry point of sphingolipid metabolism which forms the first 
sphingolipid in the de novo pathway is serine palmitoyltransferase SPT. S1P lyase is the unique 
exit point which breaks down S1P into non-sphingolipid molecules. In between, The SLs 
metabolic pathway displays a complex network of reactions resulting in the formation of a 
variety of SLs, with Ceramide as the central molecule of SLs biosynthesis, catabolism, and as 
precursors of complex SLs 6,7,20. Ceramide biosynthesis is complex and involves at least three 
pathways; de novo biosynthesis pathway, Sphingomyelin (SM) cycle, and salvage pathway 
(Figure 5).  
1.1.2.1   De novo biosynthesis  
The de novo pathway starts in the endoplasmic reticulum (ER) with the condensation of L- 
serine and palmitoyl-CoA catalyzed by SPT to generate 3-ketodihydrosphingosine and this step 
is considered to be the rate-limiting step for this pathway. 3-Keto-dihydrosphingosine is 
subsequently reduced to form dihydrosphingosine (sphinganine), which is then N-acylated 
with various fatty acids of different chain lengths and/or differing degrees of saturation to 
produce dihydroceramides (dhCer). The latter reaction is catalyzed by one of six different 
dihydroceramide synthase (CerS1-6), each with specific fatty acyl-CoA chain length 
preference. Most dhCer are then desaturated by dhCer desaturase, generating a 4,5-trans-
double bond to form Ceramides.6,21 Ceramide is then transported to the Golgi apparatus by 
vesicular or protein-facilitated transport (ceramide transporter (CERT) ) for the subsequent 
formation of complex sphingolipids.  
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Figure 5. Bioactive Sphingolipid metabolic pathways. CDase, ceramidase; CK, ceramide 
kinase; DAG, diacylglycerol; GCase, glucosyl ceramidase; GCS, glucosylceramide synthase; 
PC, phosphatidylcholine; SK, sphingosine kinase; SMase, sphingomyelinase; SMS, 
sphingomyelin synthase; SPPase, sphingosine phosphate phosphatase; SPT, serine palmitoyl 
transferase.7 
1.1.2.2   Sphingomyelin cycle 
The sphingomyelin cycle is the second major metabolic pathway for ceramide generation. This 
pathway, which occurs mainly in the plasma membrane and mitochondria, involves the 
hydrolysis of phosphodiester bonds in sphingomyelin by alkaline, acid or neutral 
sphingomyelinases (SMases) to provide ceramide and phosphorylcholine.22,23 
1.1.2.3   Salvage pathway 
Furthermore, ceramide can also be generated from the lysosomal degradation of complex 
sphingolipids, mainly sphingomyelin and glycosphingolipids which are broken down 
eventually to sphingosine. Sphingosine can leave the lysosome and re-enter pathways for 
synthesis of ceramide through re-acylation reactions. This latter pathway is called recycle or 
salvage pathway and involve several key enzymes like SMases and glycosphingolipids 
hydrolases.19,22,24 
1.1.3   Compartmentalization of metabolites and enzymes of the SLs pathways 
The enzymatic reactions of SLs metabolism are distributed throughout different cellular 
compartments as presented in Figure 6. De novo Cer synthesis occurs on the cytosolic surface 
of the ER and possibly in ER-associated membranes, such as the perinuclear membrane and 
mitochondria-associated membranes.6  
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The synthesis of more complex SL metabolites like SM and Glucosylceramide (GlcCer) occurs 
in the Golgi apparatus and therefore Cer is transported from the endoplasmic reticulum to the 
Golgi apparatus through two known pathways. First, by the CERT where SM is formed from 
the transported Cer. Second, the vesicular transport of Cer on which the synthesis of GlcCer is 
based. Subsequently, the transport protein FAPP2 delivers GlcCer as a precursor for 
glycosphingolipid (GSL) synthesis. In contrast to luminally/extracellularly oriented SM and 
complex GSLs, Both Cer and GlcCer are synthesized on the cytosolic face. 25 
The complex SLs, SM, and GSLs are then transported to the plasma membrane via vesicular 
trafficking. There, SM can be metabolized by SMases to Cer, and accordingly other bioactive 
lipids. 
 
Figure 6. Compartmentalization of SL pathway metabolites and enzymes. 3KdhSph, 3-keto-
dihydrosphingosine; dhSph, dihydrosphingosine; MAMs, mitochondria associated 
membranes.6 
SLs recirculation from the plasma membrane may occur through the endosomal pathway. In 
the lysosomal compartment, SM and GSL are metabolized to Cer which is subsequently 
degraded by acid ceramidase CDase to form sphingosine. Due to its positive charge, the 
salvaged sphingosine can leave the lysosome and dissolve adequately in the cytosol to move 









1.2   Sphingomyelinases 
1.2.1   Sphingomyelin 
Sphingomyelin SM is the most abundant complex sphingolipid in mammalian cells and 
represents about 85% of all sphingolipids in humans. It has an essential role in eukaryotic cell 
viability as evidenced by the inability of mammalian or yeast cells to survive in culture when 
they are unable to produce SM.26 SM is preferentially concentrated in the outer leaflet of the 
plasma membrane. Its high packing density and affinity for sterols provide a rigid barrier to the 
extracellular environment and play a role in the formation of lipid rafts which are specialized 
areas in cellular membranes with important functions in signal transduction and membrane 
trafficking. 27 
 
Figure 7. The sphingomyelin cycle demonstrating the essential enzymes and byproducts. 
Structurally, SM consists of a ceramide unit with a phosphorylcholine (PC) moiety attached to 
position 1 of the sphingoid base component. SM obtained from natural sources, such as eggs 
or bovine brains, contains fatty acids of various chain lengths. Palmitic acid (16 C) and stearic 
acid (18 C) are the most abundant fatty acid component of SM 28,29. The SM content in a cell 
is strictly regulated by the enzymes of SM metabolic pathways whose activities create a balance 
between SM synthesis and degradation (Figure 7). SM is an essential modulator of plasma 
membrane properties (due to the structural variability) which influences the membrane 
gathering of proteins involved in cellular proliferation, growth, and apoptosis as well as being 
an important source of ceramide. So its levels are critical for cell function.30 
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1.2.2   Sphingomyelinases subtypes 
Sphingomyelinases SMases (Sphingomyelin phosphodiesterases) catalyze the reaction of SM 
hydrolysis. They hydrolyze the phosphodiester bond of SM to generate Cer and PC. Three 
types of SMases can be distinguished based on optimal pH values required for their activation: 
acid (ASM), alkaline (alk-SMase), and neutral (n-SMase) as presented in Table 130–32. They 
differ not only in their optimum pH but also their dependence on the presence of divalent 
cations and subcellular localization.33  
1.2.3   Acid Sphingomyelinase 
Acid sphingomyelinase (ASM) is a sphingomyelin hydrolyzing enzyme that works optimally 
at acidic pH 34. After reporting that the deficiency of ASM was responsible for the rare, 
recessively inherited lysosomal storage disorder, Niemann–Pick disease (NPD), intensive 
efforts to purify and characterize it were stimulated35–38. Because the acidic pH optimum of the 
enzyme in vitro (4.5 and 5.0), as well as the fact that the majority of storage material in NPD 
patients was found in lysosomes and/or late endosomes, the enzyme was classified as a 
lysosomal protein39. In the late 1980s and early 1990s, complementary DNA (cDNA) and gene 
encoding of ASM (designated Sphingomyelin phosphodiesterase 1 ‘’SMPD1’’) were 
cloned40,41. Later, a zinc-dependent, secreted form of ASM that also was encoded by the 
SMPD1 gene was identified42,43. The biological function of the secreted form remained 
unknown but There is now growing evidence suggesting that this ASM form may play a role 








Table 1. Different Sphingomyelinases and their characters.  I/R, ischemia/reperfusion 32,56
Group Acid sphingomyelinases Neutral sphingomyelinases 
Alkaline 
sphingomyelinase 


































Extracellular in intestines 
and liver 
Biochemical properties pH 5 optimum 
Zn2+, pH 5 
optimum 
Mg2+, pH 7.4 optimum pH 8.5 optimum 
Biological effects 
- Post-IR cell death, contractile dysfunction 
- Vascular tone constriction 
- Oxidized phospholipids -induced      
   apoptosis 
- 
- Growth 
- TNF-, ROS-,    
   oxLDL 
- Induced  
  proliferation 
- TNF-, IL-1,   
   hypoxia/    
   reoxygenation 
- Induced   
  apoptosis 
- Dietary SM digestion and  
  ceramide formation46  
Pathophysiology 
- Niemann-Pick   
  disease47 
- Atherosclerosis 
- Niemann-Pick   
  disease47 
- Atherosclerosis 





- Heart failure 
- Colon carcinogenesis49 
Biological/pharmacological 
inhibitors 
Glutathione,  D609, Desipramine50, NB6, L-
Carnitine, ARC-39 
Glutathione51, 










The following studies revealed that the L-SMase seems well suited to operate at the low pH of 
the endo-lysosomal compartment while S-SMase is proposed to participate in SM hydrolysis 
at the neutral pH of the extracellular milieu or in association with lipoproteins in serum.57  This 
is because an increase of the pH only alters the substrate affinity i.e. the Km value of the enzyme 
while the activity (Vmax) of the ASM is not affected. The substrate affinity, however, is 
regulated by the presence of extracellular factors such as LDL or by membrane co-factors that 
might compensate for the reduction of substrate affinity restoring ASM activity even at neutral 
pH values.58  
Furthermore,  both S-SMase and L-SMase were demonstrated to be zinc metalloenzymes. The 
apparent differences in zinc-dependence of the lysosomal and secreted ASM forms were due 
to differential cellular trafficking that either exposed or sequestered the enzyme from cellular 
pools of zinc44,57. The Zn2+-independency of L-SMase can be explained by the fact that this 
form of the enzyme, as isolated from cell homogenates, is already saturated with Zn2+ and thus 
requires no exogenous Zn2+ for enzymatic activity59. Furthermore, as is often the case with 
zinc-metalloenzymes, Zn2+-bound L-SMase cannot be readily stripped of its metal by short-
term EDTA treatment 45. 
1.2.4   Niemann–Pick disease 
By the late 1960s, it was reported that the deficiency of ASM is the cause of the recessively 
inherited rare lysosomal storage disorder, Niemann–Pick disease (Types A and B NPD). Both 
forms of NPD are caused by recessive mutations in the ASM encoding gene SMPD160–64. Type 
A NPD is an infantile form of ASM deficiency, characterized by a rapidly progressive 
neurodegenerative course that leads to death by age 2–3. In contrast, Type B NPD is the later-
onset form in which patients show limited or no neurological symptoms but may exhibit severe 
and progressive visceral organ deformities, including hepatosplenomegaly, pulmonary 
insufficiency, and cardiovascular disease. Types A and B NPD are differently clinically 
presented most likely due to small differences in the amount of residual ASM activity 60. The 
clinical findings in NPD are most likely related to lipid storage in lysosomes and/or endosomes. 
The recent data which reveal the important role of ASM in membrane formation and function 
propose that the functional shortage of the enzyme at the cell surface also could contribute to 








Unlike NPD types A and B, which result from mutations in SMPD1, Niemann–Pick disease 
type C results from mutations in NPC1 and NPC2. It is also a lipid storage disease that can 
present in infants, children, or adults 65–67. NPC1 and NPC2 encode in cholesterol trafficking 
involved proteins in the endo-lysosomal compartment, and mutation of either of these proteins 
results in massive accumulation of unesterified cholesterol in perinuclear lysosomes68. 
Fibroblasts from NPD-C patients exhibit marked inhibition of aSMase activity in cellular 
extracts despite the absence of genetic aberrations in SMPD169,70. This Loss of aSMase activity 
occurs via post-translational mechanisms and is a direct result of the accumulation of 
cholesterol in the endo-lysosomal compartment. Whether the functional loss of ASM activity 
is a result of altered trafficking (e.g. cholesterol influences trafficking of ASM precursor), or 
via direct action on the enzyme is unclear 44. 
1.2.5   Structure and catalytic mechanism of the acid sphingomyelinase 
ASM is synthesized and differentially modified post-translationally in the endoplasmic 
reticulum and Golgi to yield distinct lysosomal and secreted forms71. ASM has an NH2-
terminal ER signal sequence that is sufficient for the co-translational introduction of the nascent 
precursor polypeptide into the endoplasmic reticulum (Figure 8A). Mutated human ASM 
lacking a signal peptide results in the production of a non-glycosylated, cytosolic protein that 
lacks enzyme activity in cellular extracts, and is not secreted72. Next to the signal peptide,  The 
primary structure of the N-terminal of ASM contains a saposin-like (SAP) domain extending 
from amino acid 89–16573. SAPs (sphingolipid activator proteins) are non-enzymatic 
glycoproteins predominantly found in the acidic compartment and function to facilitate 
degradation of various sphingolipids via mobilizing lipids from membranes, thus exposing 
substrates to the active site of the respective enzyme44,74.  
The SAP domain is separated from the catalytic domain and thus has been postulated within 
ASM functions to be as an intramolecular activating region for SM hydrolysis44. The linker 
connecting ASMcat to ASMsap is proline-rich and mostly rigid, wrapping itself around the 
catalytic domain as an L-shaped strap71. The presence of the SAP domain and proline-rich 
linker distinguishes ASM from all the other structurally known proteins75. 
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Figure 8. Structure of acid sphingomyelinase. A) Primary structure of ASM polypeptide. B) 
Stylized conformation of mature ASM. Domain structure, N-glycosylation sites, and disulfide 
bridges are shown. Signal peptide (amino acids 1–46), SAP domain (89–165), Pro-rich domain 
(166–198), metallophosphoesterase/catalytic domain (199–461), C-terminal domain (462–
629). N-glycosylation sites (Asn86, Asn175, Asn335, Asn395, Asn503, Asn520). Disulfide 
bridges (Cys89–Cys165, Cys92–Cys157, Cys120–Cys131, Cys221–Cys226, Cys227–Cys250, 
Cys385–Cys431, Cys584–Cys588, Cys594–Cys607). 44 
The catalytic domain adopts a metallophosphatase fold and belongs to the calcineurin-like 
phosphoesterases structural family and resembles recent structures of the ASM-like 
protein71,75,76. The ASM metallophosphatase domain is featured with the long β stranded loops 
which extends toward the zinc ions. Beside mediating zinc and substrate binding, these loops 
form the interfaces to the proline-rich linker, saposin, and C-terminal domains75. 
The active site in ASM defines a stringently specific for zinc and the sphingomyelin phosphate 
group. The two zinc ions are coordinated by Asp206, His208, Asp278, Asn318, His425, 
His457, His459, and the catalytic water molecule. During the substrate recognition, it is 
speculated that - as with other phosphoesterases from the calcineurin-like superfamily- the 
dimetal zinc center coordinates the two unesterified oxygen atoms of the substrate 
phosphodiester as well as the nucleophilic water (Figure 9). Following that, the hydroxide 
initiates a nucleophilic attack on the phosphorus of sphingomyelin. The arrangement of the 
active site allows the phosphate oxygen on the ceramide side to extract a proton from either 
His319 of His282. The His282 imidazole ring is stabilized by π–π stacking interaction with 
Tyr488 and polar interaction to the Asp251 carboxylate group, while the His319 is involved in 
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water-mediated hydrogen bonding. As a result, H319 is a more energy favored hydrogen donor 
in the reaction.  
It is proposed that the imidazole ring on H319 is the source of the proton to the oxyanion of 
the ceramide leaving group. The solvent accessibility allows quick exchange of protons on both 
H319 and the nucleophile water in the regeneration step. Consistent with this hypothesis, 
mutation of H319 to tyrosine causes severe ASMD75–77. 
 
Figure 9. Proposed catalytic mechanism for the hydrolysis of phosphodiesters by ASM78. 
The last domain is the C-terminal domain which contributes to the stabilization of the active 
site conformation75. The relevance of C-terminal modification in the context of the maturation 
of S-ASM and L-ASM is still not fully discovered. However, given that C-terminal processing 
for other lysosomal enzymes like acid β-glucosidase and cathepsin D has been reported, C-
terminal modification of Cys629 may serve as a cellular mechanism of ASM 
maturation/activation44,79. 
The presence of eight intramolecular disulfide bonds is a characteristic structural feature of 
ASM (Figure 8). Most of the disulfides in ASM are solvent accessible and therefore the 
exposure of these residues may make ASM sensitive to redox conditions51,80. Only sixteen of 
ASM's seventeen cysteine residues are involved in disulfide bond formation. Deletion or 
oxidation of the unbridged, carboxyterminal Cys629 resulted in a 4–5-fold increase in ASM 
activity44. 
There are six predicted N-glycosylation sites in the ASM polypeptide chain (Figure 8), of 
which five are utilized (Asn86, Asn175, Asn335, Asn395, and Asn520 — not Asn503)44. 
Elimination of the four N-terminal glycosylation sites doesn’t affect lysosomal targeting, 
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processing, or enzymatic activity. However, removal of the two C-terminal N-glycosylation 
sites hinders the maturation of the enzyme.  
Rapid cleavage of the primary translation polypeptide to an enzymatically inactive protein was 
observed in case of the absence of the fifth glycosylation site, whereas deletion of glycosylation 
site six led to the formation of an inactive ASM precursor81. In addition to mediating proper 
folding and trafficking, the glycosylation of ASM is believed to has a protective role to prevent 
destruction in the harsh environment of the lysosome. Glycosylation may also be important for 
maintaining the mature enzyme in an active conformation, as in vitro glycosidase treatment 
results in loss of activity82,83.  
1.2.6   Sphingomyelinase assays 
Considering the broad variety of different cellular events where sphingomyelinases are 
involved, they have emerged as a new drug target for the treatment of atherosclerosis, 
ischemia/reperfusion injury, lung inflammation, diabetes, and obesity, as well as rare and 
neglected diseases such as pathogen infection (Neisseria gonorrhoeae)  and Niemann Pick 
Disease types A and B. One of the prerequisites for a detailed study of the enzyme and the 
search for pharmacological inhibitors is a sensitive and selective determination of the ASM 
activity in biological samples (tissue homogenate, serum, urine, etc.). Thus, the need for a 
valuable, reliable, and rapid method for determination of sphingomyelinase (SMase)-activity 
is highly imperative.56,84,85 Over the years, a significant amount of effort has been dedicated to 
develop an ASM activity assay for the screening and diagnosis of NPD A and B and other 
Smase related biological events86. Several SMase screening assays have been reported 
including fluorogenic, colorimetric, and radioactive assays87–91.  
1.2.6.1   Radioactive Sphingomyelinase  assay 
Historically, radioactive assay of SMases is considered as one of the earliest established 
characterization methods92. The principle of this method is to use a radiolabeled 
sphingomyelin, with a 14C-label on the phosphocholine93, as a substrate for the enzyme. After 
incubation of the substrate with the enzyme, the labeled phosphocholine can be separated from 
the remaining, unhydrolyzed sphingomyelin by extraction with a mixture of chloroform and 
methanol. The intact sphingomyelin and ceramide are captured in the organic phase, whereas 
the labeled product, phosphocholine is very polar and therefore soluble in water, partitions to 
the upper aqueous phase. Radioactivity in an aliquot of the upper phase can be counted in a 
liquid scintillation counter as a relative measure of sphingomyelin hydrolysis88,94. 
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Alternative methods to the chloroform/methanol extraction process were explored to eliminate 
the dangers associated with chloroform and methanol on both the operators and the equipment. 
As phenyl-sepharose beads could capture the hydrophobic, lipophilic components of the ASM 
reaction they were thus used for their ability to separate unreacted hydrophobic sphingomyelin 
substrate from the radiolabeled phosphorylcholine product. The advantages of this bead-based 
extraction method were its lower cost, as well as its ability to screen for inhibitors of ASM 
without exposure to organic solvents87. Related to the radiolabeling based analysis, 
radiolabeled dihydrosphingomyelin95, [3H]ceramide-labeled sphingomyelin96 and 
sphingomyelin (choline-methyl- 3H)87 were also used for sphingomyelinases monitoring. In 
addition to the price and the high equipment/safety demands97, this assay also includes an 
aqueous/organic separation step. So, it is heterogeneous which excludes the possibility of real-
time tracking of the reaction. Despite that, the unequaled advantage of radiolabeling is the use 
of a substrate that behaves biologically exactly like its natural substrate. 
1.2.6.2   Chromogenic Sphingomyelinase  assay 
Due to the forenamed drawbacks of the radiochemical assay, an early need for alternative 
methods has emerged. The moderate outlay in equipment and the simple implementation 
predestine spectroscopic techniques for assay development98. This is particularly true for 
screening applications, i.e. the routine testing of large substance libraries for biologically active 
molecules (inhibitors etc.)99,100. The growing interest of ASM as a diagnostically relevant 
analyte, therefore, encouraged the development of synthetic, chromogenic or fluorogenic 
alternative substrates that indicate the activity of the enzyme through the formation of colored 
or fluorescent compounds86. 
 








Early methods applied artificial chromogenic substrates, such as 2-hexadecanoylamino-4-
nitrophenylphosphorylcholine (HDA-PC). It is dissimilar to sphingomyelin only by having an 
aromatic ring instead of a long aliphatic chain and a nitro group replacing the primary hydroxyl 
one carbon removed102,103. When HDA-PC is incubated with pure ASM or various tissue 
preparations, phosphorylcholine is enzymatically cleaved from the molecule. Sufficient 
sodium hydroxide solution is then added to produce a yellow color with 2-N-acylamido-4-
nitrophenol, the other product of the reaction as in Scheme 1. Quantitation of the 
sphingomyelinase activity in the various preparations can be derived through the determination 
of the color intensity. A potential pitfall of using HDA-PC for the laboratory diagnosis of 
patients with sphingomyelinase deficiency is a false negative result, e.g. normal enzyme 
activity with the laboratory test in patients where this enzyme is deficient under physiological 
conditions in vivo. However, it is generally agreed that the technical advantages of these assays 
outweigh the risk of missing a diagnosis owing to false-normal enzyme activity104,105.  
1.2.6.3   Fluorogenic Sphingomyelinase  assay 
As the fluorescence is much more sensitive in addition to the fact that the absorption of the 
sample matrix is usually considerable, a new fluorogenic assay was developed for accurate 
determination of the ASM activity105. In this assay the non-fluorescent 6-Hexadecanoylamino-
4-methylumbelliferylphosphorylcholine (HMU-PC) is used as a  specific substrate for ASM. 
Upon cleavage of HMU-PC with ASM as in Scheme 2, the fluorescent 6-hexadecanoyl-4-
methylumbelliferone (HMU) is released and quantified as a measure of the ASM activity85. 
 
Scheme 2. Cleavage of 6-Hexadecanoylamino-4-methylumbelliferylphosphoryl choline 
(HMU-PC) by ASM. 
The commercial frequently used amplex red® assay is a coupled enzyme assay including a four-
step enzymatic procedure. First, sphingomyelinase is used to hydrolyze the sphingomyelin 
present in test samples to ceramide and phosphorylcholine. After the action of alkaline 
phosphatase, which hydrolyzes phosphorylcholine to choline, choline is oxidized by choline 
oxidase to betaine and H2O2.  
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Finally, H2O2, in the presence of horseradish peroxidase, reacts with dihydroxyphenoxazine 
(Amplex® Red; AR) to generate the highly fluorescent product resorufin52,106,107 as 
demonstrated in Scheme 3. If ASM is to be assayed, pH adjustment is required after initial 
sphingomyelin breakdown108, which further complicates the assay. Not only does its 
dependence on three consecutive enzymatic conversions predispose this assay to false inhibitor 
hits, but also absorption or emission of light by the compounds to be tested. 
 
Scheme 3. Schematic representation of the Amplex® red based ASM assay. 
Another fluorescence-based approach was suggested by Gaudino et al. to develop a more 
efficient sphingomyelinase assay. They proposed a sphingomyelin derivative that could be 
attached to a solid support via the ceramide moiety and that contained a fluorescent tag in the 
phosphocholine moiety (Figure 10). The ceramide portion of this substrate, when cleaved by 
sphingomyelinase, would be retained on the solid support along with unreacted starting 
material while fluorescently labeled phosphocholine would go into the solution phase. The 
solution phase could then be removed and phosphocholine content measured 
spectrophotometrically. Solid-phase attachment of sphingomyelin was envisioned as occurring 
via a biotin/avidin (or streptavidin) interaction109. A solid conclusion is difficult to be derived 
from this study due to the small number of derivatives examined but it can be said that all the 
three derivatives are ASM substrates to different extents. Compound A with the minimal 
structural deviation from the natural substrate was cleaved by ASM at 77% of the rate observed 
for 14C-sphingomyelin. However, derivatives B and C modified with a biotin anchor also had 
acceptable hydrolysis rates, which are about three to six times lower than those of the natural 
substrate. 
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Figure 10. Sphingomyelin analogues developed by Gaudino et al. and their cleavage rate 
compared to 14C-sphingomyelin109. 
The relative positioning of the ammonium group in Compound A and the ammonium group in 
sphingomyelin to the cleavage site is identical, therefore this cleavage rate study suggests that 
for human placenta acidic sphingomyelinase, the ammonium group of sphingomyelin is 
important but not absolutely essential for substrate recognition. Modifications of the head 
group with a significantly larger space requirement compared to choline were also tolerated. 
Follow-up studies combining both the ammonium group and biotin anchor were not published, 
which is why it must be assumed that the material was inferior to the previous methods.56,109 
Some fatty acid-labeled fluorescent sphingomyelin analogs were also developed and used for 
several SMases110 where both the substrate and the product usually remain in the hydrophobic 
fraction and have to be separated by either thin layer chromatography (TLC) or by other 
chromatographic methods like high performance liquid chromatography (HPLC)111. Different 
mass spectroscopy based methods were also reported for ASM activity quantification. Some 
of them were reported as robust and suitable for laboratory diagnosis of Niemann Pick 
disease112–114. 
The recent X-ray characterization of the enzyme71 provides a reliable structural basis for a 
targeted synthesis of pharmacologically interesting inhibitors of ASM (rational drug design). 
This also increases the demand for a high-throughput, homogeneous assay to be able to 
evaluate these new substances efficiently. Arenz  et al. are working on the development of 
FRET-based ASM probes in an attempt to compensate for the absence of a homogeneous ASM 
assay for more than 50 years of research.  
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1.2.6.4   Sphingomyelinase FRET substrates  
Förster resonance energy transfer (FRET) is the radiation-free transfer of energy from one 
fluorescent dye to another. The main prerequisites for this transfer are the spectral overlap of 
the emission spectra of the donor dye with the excitation spectra of the acceptor dye and the 
spatial proximity of these dyes. Once a FRET pair has been defined, the first dye (FRET donor) 
with the shorter excitation wavelength is exited. If the FRET efficiency is high enough, the 
donor dye will transfer all its emission energy to the FRET acceptor, which is then excited and 
emits fluorescent light at a wavelength higher than the emission wavelength of the donor dye. 
Therefore, in an ideal FRET pair, the FRET donor is excited, but only the FRET acceptor is 
emitting fluorescent light. In a setup in which the enzyme or process of interest will form a 
FRET pair or destroy an existing FRET setup, the change in fluorescence will affect both dyes 
in way that the emission of one dye is increased, while the fluorescence intensity in the second 
dye is decreasing. Since both effects are contrariwise, they both contribute to the 
responsiveness and thus to the sensitivity of the probe. Furthermore, the ratio of both 
fluorescence intensities is not dependent on the absolute but only of the relative concentrations 
of the intact FRET system on the one side and the free independent dyes on the other side. The 
latter feature also known as “ratio-imaging” is a significant advantage over quenched probes 
or turn-on probes, in which the observed absolute fluorescence intensity is dependent on many 
factors like cellular delivery or export and thus not indicative of the cleavage (or formation) 
ratio (Figure 11). 115 
 
 
Figure 11. Illustration of the concept of ratio imaging. A) Time response of a turn-on probe, 
often allowing only qualitative information B) Increase in product fluorescence with a 
concomitant decrease in substrate florescence indicates the relative cleavage rate of probe 
molecules C) Time response of a typical FRET probe cleavage, providing relative cleavage 








Some impressive examples of FRET pair formation exist in the field of small analyte 
determination like Ca2+, which can be sensed by a tandem fusion protein of calmodulin with 
two different fluorescent proteins116. Small molecule sensors have been described for reactive 
specimen like cellular thiols, as exemplified in Figure 12A 117. A few substrates that exhibit 
fluorescence resonance energy transfer (FRET) have been synthesized and used successfully 
in the past to monitor enzyme activities118. An example includes probe CPF4 for monitoring 
phosphodiesterase activity 119 (Figure 12B). The first FRET probe in the lipid field has been 
described by Wichmann et al., who synthesized a FRET probe for phospholipase A2 (PLA2)120. 
The molecule mimicking phosphatidylcholine contained an NBD dye as FRET donor in the 
acyl portion, while a Nile Red dye was used as a FRET acceptor in the second lipid tail as in 
Figure 12C. This probe showed an impressive 70-fold FRET response upon cleavage and was 
used to monitor PLA2 activity in live cells 118. The specificity of the probe for PLA2 was 
ensured by replacing the SN1 ester bond with an inert ether linkage, making cleavage of the 









Figure 12.  Examples for FRET probes for enzymes monitoring. A) FRET probe for fast Thiol‐
Quantification Assay of Glutathione Reductase. B) FRET probe CPF4 for monitoring 
phosphodiesterase activity. C) FRET probe for phospholipase A2 (PLA2).115 
To further extend the applicability of FRET probes, an acid sphingomyelinase FRET-probe 
was designed by Pinkert et al.121 using the previously described NBD/Nile Red pair122. In 
contrast to ceramide, where both dyes inherently had to be incorporated into both lipid tails, 
the choline head was modified with the relatively polar NBD and the membrane-resident part 
with Nile Red, respectively (Figure 13A). Although the resulting sphingomyelin analogue was 
readily cleaved by recombinant human ASM (rec ASM), only a low ratio change was observed. 
While the acceptor Nile Red fluorescence declined by a factor of 3-fold, a concomitant change 
in donor NBD fluorescence was not observed (Figure 13 B), which was obviously due to the 
quenching of NBD fluorescence in the aqueous environment.  
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To make use of the NBD quenching effect after probe cleavage, a second probe was synthesized 
in which NBD was the FRET acceptor. For this setup, a coumarin dye was selected as a suitable 
FRET donor. Indeed, upon cleavage of this probe, an increase in coumarin fluorescence was 
accompanied by a very effective decline of the NBD fluorescence (Figure 13C) yielding an 
about 80-fold ratio change 121. Before its application in cell-based assays, the probe was 
thoroughly tested. The probe allowed differentiation of different rec ASM concentrations over 
3 orders of magnitude and incubation with different inhibitors of acid sphingomyelinase123,124 
showed a dose-dependent inhibition of the FRET change as presented in Figure 13D. 
A                                                                        B 
 








Figure 13. A) Structures of FRET probes developed by Pinkert et al. B) Fluorescence change 
of NBD/NR FRET probe upon incubation with ASM. C) Fluorescence change of probe 
Coumarin/NBD in presence of ASM. D) NBD fluorescence of the second probe in presence of 
ASM and different inhibitor concentrations.115 
The second FRET probe  was converted into a BSA complex and its cleavage was monitored 
in different cell types. All experiments showed an apparent probe cleavage, for at least 48 h. 
Overexpression of ASM in wildtype Mouse Embryonic Fibroblasts  (MEFs) however 
significantly increased FRET change, showing that different ASM levels can be differentiated 
under live cell conditions. 
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In a recent study, Kappe et al. presented a developed form of the ASM FRET probes to address 
the shortcoming of ultraviolet (UV) excitation range of the former Coumarin/NBD probe. A 
new attempt towards a FRET substrate excitable in the visible range was made. BODIPY dye 
was introduced into the fatty acid part and a relatively polar fluorescein (FAM) residue (Ex. 
485 nm/ Em. 518 nm) into the choline analogue head group to keep the polarity and membrane 
anchoring as close as possible to nature (Figure 14A).125 
 
             
 
 
Figure 14. A) Structure of the visible range FRET probe. B) The Probe (Ex. 485 nm) before 
(black) and after (red) incubation with ASM.125 
Upon incubation of a micellar solution of the novel substrate with rec ASM, the BODIPY 
acceptor fluorescence appeared to be almost unchanged, similarly to results with the Nile red 
containing probes121,122. Surprisingly, the fluorescence of FAM increased significantly by more 
than 100-fold as in Figure 14B. The new substrate enabled also differentiating between 
different concentrations/activities of ASM and allows for the first time to monitor relative 









1.2.6.5   Two-photon excitation microscopy for the study of living cells 
The effective sensitivity of fluorescence microscopy in live cells is limited by out of focus 
background signal, photobleaching and cells are prone to phototoxicity, especially when a short 
 B A 
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wavelength is used. A further limitation is that in many biological specimens, autofluorescence 
is a large problem that excitation/emission filters might not completely get rid of126. This out 
of focus background and autofluorescence signal introduce a diffuse background fluorescence 
without any spatial information encoding, and therefore act to reduce the image contrast127.To 
reduce the limitation of imaging extended samples and enable high-resolution 3-D imaging, 
the confocal microscope was developed with a confocal pinhole used to get rid of the out-of-
focus background and produce a higher signal-to-noise ratio in the final image which 
corresponds to a thin (<1 μm) “optical section” (Figure 15)128. 
 
Figure 15. Different types of microscopy: (a) wide-field microscopy; (b) confocal 
microscopy.129 
Two-photon excitation (2PE) microscopy is an advanced alternative to confocal microscopy 
that provides clear superiority for three-dimensional imaging. The main advantage of 2PE  is 
the high localization of the excitation area (Figure 16) and the full detection of the emitted 
light because the full sensitive area of the detector is used in contrast to confocal microscopy. 
This allows the application of 2PE to thick, intact tissues such as brain slices, embryos, whole 
organs, and live animals (intra-vital imaging).127,130 
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Figure 16. a) Simplified Jablonski scheme for one-photon (exemplified by 380 nm) and two-
photon excitation. Fluorescent emission (cyan) within a biological sample in response to b) 
one-photon, c) two-photon excitation.131 
The first prediction of two-photon absorption was by Göppert-Mayer (1931)132. She proposed 
that one atom or molecule should be capable of absorbing two photons simultaneously within 
10x-16–10x-17 s. The unit of two-photon absorption cross-section (GM) is named in her honor 
(1 GM = 10−50 cm4 s photon−1). Because it is a rare event at ordinary light intensities, it was 
only in the 1960s, after the development of laser sources, that the prediction could be 
verified132. The main difference between one-photon absorption (1PA) and two-photon 
absorption (2PA) is the ability to approach highly energetic excited states using relatively low-
energy photons (Figure 16), and the I 2 dependence of the process which allows for excitation 
of a chromophore with a high degree of spatial selectivity in three dimensions using a tightly 
focused beam133, whereas 1PA depends linearly on the intensity132.  
Molecules with a large two-photon absorption cross-section (σ) are in great demand for a 
variety of applications, including 2P fluorescence microscopy, optical limiting, three-
dimensional optical data storage, and two-photon induced biological caging studies134. 
Exploring molecules that exhibit intense 2PA to open new pathways into its use and broaden 
existing 2PA applications is also a scientific challenge to explore the limits of the 2PA cross-
section (σ) and to understand the structure-property relationships. Toward this goal, many 
research groups have done extensive research over the past decades133–142. The field of 
sphingolipids in general and sphingomyelinases monitoring especially are also in high need of 
developing new probes that can readily obey 2PE for deeper and clearer imaging and thus better 
understanding of the related biological events and pathological disorders. 
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1.3   Application of lanthanide luminescence in probing biological species 
1.3.1   Luminescent lanthanide (III) complexes overview 
Luminescent lanthanide (Ln) (III) complexes (LLCs) are getting increased attention in a wide 
range of bioanalytical applications, particularly those of europium(III) and terbium(III). Those 
lanthanide-based luminescent probes are particularly attractive for their long luminescence 
lifetimes. This long decay times offer a tremendous advantage for the time-gated measurement 
of biological samples wherein interfering short-lived autofluorescence and scattering is 
suppressed, drastically improving signal-to-noise ratio and increasing overall probe sensitivity. 
Compared to the conventional organic fluorophores, Ln(III) complexes offer several other 
advantages for use in biological applications. This includes a large separation between 
absorption and emission spectra which minimize the excitation light interference. They also 
exhibit a line-like emission spectra with clearly defined bands, allowing ratiometric 
analyses143–145 . Because of their unrivaled aforementioned photophysical properties, LLCs are 
particularly useful as energy donors for FRET systems allowing much longer emission 
lifetimes to be observed for a conventional organic fluorophore, following excitation from a 
lanthanide donor146. 
Lanthanides possess intrinsic luminescence that originates from f−f electron transitions in the 
4fn shell of the [Xe]5s25p6 configuration and offer unique properties for optical imaging 
contrast agents that overcome current limitations of their organic homologous. First, due to 
shielding from the chemical environment by the filled, energetically lower 5s and 5p sub-shells, 
the 4f orbitals do not directly participate in chemical bonding. Thus, the emission wavelengths 
of lanthanides are minimally disturbed by the surrounding matrix and ligand field, resulting in 
sharp, line-like emission bands with the same fingerprint wavelengths and narrow peak widths 
of the corresponding free Ln(III) salts. Second, the f−f transitions are formally forbidden by 
the spin and Laporte rule making  the direct excitation of Ln(III) ions is very inefficient but 
feature long excited-state lifetimes in the milli- to microsecond range. This property lends 
luminescent lanthanides to time-gated or time-resolved live-cell or in vivo imaging. Such an 
approach enhances signal-to-noise ratios through the elimination of interferences from 
scattering and short-lived autofluorescence of biological constituents as already mentioned. 
Finally, because the differences in electronic properties between the different Ln(III) ions 
reside in the shielded 4f orbitals, varying the metal center imposes minor effects on the 
chemical properties of the Ln(III) complex, allowing for facile multiplexing for ratiometric or 
multimodal applications.143,147 
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1.3.2   The antenna effect 
The lanthanide ions (f-f transitions) have very weak absorption coefficients (ε), which makes 
direct photo-excitation of the lanthanide ions difficult. Intense light sources such as lasers are 
required to achieve the excited states of Ln(III) ions by direct excitation and are impractical for 
the majority of biological imaging. However, this can be overcome by using the large 
absorption cross-section of the organic chromophores and the energy transfer from organic 
chromophores to lanthanide ions.143,147 
 
Figure 17. A) General architecture of luminescent lanthanide complexes showing the antenna 
effect: Excitation light excites the antenna, followed by energy transfer to the Ln(III) ion, which 
consequently emits light (upper). Jablonski Energy Diagram of Absorbance Energy Transfer 
Emission (AETE) mechanism for a Ln3+ complex (lower). B) Luminescent 4f−4f transitions of 
europium and terbium complexes and commonly observed emission wavelengths to emit red 
and green light, respectively.143 
Thus, to design highly luminescent Ln3+ complexes, Weissman 148, first noticed the 
sensitization process in which the energy transfer takes place from coordinated ligands to the 
central metal ion. Light absorbed to the short-lived singlet excited state of the antenna (S0 → 
S1) can undergo non-radiative intersystem crossing to the longer-lived triplet excited state (S1 
→ T1). The non-radiative energy transfer from the T1 state of the antenna to the lowest 
5DJ 
excited state of the lanthanide is the sensitization step resulting in metal-centered luminescence 
(Figure 17A). Energy transfer can also occur directly from the S1 state, but energy transfer 
from the T1 state is generally accepted as the mechanism due to its long lifetime.  Final 
transitions from the 5DJ excited state to the 
7FJ ground state of the lanthanide emit photons 
characterized by a series of specific bands in the visible (Eu(III) and Tb(III)) and near-IR 
(Dy(III) and Sm(III)) wavelengths ( Figure 17B) .143,144  
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The nature of the sensitizing group can be particularly useful in designing responsive 
lanthanide probes, as changes to the antenna can modulate its absorption or energy transfer 
properties. These changes can result from irreversible reaction with biological analytes or 
reversible non-covalent interactions, disturbing the singlet or triplet excited states of the 
antenna.144 
1.3.3   Design strategies for reactivity based lanthanide probes  
According to the previous sections, the luminescence of lanthanides is depending on the next  
four parameters:149,150 
1- The efficiency of the antenna’s triplet excited state population. 
2- The energy of the triplet excited state of the antenna relative to the 5D excited state of 
the lanthanide ion. 
3- The distance between the antenna and the lanthanide ion. 
4- The number of coordinated water molecules. 
Accordingly, these parameters can be manipulated to rationally design responsive luminescent 
probes. 
1.3.3.1   Modulating luminescence via the Antenna−Ln distance  
The energy transfer from the triplet excited state of the antenna to the metal ion drives to the 
sensitization of lanthanide complexes. The distance-dependence of this energy transfer process 
was exploited to modulate luminescence by altering the distance between the antenna and the 
metal center143. Distance modulation through analyte binding can be either by bringing the 
antenna in close proximity to the lanthanide ion as figured in Figure 18A, conjugating the 
antenna to the lanthanide complex as in Figure 18B, thereby starting the sensitization, or 
displacing a weakly coordinated antenna, thereby turning off the lanthanide’s luminescence as 
in Figure 18C 151. 
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Figure 18. Modulating luminescence via the Antenna−Ln distance.151 
An example of this class of sensors is the peptidic terbium probe synthesized by Schneider et 
al. for the luminescent determination of environmental redox potential. The linker contained a 
peptide sequence with a moderate propensity for β-sheet formation with cysteines that could 
respond to the environment (Figure 19A). Under reducing conditions, the cysteines remain 
protonated and the peptide prefers a flexible conformation with a long antenna−Ln distance 
and thus a weakly luminescent species. In contrast, oxidizing conditions induced disulfide bond 
formation between the cysteines and stabilized a β-sheet conformation, thereby bringing the 
antenna near the lanthanide and producing a highly luminescent species.152  
Based on the advantage of the catalytic role of copper(I) in Huisgen 1,3-dipolar cycloaddition 
(“click”) reactions, Viguier and Hulme designed a “turn-on” probe by attaching an alkyne-
containing europium complex to a dansyl azide antenna. The covalent bonding of the antenna 
near the metal ion resulted in a 10-fold enhancement of luminescence compared to the free 
Eu(III) chelate (Figure 19B). This sensor could be a promising example of how components 
of existing synthetic methodologies will be manipulated for imaging applications. 153 
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Figure 19. Examples of luminescent lanthanide sensors based on Modulating luminescence 
via the Antenna−Ln distance. 
A “turn-off” luminescent europium complex was developed by Gunnlaugsson et al. in which 
displacement of a coordinated antenna by an analyte results in a sensor that senses anions via 
a displacement assay. The phenyl or naphthyl antennae are linked to a labile β-diketonate 
ligand. Displacement of the β-diketonate by a stronger chelating anion decreases the 
luminescence intensity of the europium as in Figure 19C.154  
1.3.3.2   Modulating luminescence via coordinated water molecules 
 The long lifetimes of the 5D excited states of the lanthanides render them particularly 
susceptible to quenching via nonradiative energy transfer to nearby O–H and N–H oscillators 
of lower energy. Since the fourth overtone of the O–H oscillator of water is slightly lower in 
energy than the excited 5D states of europium and terbium, water molecules coordinated to 
these lanthanides are excellent quenchers of the metal’s luminescence151. Therefore, in 
luminescent applications, lanthanides are typically chelated with multidentate ligands which 
protect the metal center from solvent coordination. Chelators such as EDTA derivatives, crown 
ethers, BAPTA (1, 2-bis(o-aminophenoxy)ethane-N, N, N’, N’-tetraacetic acid), aza crown 
ethers or cryptands are frequently used as recognition elements for metal ions155. For  biological 
imaging, chelation attenuates the toxicity of free lanthanide ions143. Since lanthanide ions 
typically adopt coordination numbers of between 8 and 9 in aqueous solution, the number of 
coordinated water molecules is readily governed through ligand design156. 
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Figure 20. Modulating the luminescence of lanthanide complex via displacement of 
coordinated water molecules. ET : Energy transfer ; Qu: Quenching. 
If the Ln(III) coordination sphere is not fully saturated, water molecules will occupy the free 
coordination sites, resulting in quenching of luminescence. The quenching effect of bound 
water molecules can be utilized for the design of responsive Ln(III) complexes, wherein water 
molecules coordinated on the lanthanide ion can be readily displaced by hard anions such as 
carboxylates and phosphates151,156. Therefore, in principle, a lanthanide complex comprising 
an antenna and one or more open coordination sites can be used as a turn-on sensor for hard, 
preferably polydentate, anions. In the off state, the open coordination sites will be filled with 
exchangeable water molecules that will quench the emission of the lanthanide. Displacement 
of these coordinated water molecules by hard anions eliminates this quenching, thereby 
increasing luminescence from the lanthanide as sketched in Figure 20. One should note that 
lanthanides are hard, oxophilic ions that preferentially bind carboxylates and phosphates, 
thereby limiting the number of analytes that can be targeted using this approach151. 
Based on the fact that anions are ubiquitous throughout biological systems, their determination 
is an essential tool in environmental monitoring. The presence of anions plays an important 
role in biomedical and catalytical processes, whilst pollutant anions have been linked to 
eutrophication of rivers (from the overuse of phosphate-containing fertilizers) and 
carcinogenesis (metabolites of nitrate)157. Therefore, the design of anion-sensitive probes with 
sufficient sensitivity and selectivity is a demanding task in analytical sciences and chemical 
sensor technology 158. Primarily, probes for the detection of biologically relevant anions such 
as phosphates, acetate, carbonate, or halides were in the focus over the past years 159,160. The 
problem in using this approach to detect oxoanions is achieving sufficient selectivity over other 
oxoanions also present in the media. pH-dependence of analyte speciation and binding affinity 
must be carefully taken into consideration. 
Stephan Butler reported two water-soluble luminescent probes [Eu.L1–2]+ , each capable of 
binding and sensing fluoride in pure water samples, with minimal interference from other 
anions.  
Introduction 




Fluoride binds reversibly to each probe, displacing the coordinated water (Figure 21 A), 
resulting in a 9-fold enhancement in the overall emission intensity and dramatic changes in 
emission spectral form.161 
 
Figure 21. luminescent lanthanide sensors based on modulating the luminescence of lanthanide 
sensors via the number of coordinated water molecules. A) Europium complexes for 
quantitative determination of fluoride in pure water161. B) Europium sensor for the selective 
luminescent detection of malonate162. C) A pH-responsive lanthanide luminescent probe143.  
Some selectivity for oxoanions has been achieved in water as reported by The Gunnlaugsson 
group. They developed a bismacrocyclic dinuclear europium sensor (Figure 21B) for the 
selective luminescent detection of malonate. In pH 6.5 solutions, small dicarboxylic acids such 
as succinic, malonic, aspartic, or glutaric acid were shown to be bind also. However, only 
malonic acid gave rise to selective Eu(III) luminescent enhancements, as the emission was 
reduced for all of the other acids.162 
Parker and coworkers developed a pH-sensitive europium sensor based on the intramolecular 
displacement of a bound water molecule following the deprotonation of the sulfonamide 
antenna. Under acidic conditions, the complex coordinates two water molecules that quench 
the luminescence of the europium. However, at alkaline pH, deprotonation of the sulfonamide 
enables direct coordination of the lanthanide by the nitrogen (Figure 21C). The concomitant 
displacement of both inner-sphere water molecules results in a significant increase in europium 
luminescence.163 
Several more examples have emerged that demonstrate the potential of bound water 
displacement in biological applications and due to space limitations, the reader is referred to 
additional examples provided in different review articles.164–167 
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1.3.3.3   Modulating luminescence via direct coordination of the antenna or modulation 
of the Antenna Excited State 
Effective sensors can be designed by combining both previous principles if one targets a 
chromophore that is directly capable of coordinating the lanthanide. The use of a stable 
lanthanide complex with one or more open coordination sites is required and the targeted 
analyte should be both an effective sensitizer and a hard  ligand.151 
Coordinately unsaturated terbium complexes possess two labile metal-bound water molecules 
were designed according to this strategy by Gunnlaugsson et al168. Water molecules can be 
displaced when terbium chelates aromatic carboxylic anions such as salicylic acid in water, 
which gives rise to a significant increase in the Tb(III) luminescence. 
 
Figure 22. Caged antenna approach for the detection of hydrogen peroxide. 
Altering the antenna excited state through chemoselective reactions with analytes is a 
promising approach for detecting reactive small molecules like hydrogen peroxide, and nitric 
oxide. Lippert et al. developed lanthanide-based luminescent probes for the detection of 
hydrogen peroxide (H2O2) in living systems as shown in Figure 22. The chemoselective 
reaction of these caged antenna probes with H2O2 activated the formation of the sensitizer and 
enhanced the luminescent intensity by 6-folds169. 
Some other strategies are relying on modulating the luminescence of a complex by altering the 
triplet state T1 of the antenna through an analyte triggered chemical modification. This 
approach requires an antenna that can selectively react with the desired analyte to give a 
product that has a triplet state of substantially different energy from the pre-antenna151,170. 
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2   Objectives of the present work    
The overall aim of the present study was the synthesis and characterization of novel chemical 
tools for the  in vitro and in vivo investigation of lipid metabolism. The main focus was on the 
monitoring of the acid sphingomyelinase, a key enzyme in the sphingolipid signaling network.  
2.1   Design and synthesis of novel Europium complexes for ASM monitoring  
Luminescent lanthanide complexes (LLCs) are widely used probes implemented for phosphate 
anion detection. Our goal was to apply this approach for monitoring the ASM cleavage product, 
phosphocholine (PC), as a measure of ASM activity. We hypothesized that the released PC can 
displace the coordinating water molecules on the metal sphere and give rise to luminescence 
enhancement which can be further quantitively correlated to the ASM activity (Figure 23). 
 
 
Figure 23. Hypothesis of ASM monitoring using LLCs. 
 
2.2   Design, synthesis and characterization of ASM FRET probes 
Our goal was to achieve the design and synthesis of ASM-FRET probes (Figure 24) for better 
ASM monitoring and quantification in addition to broadening the applications for the already 
synthesized probes. 
 
Figure 24. General structure for the ASM FRET probes. D: FRET donor, A: FRET acceptor, 
R&R’: H or CH3. 
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2.2.1   ASM-FRET probe with better two photon excitability 
Given the advantages of 2PE microscopy, a novel and more efficient 2P excitable FRET probe 
was envisioned. Our goal was to use the recently reported171 bromo-coumarin moiety with its 
significantly high 2PE cross-section as a FRET donor to enhance the 2P-excitability of the 
probe (Figure 25). In addition, the red shift of the new coumarin could result in a better 
donor/acceptor spectral overlap and accordingly a more efficient energy transfer. 
 
Figure 25. Envisioned FRET-donor modification for better 2P- excitability. 
2.2.2   Sphingomyelinase-FRET probes with quaternary ammonium center 
Due to the importance of the ammonium group109 for the recognition and thus hydrolysis of 
sphingomyelin analogues by sphingomyelinases, we hypothesized that a sphingomyelin 
mimicking FRET probe with a quaternary ammonium group (Figure 24) would be highly 
recognizable and rapidly cleavable. It could also be a substrate not only for ASM but may be 
for nSMases and other comparable sphingomyelinases. 
 
Figure 26. Partial schematic representation of the envisioned synthesis of an ASM-FRET 
probe with a quaternary ammonium group. a: phosphorylation, b: Quaternization and labelling, 
Dye: could be the FRET donor or acceptor.  
The synthetic goal was to apply a sphingosine phosphorylation strategy which enables the 
insertion of a quaternary ammonium group accompanied/or followed by the labeling with the 
fluorescent dye as schemed in Figure 26. Incorporation of a terminal functional group like 
alkyne functionality can serve as a bioorthogonal handle for the introduction of a wide range 
of fluorophores or other labeling agents using aqueous phase chemistry.  
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2.2.3   Synthesis of the originally reported probes for novel applications   
A high throughput screening (HTS) for potential ASM inhibitors was planned using the 
reported ASM FRET probe121. For this purpose, a more economically affordable upscaling of 
the synthesis was envisioned.  
The reported NBD mono-labelled probe56  was proved as an in vitro ASM turn-off probe. 
Resynthesis and testing of this probe as a potential in vivo ASM quenched probe for studying 
inhibitors and ASM deficient cells were envisioned. 
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3   Results and Discussion 
3.1   5- and 4- dentate europium Complexes for anion sensing and their applicability to 
enzymatic dephosphorylation reactions                                        
As discussed in section 1.3, luminescent lanthanide complexes (LLCs) are promising tools for 
phosphate species detection. They are characterized by their long luminescence lifetimes which 
makes them suitable for the time-gated measurement of biological samples wherein interfering 
short-lived autofluorescence and scattering are suppressed. They also exhibit large separation 
between absorption and emission spectra and line-like emission spectra with clearly defined 
bands. This behavior minimizes the excitation light interference and allows ratiometric analysis 
143–145. As phosphocholine PC is the cleavage product of SM hydrolysis by ASM, we proposed 
that the quantitative detection of this PC using LLCs can be a good monitoring tool for ASM. 
For this purpose, we designed and synthesized two Eu complexes and tested them for the 
detection of different phosphate species including PC. Their applicability to enzymatic 
dephosphorylation reactions was also studied. 
3.1.1   Synthesis of the 5-dentate europium complex  
 
The 5-dentate 5-D+ complex was prepared in seven steps starting from commercially available 
chelidamic acid (Scheme 4). In the first step, diethyl 4-bromopyridine-2, 6-dicarboxylate 101 
was synthesized by heating chelidamic acid with phosphorus pentabromide followed by the 
esterification with ethanol. The yield was 90% which is comparable with the reported data172–
175. In general, this reaction consists of two steps, bromination, and esterification and they are 
easily exchangeable with a neglected yield difference176,177. The ester groups were then reduced 
with NaBH4 to yield 4-Bromo-2, 6-pyridine-dimethanol 102
178. The reported purification led 
to very low yield (~15%) and the trials of using column chromatography for purification failed 
due to the dissolution of silica in the highly polar mobile phase needed to elute such a polar 
chelating compound. Finally, the continuous extraction with chloroform for one day (Soxhlet 
extraction) resulted in a 70% yield. 4-Bromo-2, 6-pyridine-dimethanol 102 was then 
transformed to bromomethyl functions using phosphorous tribromide to yield the tri-
brominated intermediate 103 in 68% yield179. This strategy of reduction/bromination before 
the cross-coupling (step e in scheme 1) was followed to avoid any possible side reactions such 
as bromination of the triple bond which can occur in case of the active brominating reagents 
such as PBr3. 
180 
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Scheme 4. Synthesis of the 5-D+ complex. a) PBr5, 90 °C, 2.5h, 0°C, EtOH, 90%; b) NaBH4, 
EtOH, 0 °C, -80°C, 12h, Soxhlet extraction, 70%; c) PBr3, CHCl3, 62°C, 4h, 68%; d) Ethyl 2-
(methylamino)acetate hydrochloride, K2CO3, CH3CN, 83°C, 4h, 72%; e) 4-ethynyl-N,N-
dimethylaniline, THF, Pd(PPh3)2Cl2, CuI, Et3N, 3h, RT , 50%;  f) KOH, MeOH, 65°C, 3h, 89%; 
g) EuCl3·6H2O, H2O, pH 5 - 6.5, 2h, RT. 
 
The symmetric ethyl 2-(methylamino)acetate chelating arms were introduced by reaction with 
a four-fold excess of ethyl-2-(methylamino) acetate following the procedure of similar 
coupling181 to afford compound 104 in a good yield. The time and number of equivalents were 
enough to fully substitute both sides and thus no unsubstituted or singly substituted byproducts 
were detected. The structure of this new compound was confirmed using 1H and 13C NMR (see 
experimental) which revealed doubly integrated intensity for each peak in case of 1HNMR and 
number of peaks which are half of the number of the common carbon atoms in 13C NMR due 
to the symmetry of the structure. 
The antenna chromophore ligand 105 was obtained via Sonogashira coupling of 104 with 4-
ethynyl-N, N-dimethylaniline. During the first trials following similar coupling procedures 
182,183 which include refluxing for overnight and a relatively higher palladium catalyst 
concentration, two main problems were faced: the first one is the very low yield due to the 
formation of the homocoupling byproduct and the second is the difficulty of the product 
purification from the catalyst side product triphenylphosphine oxide (Figure 27). To minimize 
the formation of the homocoupling product, 4-ethynyl-N, N-dimethylaniline was added drop- 
wisely at 0°C and then the reaction was stirred at room temperature for only 4 h.   
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Figure 27. Cross coupling Reaction. A) Homocoupling product structure and NMR 
characterization after isolation from the product 105 reaction mixture; B) triphenyl phosphine 
oxide structure and interference with the 1H-NMR spectrum of compound 105; C) 1H-NMR 
spectrum aromatic section of compound 105 after optimization and purification. 
With this strategy combined with using the least possible equivalents of the palladium catalyst, 
the yield of the product was improved to 50%, and the resulting triphenylphosphine oxide could 
be highly minimized and removed with column chromatography. The ethyl esters were then 
hydrolyzed to get the free carboxylate moieties. Both acidic and alkaline hydrolysis were tried 
but finally, the alkaline hydrolysis was considered for its better yield and ease of isolation of 
the product 106. The 5-dentate ligand was directly complexed with EuCl3·6H2O in aqueous 
solution affording the 5-dentate complex 5-D+ which was used for the next fluorescence studies 
in solution form without further purification.  
3.1.2   Synthesis of the 4-dentate europium complex  
The 4-dentate 4-D+ complex was prepared in six steps starting from the previously prepared 
intermediate 101 (Scheme 5). 101 was partially reduced to the corresponding alcohol 107 
following the previous reduction procedure but with only 1.14 equivalent of NaBH4. The 
reaction mixture was stirred for only 1h at room temperature to avoid full reduction of the 
starting compound. The bromination of the former product revealed compound 108 in a very 
good yield. The ethyl 2-(methylamino) acetate chelating arm was introduced similarly by 
reaction with ethyl-2-(methylamino) acetate resulting in 109.  
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The previously established Sonogashira coupling conditions were used also to get the antenna 
chromophore ligand 110 with a 10% higher yield.  Alkaline hydrolysis of the ethyl esters gave 
the product 111 in a 90% yield which was then complexed with Europium following the same 
previous procedure to get the 4-D+.  
 
 
Scheme 5. Synthesis of the 4-D+ complex. a) NaBH4, EtOH, RT, 1h, 38%; b) PBr3, DMF , 
RT, 3h, 95%; c) Ethyl 2-(methylamino)acetate hydrochloride, K2CO3, CH3CN, 83°C, 18h, 
60%; d) 4-ethynyl-N,N-dimethylaniline, THF, Pd(PPh3)2Cl2, CuI, Et3N, 5h, RT , 60%; e) KOH, 
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3.1.3   General properties of the europium complexes 
The spectral properties of the europium complexes were measured by Prof. Michael 
Schäferling and are summarized in Table S 1, including the absorption maxima and molar 
absorption coefficients .  The number water molecules q(H2O) in the first coordination sphere 
of europium is calculated on the basis of difference of the mean lifetimes M in H2O
  and D2O, 
according to the equation derived by Supkowski and Horrocks:184  
 
q(H2O) = 1.11[M
-1(H2O) -  M
-1(D2O) -/0.31]   
                            
 The calculated values for q(H2O) clearly indicate the increasing number of coordinated water 
molecules by reducing the binding sites of the ligand. These are in good correlation to the 
theoretical quantities of four and five bounding water molecules for five and four-dentate 
complexes, respectively (based on a maximum number of nine binding sites for Eu3+)185186. It 
is obvious that the mean lifetimes in water decrease with the number of free binding sites at 
the europium center due to increased coordination of quenching water molecules. On the other 
hand, the mean lifetimes in D2O increase from 5-D+ to 4-D+ . In absence of quenching water 
molecules, the efficiency of the energy transfer from antenna chromophore to europium is the 
most important factor.  
In the case of 4-D+, one binding carboxylic acid group is directly attached to the pyridine ring. 
This causes closer coordination of the europium to the antenna chromophore compared to 5-
D+ with the longer ethyl 2-(methylamino) acetate binding arms, thus leading to a more efficient 
energy transfer. This is in accordance with the previous observations181. Competing 
radiationless deactivation processes are minimized with shorter europium-ligand distances. 
Correspondingly, the asymmetric five dentate complex with a shorter binding arm described in 
the previous reference181 had a significantly longer lifetime in D2O than 5-D+. The higher 
efficiency of the energy transfer with shorter binding arms leads to an increasing intensity of 
the 617 nm emission of Eu3+ from 5-D+ to 4-D+ with relative intensities of 1:5 respectively 
(time-gated detection). Figure S 3 in the Supporting Information shows the fluorescence 
spectra of the corresponding ligands before and after the complexation of Eu3+. They also 
indicate the increasing energy transfer efficiency.  
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3.1.4   Luminescence response of the 5-dentate complex (5-D+) 
The effect of different phosphate anions on the luminescence intensity of 5-D+ was studied. 
Variable effects, which occur in all cases immediately were noticed as in Figure 28. ATP has 
the highest increasing effect on the luminescence intensity of 5-D+  compared to the other 
anions. Two-fold excess of ATP resulted in a twenty-fold increase of luminescence intensity 
while saturation of the effect was observed at higher concentrations. Selective response of the 
5-D+ to di- and tri-phosphates could be observed at ratios higher than 1:5 (anion:5-D+).  
 
Figure 28. The Normalized luminescence responses (I/I0) of 5-D+ to ATP, ADP, CTP, PPi and 
citrate in TRIS buffer (pH 7.4). (Conc. of 5-D+ =50 µmol L-1),  I0 is the luminescence intensity 
in the absence of phosphate; λex = 345 nm, λem = 618 nm; time-resolved measurement, Lag 
time: 100 µs, signal integration time: 400 µs. 
To study the effect of the nucleoside part on the luminescence intensity change, we compared 
the effect of two different triphosphates moieties (ATP and CTP) and two different diphosphate 
moieties (ADP and PPi). The difference was significant comparing ATP and CTP while in the 
case of ADP and PPi no significant difference was observed. It was concluded that the overall 
effect is a combination of both the number of phosphate groups and the size of the nucleoside 
part (in addition to other factors), but the dominant contribution of effect is that the number of 
phosphates. Comparing the effect of AMP and Pi as in Figure 29 revealed that the presence of 
the nucleoside part in AMP neutralized the strong decrease of the luminescence intensity 
caused by Pi which seems to interfere with the energy transfer between The europium and the 
antenna chromophore.  
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Assessment of the effect of citrate as a carboxy anion on the luminescence intensity of the 5-
D+complex revealed an intensity triplication by the addition of an equimolar amount of citrate. 
2:1 ratio of citrate to 5-D+ increased the luminescence intensity by about four-folds. 
 
Figure 29. The Normalized luminescence responses (I/I0) of 5-D+ to AMP and phosphate (Pi) 
in TRIS buffer (pH 7.4). (Conc. Of 5-D+=50 µmol L-1), I0 is the luminescence intensity in the 
absence of phosphate; λex = 345 nm, λem = 618 nm; time-resolved measurement, Lag time: 100 
µs, signal integration time: 400 µs. 
For purposes of assay transfer and better applicability, the reproducibility of the response was 
assessed using different plate readers in two different institutes and the results were identical 
to a higher extent. Figure S 4 in the Supporting Information shows the effect of ATP on the 
luminescence Intensity of 5-D+ using two different microplate readers.  
3.1.5   Luminescence response of the 4-dentate complex (4-D+) 
A significant change in the response behavior to the different anions was observed due to the 
additional free binding site at the 4-D+ complex. Compared to a twenty-fold increase in the 
case of the 5-D+ complex, only a three-fold increase in the luminescence intensity could be 
observed after the addition of a two-fold excess of ATP to the 4-D+ complex (Figure 30). 
Accordingly, the slope of the linear fit in the concentration range from 0 to 30 µmol L-1 ATP 
is less steep and the LOD for ATP determination amounts 3.6 µmol L-1  (for c = 50 µmolL-1 of 
4-D+). Only a two-fold increase of luminescence intensity was observed after adding the same 
amount of ADP which figures out the significant effect of the number of phosphate groups. 
With its different nucleoside part, CTP afforded about a 2.5-fold increase in the luminescence 
intensity. PPi unexpectedly resulted in a decreased luminescence intensity to half of the initial 
value at a molar ratio of 1: 5 PPi: 4-D+ complex. 
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Figure 30. The Normalized luminescence responses (I/I0) of 4-D+ to ATP, ADP, CTP, PPi and 
citrate in TRIS buffer (pH 7.4). (Conc. Of 4-D+ =50 µmol L-1),  I0 is the luminescence intensity 
in the absence of phosphate; λex = 345 nm, λem = 618 nm; time-resolved measurement, Lag 
time: 100 µs, signal integration time: 400 µs. 
Anions with a single phosphate group (Pi and AMP) revealed a significant decrease of the 
luminescence intensity, regardless of the presence or absence of the nucleoside (Figure 31). 
This opposite effect of PPi and monophosphates proposes a different explanation for the 
luminescence response than the replacement of coordinating water molecules. Most likely, the 
interference of the coordination of europium to the ligand and consequently the energy transfer 
by these anions. With β-diketonate ligands a displacement of the ligand was found after the 
addition of PPi or ATP, generating a luminescence decrease
187. This was also observed using 
tetracycline as sensitizing ligand188. 
 
Figure 31. The Normalized luminescence responses (I/I0) of 4-D+ to PPi, AMP and Pi in TRIS 
buffer (pH 7.4). (Conc. Of 4-D+ =50 µmol L-1) I0 is the luminescence intensity in the absence 
of phosphate; λex = 345 nm, λem = 618 nm; time-resolved measurement, Lag time: 100 µs, 
signal integration time: 400 µs. 
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3.1.6   Optimization of the phosphate complex reaction for monitoring the acid  
sphingomyelinase activity 
Inspired by the response of the synthesized complexes to different phosphate species, we 
commenced to optimize the application of the complexes to be used for monitoring the acid 
sphingomyelinase activity. 
 3.1.6.1   Luminescence response of 4-D+ and 5-D+ complexes to phosphorylcholine 
The effect of phosphorylcholine PC, the phosphate species which results from the enzymatic 
cleavage of sphingomyelin, on both 4-D+ and 5-D+ was studied using the standard condition 
for the previously studied anions (Figure 32 A). The response of the 5-D+ complex to an 
increasing concentration of phosphorylcholine was not significant in general although it 
showed a slightly decreasing change of the luminescence intensity in the lower concentration 
range. On the other hand, the change of the luminescence intensity of the 4-D+  complex upon 
addition of increasing concentration of phosphorylcholine was significant and comparable to 
the effect of AMP, Pi in Figure 31. The addition of an equimolar amount 1:1 ratio of 
phosphorylcholine to 4-D+ decreased the luminescence intensity to about one fifth of the initial 
intensity.  
       
Figure 32. Normalized luminescence responses (I/I0) of 4-D+
  and 5-D+ to PC. A) Conc. Of 
Complex =50 µmol L-1 B) Conc. of Complex =10 µmol L-1 . TRIS buffer (pH 7.4), I0 is the 
luminescence intensity in the absence of PC; λex = 345 nm, λem = 618 nm; time-resolved 
measurement, Lag time: 100 µs, signal integration time: 400 µs. 
To use a more realistic concentrations for an enzymatic reaction, a new experiment with a lower 
concentration scale of both the complexes (10 µmol L-1) and the tested phosphorylcholine (0-
15 µmolL-1) were used keeping the same other conditions of the previous experiment. 
Interestingly, both complexes showed a similar behavior at this concentration scale (Figure 32 
B).  
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For quenching 50% of the luminescence intensity of the 4-D+, 0.9:1 ratio of phosphorylcholine 
to complex was needed while only  0.6:1 ratio was needed in the case of the 5-D+. Because of 
the stability of response to phosphorylcholine in the case of 4-D+   in both concentration scales, 
it was selected for the next optimization step. 
3.1.6.2   The effect of the acidic pH on the responsiveness of the 4-D+ Europium complex   
Because the pH optimum of the acid sphingomyelinase in vitro was between 4.5 and 5.0 60, our 
next optimization step was to check the validity of the 4-D+  complex response at this acidic 
pH range. A general decrease of the luminescence intensity was observed before the addition 
of phosphorylcholine (Figure 33A). It is reported that in case of the complexation of metal 
ions with acidic ligands like carboxylates, the complexation process is accompanied by 
deprotonation of ligand 189. So, this luminescence quenching can be referred to the suppression 
of deprotonation at this acidic pH and thus the decrease of complexation efficacy. Despite this 
general intensity decrease, the behavior of the 4-D+  complex was similar to that at pH 7.4 upon 
addition of different concentrations of phosphorylcholine. 50% luminescence intensity 
decrease of the 4-D+ was observed at 0.75:1 molar ratio of phosphorylcholine to the complex.  
    
Figure 33.  A) luminescence responses of 4-D+  to PC at pH 7.4 (blue) and pH 5 (brown); B) 
Normalized luminescence responses (I/I0) of 4-D+
  to PC at pH 5; Conc. Of 4-D+=10 µmol L-1 
; λex = 345 nm, λem = 618 nm, time-resolved measurement, Lag time: 100 µs, signal integration 
time: 400 µs. 
3.1.6.3   Simulation of the acid sphingomyelinase hydrolytic reaction 
 As the acid sphingomyelinase hydrolytic reaction contains two phosphate species, 
sphingomyelin SM and phosphorylcholine PC with a ratio that changes during the enzymatic 
reaction, the need to simulate this reaction and expect the kinetic complex response is essential.  
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The first step was to study the effect of sphingomyelin as a phosphate-containing molecule on 
the luminescence intensity of the 4-D+ complex and then using a series of different SM/PC 
ratios starting from 100%SM (to simulate the starting concentration) till 100% PC (to simulate 
the completion of the enzymatic reaction). 
The addition of 1:1 molar ratio of sphingomyelin to the 4-D+ complex revealed about 1.4 folds 
increase of the luminescence intensity of the complex (Figure 34 A). So, we have now two 
opposite effects of both sphingomyelin and phosphorylcholine which mean theoretically that 
after the addition of sphingomyelin to the complex and waiting until reaching the stable 
intensity of the mixture, the enzymatic cleavage resulting in phosphoryl choline could be then 
monitored by following the decreasing effect of this phosphorylcholine on the luminescence 
intensity of the complex.  
Figure 34 B shows the simulation reaction of ASM in which we started the measurement after 
the addition of sphingomyelin and getting a stable intensity which considered as I0. Then as 
expected, 1:4 PC/SM ratio (simulate 20% cleavage) resulted in a 10% intensity decrease and a 
2:3 PC/SM ratio (simulate 40% cleavage) resulted in about 30% luminescence intensity 
decrease. Using increased portions of phosphorylcholine (simulating 60% and 80 % cleavage), 
a different behavior was observed where a 1,13 folds intensity increase compared to I0  and a 
comparable intensity to I0 were observed respectively. This means that at these ratios the 
combination of both phosphates has a different mechanism of action which results in an overall 
increase of intensity. Finally, as already established, simulating 100% cleavage by the addition 
of only phosphorylcholine reveals about 50% intensity quenching.  
       
Figure 34.  A) Normalized luminescence responses (I/I0) of 4-D+
  to SM at pH 5, Conc. of 4-
D+=50 µmol L-1; B) Simulation reaction of ASM and the normalized response of 4-D+  to the 
PC/SM mixture at pH 5;Conc. of 4-D+=10 µmol L-1. λex = 345 nm, λem = 618 nm, time-resolved 
measurement, Lag time: 100 µs, signal integration time: 400 µs. 
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Although the simulation reaction revealed a non-steady overall response of the 4-D+ complex 
to the ASM phosphate mixture, it still has a linear response in the first part which simulates till 
about 40% cleavage of sphingomyelin. Based on the already collected findings, we decided to 
go forward directly to the enzymatic reaction to test the applicability of the assay before putting 
more effort into the detailed optimization. 
3.1.6.4   Monitoring the ASM cleavage reaction using the 4-D+ complex 
After studying the effect of different parameters related to the acid sphingomyelinase enzyme 
reaction on the 4-D+ complex, we started to use this complex for monitoring the activity of this 
sphingomyelin cleaving enzyme. The strategy was to add our luminescent complex to the 
enzyme buffer, adding the enzyme-substrate (SM), waiting until we get the maximum intensity 
increase and then adding the enzyme to the mixture and measuring the luminescence intensity 
in a real-time pattern. Applying this strategy, we noticed a time-dependent decrease of the 
luminescence intensity independently from the presence of the enzyme or the substrate as in 
Figure 35. In the experiment where the enzyme was added to the complex and the substrate 
mixture, a time dependent decrease of intensity was observed which was the same situation in 
case of the complex only and the complex plus substrate mixture. This means that the decrease 
of the intensity is either not a response to the enzymatic reaction only or not a response to the 
enzymatic reaction at all.   
 
Figure 35. Monitoring the ASM cleavage reaction using the 4-D+ complex. Conc. of SM=10 
µmol L-1; Conc. of ASM =2µgm L-1; Conc. of 4-D+=10 µmol L-1; ASM buffer: (0.1 M NaOAc 
pH 5.0, 150 mM NaCl, 0.1 mM ZnSO4, 0.1% TritonX-100); λex = 345 nm; λem = 618 nm; time-
resolved measurement; Lag time: 100 µs; signal integration time: 400 µs. 
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The only variable in this experiment was the enzyme buffer which seems to have a strong 
quenching effect on the complex luminescence intensity. To confirm this assumption, a new 
experiment to study the luminescence intensity stability of the  4-D+ complex in the acid 
sphingomyelinase buffer was done as in Figure 36.  
 
Figure 36. The luminescence intensity stability of the 4-D+ complex in the acid 
sphingomyelinase buffer; Conc. of 4-D+=50 µmol L-1; ASM buffer: (0.1 M NaOAc pH 5.0, 
150 mM NaCl, 0.1 mM ZnSO4, 0.1% TritonX-100); λex = 345 nm; λem = 618 nm; time-resolved 
measurement; Lag time: 100 µs; signal integration time: 400 µs. 
As expected, after about 10 minutes of incubating the complex with the buffer, 50% quenching 
was observed. And after 1 hour, 70% of the luminescence intensity was quenched due to the 
buffer constituents. The exact interacting buffer constituent/s with the 4-D+ complex was not 
defined although the interaction of Zinc(II) and Triton X with the Europium(III) complexes is 
reported 190191. The quenching effect of acidic pH was excluded in this case because in our 
previous optimization experiments this quenching wasn’t time-dependent. As the applicability 
of the assay looks limited, we did not deeply investigate the cause of this quenching.  
3.1.6.5   Heterogenous assay of the acid sphingomyelinase using the 4-D+ complex 
As a last trial we tried to apply the europium complex luminescence intensity change for 
monitoring the activity of the  acid sphingomyelinase in a heterogeneous manner. Because our 
trials to use the complex as an internal probe during the enzymatic reaction was not successful, 
we used the established strategy for monitoring the sphingomyelinases activity in which the 
substrate incubated with the enzyme, then the released phosphorylcholine can be separated 
from the remaining, unhydrolyzed sphingomyelin by extraction with a mixture of chloroform 
and methanol.  
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Thus,  the un-cleaved sphingomyelin and the resulted ceramide are captured in the organic 
phase, whereas the phosphorylcholine, partitions to the upper aqueous phase which can be 
separated and measured depending on the nature of the assay as a relative measure of 
sphingomyelin hydrolysis94,192.  
We Applied the same procedures and separated the aqueous phase from different experiments 
containing different controls and different acid sphingomyelinase concentrations. Then we 
tested the effect of this phosphorylcholine containing aqueous phases on the luminescence 
intensity of the europium complex (Figure 37).  
 
Figure 37. Heterogenous assay of  acid sphingomyelinase using the 4-D+ complex. TRIS buffer 
(pH 7.4); I0: Luminescence intensity of  4-D+ complex only; λex = 345 nm; λem = 618 nm; time-
resolved measurement; Lag time: 100 µs; signal integration time: 400 µs. 
Unfortunately, we observed that the addition of the aqueous phase solution to the complex 
caused a luminescence quenching which is the same with the three different enzyme 
concentrations. This means that the differentiating power of the probe between the three 
different experiments with their different phosphorylcholine concentrations is not significant. 
The control experiments with either the enzyme or the enzyme buffer only revealed the same 
quenching behavior which excludes any probability of phosphorylcholine contribution in this 
luminescence change. This quenching was also observed with the control experiment 
containing only the substrate (sphingomyelin) which should remain in the organic phase after 
the extraction process. These observations enhance the assumption of the interference of the 
acid sphingomyelinase reaction buffer with the complex/phosphate reaction.  
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3.1.6.6   Monitoring the activity of neutral sphingomyelinase 2 using the 5-D+ complex 
Due to the relative similarity between the buffers of both nSMase 2 and that of our primary 
experiments in addition to the pH 7.4, we tried monitoring the nSMase 2 activity using our 
europium complexes. Firstly, we checked the stability of both 4-D+ and 5-D+ complexes in the 
nSMase 2 Buffer as in Figure 38. Both complexes revealed good  luminescence stability over 
time with a slight decrease in intensity in the case of the 4-D+ complex. 
 
Figure 38. Stability of  4-D+ and 5-D+ complexes in nSMase 2 Buffer over time. nSMase 2 
buffer: 50 mM M Tris/HCl pH 7.4, 150 mM NaCl, 0.1% TritonX-100, 5 mM MgCl2; Conc. of 
4-D+& 5-D+  =5 µmolL-1; I0: Luminescence intensity of  4-D+& 5-D+   complex at T0; λex = 345 
nm; λem = 618 nm; time-resolved measurement; Lag time: 100 µs; signal integration time: 400 
µs. 
The next experiment was the simulation of the nSMase 2 reaction in which different ratios of 
PC/SM simulating the cleavage progress of the substrate SM were added to the 5-D+ complex 
in the nSMase 2 buffer to check the response of the complex toward the cleavage progress. A 
scale of PC/SM ratios starting from SM only till PC only was tested and the results were 
presented in Figure 39. The behavior of the complex with the ratio change was like that of the 
4-D+ complex with the ASM simulation reaction (Figure 34 B). A linear luminescence 
intensity decrease was observed with the virtual percentage of cleavage till 40%. At this 
percentage about only 50%  of the initial luminescence intensity was detected. 
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Figure 39. Simulation reaction of nSMase 2 and the normalized response of 5-D+  to the PC/SM 
mixture in nSMase 2 Buffer ;Conc. Of 5-D+=5 µmolL-1; I0: Luminescence intensity of  5-D+ 
complex + SM (5 µmolL-1);  λex = 345 nm, λem = 618 nm, time-resolved measurement, Lag 
time: 100 µs, signal integration time: 400 µs. 
After this ratio, the increase in PC portion to 50% caused a reverse response in which the 
luminescence intensity started to increase giving only a 30%  intensity decrease corresponding 
to the initial 0% cleavage. This reverse response retreated by a 70% virtual cleavage and with 
an 80% virtual cleavage reached about 45% intensity decrease of luminescence. This linear 
response till the 40% virtual cleavage is a promising sign to use this setup for the monitoring 
of nSMase 2 activity in vitro. 
The nSMase2 reaction was carried out starting with the addition of the complex to the enzyme 
buffer followed by the substrate sphingomyelin and then waiting till the luminescence intensity 
is stable. The enzyme was added to the mixture and the luminescence intensity was measured 
at 5 minutes interval as presented in Figure 40. Unfortunately, the results revealed a loss of 
differentiating ability of the probe neither between the enzymatic reactions and the controls nor 
between the enzymatic reactions with different enzyme concentrations. The validity of the 
enzyme was confirmed using NBD-labeled sphingomyelin commercially available substrate. 
Also, higher enzyme concentrations and longer reaction times were tried without any 
significant change in the results.     
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Figure 40.  Monitoring the nSMase2 cleavage reaction using the 5-D+ complex. Conc. of 
nSMase2 = (1) 30 µgmL-1, (2) 60 µgmL-1; Conc. of 5-D+=5 µmol L-1; Conc. of SM =5 µmol 
L-1 ;nSMase2 buffer: (50 mM M Tris/HCl pH 7.4, 150 mM NaCl, 0.1% TritonX-100, 5 mM 
MgCl2); λex = 345 nm; λem = 618 nm; time-resolved measurement; Lag time: 100 µs; signal 
integration time: 400 µs. 
After these different optimization steps and according to the results obtained it was concluded 
that this europium complexes-based sphingomyelinases assay is not applicable due to the 
limited specificity of the complexes response and the complex nature of the enzymatic 
reactions media in regards of interfering ions and pH ranges. 
3.1.7   Applicability of the 5-D+  to apyrase enzyme assay 
Due to the significant response of the 5-D+ to the interaction with ATP and the significant 
difference in response between ATP, AMP, and Pi, the applicability of the response for real-
time monitoring of enzymatic conversion of ATP by apyrase enzyme was evaluated. Apyrase 
decomposes ATP to AMP and phosphate according to Equation 1. 
ATP ― (apyrase) → AMP + 2 Pi                                                                               Equation 1            
Apyrase is frequently used in neurobiological studies due to the wide role of ATP as a 
neurotransmitter. It is also reported that apyrase can protect against allergic airway 
inflammation by decreasing the chemotactic migration of dendritic cells (DCs). Apyrase 
enzyme is currently used in cancer and platelet aggregation studies in humans, as well as 
herbicide resistance in plants. Apyrase inhibitors are investigated for their use to defeat tumors 
and overcome herbicide resistance. ATPase activity monitoring is often based on radiolabelled 
phosphorous or colorimetric-based phosphate detection.  
 
Results and Discussion    




However, these detection methods have limitations, as radioactive assays are exhausting and 
release hazardous waste, while colorimetric assays are often limited with background 
interference and signal stability. Thus a luminescence-based assay would provide a useful 
alternative. 193–195 
The apyrase reaction buffer was firstly used to study the effect of both high salt concentrations 
(50 µmol L-1  NaCl and 5 µmol L-1  CaCl2) and a lower pH value (6.5) on the response of the 
5-D+ complex to the corresponding anions ratio change. The interference of high salt 
concentrations on the sensing of anions by luminescent probes is known to be a fundamental 
problem181. Lower pH values are known to affect the degree of ionization of the ligand carboxyl 
groups and accordingly the complex integrity as previously addressed in this study. Although 
the extent of the luminescence response was generally decreased in the apyrase reaction buffer, 
the model calibration curve for the apyrase reaction remained the same as in TRIS buffer 
(Figure 41). However, this simulation is too simple and cannot be applied as a real calibration 
curve for a quantitative determination of apyrase activity, as the phosphate anions are released 
in two steps and different amounts of ADP are present in the reaction mixture196. 
 
Figure 41.  Normalized luminescence intensities (I/I0) of 5-D+ (c=50 µmol L
-1) in TRIS and 
apyrase buffer in the presence of different mole fractions of ATP / AMP+2 Pi. 
The real-time monitoring of the hydrolysis of ATP by four different concentrations of the 
apyrase enzyme indicated by the decreasing luminescence of 5-D+ complex is presented in 
Figure 42. The enzyme concentrations are denoted as activities in U per well (volume/well 
=100 µl) as specified by the manufacturer. Thus, the turnover of the enzymatic reaction is 
directly expressed as a change in the luminescence intensity.  
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The intensities were measured approximately every 120 second. For better comparability, the 
normalized intensities I/I0 are displayed, with I0 as the value of the initial signal directly after 
the addition of the apyrase enzyme.       
 
Figure 42. Real-time monitoring of the luminescence intensity decrease due to the hydrolysis 
of ATP (initial concentration 50 µmol L-1) by different apyrase concentrations indicated by 5-
D+ (50 µmol L-1). I0 is the intensity at T0 (apyrase buffer pH 6.5). Temperature = 30 °C. 
Apyrase activities lower than 0.005 U could not be distinguished through the time-trace of the 
signal decrease. For higher enzyme concentrations, increasing enzymatic activities can be 
correlated to the change of the initial reaction rate expressed as a signal drop per minute 
( I/min) calculated after four minutes reaction time (Table 2). 
Activity of added apyrase 
[U] 
Calculated initial reaction rate* 





Table 2. Kinetic evaluation of the apyrase assay with 5-D+; *After 4 minutes reaction time. 
The effect of the apyrase enzyme itself on the complex luminescence intensity was studied and 
showed no observable change. The enzymatic activity effect on the complex luminescence was 
confirmed by the parallel testing of the denatured enzyme as a control which showed no change 
of the complex luminescence intensity over the assay time (Figure 43). 
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Figure 43. Real-time monitoring of the luminescence intensity decrease due to the hydrolysis 
of ATP (initial concentration 50 µmol L-1) by different apyrase concentrations compared to the 
same denatured enzyme concentrations indicated by 5-D+ (c=50 µmol L-1). I0 is the intensity 
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3.1.8   Conclusion 
In this project, two Eu complexes were synthesized starting from the commercially available 
chelidamic acid in a good and pure yield (Figure 44). The two probes were designed to have a 
positive charge that can promote the binding with the phosphates. The synthesized probes 4-
D+ and 5-D+ used for detecting different phosphates and carboxylate species. The response of 
the two probes toward the studied phosphates was dramatically different which confirms the 
effect of structural and geometrical differences on the luminescence response. Two-fold excess 
of ATP resulted in a twenty-fold increase of the 5-D+ luminescence intensity while only a three-
fold increase in the luminescence intensity could be observed after the addition of a two-fold 
excess of ATP to the 4-D+ complex.  
The effect of the nucleoside part and the number of 
phosphate groups could also be detected with the 
probes. The most obvious difference in the response 
to phosphates between the two probes was with 
pyrophosphates PPi. PPi unexpectedly resulted in a 
decreased luminescence intensity to half of the initial 
value at a molar ratio of 1: 5 PPi: 4-D+ complex while 
resulted in about 5-folds increase at the same ratio 
with the 5-D+ complex. The monophosphates (Pi 
&AMP) had a clear quenching effect of both probes 
except in the case of AMP with the 5-D+.  
The probes were then applied for the monitoring of the ASM activity through the detection of 
the enzymatically released phosphorylcholine (PC). In the optimization steps, the 4-D+ 
revealed a promising decreasing response to the inorganic PC at both pH 7.4 and 5 in addition 
to the SM/PC ratio change simulation reaction. In the real enzymatic reaction, a general 
quenching effect was observed in all the experiments and this was attributed to the ASM acetate 
buffer. In a heterogenous experiment setup, similar quenching was observed without any 
enzymatic detection ability. Other trials for the monitoring of nSMase 2 could not prove the 
ability of the probes to monitor the phosphates (SM & PC) ratio change in the complex 
enzymatic reaction media despite the obvious ability in the simulation reaction containing the 
phosphates only. However, the 5-D+ complex could be used for the monitoring of the ATP-
hydrolyzing Apyrase enzyme in a real-time pattern and could differentiate between the effect 
of an 8 fold range of different enzyme concentrations. 
Figure 44. Synthesized Eu-Complexes. 
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3.2   Design, synthesis and characterization of ASM FRET probes 
3.2.1   Stereoselective synthesis of protected sphingosine 
The synthesis of the protected sphingosine was achieved following the previously established 
procedures121 (Scheme 6). Tert-butoxycarbonyl (Boc) protection of the commercially available 
L-serine followed by the Weinreb amide formation and the protection of the primary hydroxyl 
group with tert-Butyldiphenylsilyl (TBDPS) produced 203 in a very good yield in three steps. 
The introduction of a vinyl group with the Grignard reagent provided vinyl ketone 204 in 65% 
yield. Anti-selective reduction 197 of the obtained α,β-unsaturated ketone 204 using Tri-tert-
butoxyaluminohydride (TBLAH) in Ethanol/THF mixture at −84 °C revealed the desired vinyl 
alcohol (anti-product) 205 in 80% yield as a sole stereoisomer. 
 
Scheme 6. Stereoselective synthesis of the protected Sphingosine; a) Boc2O, NaOH, 1,4-
dioxane/H2O, 0°C then RT, 20h, 90%; b) NMM, dry DCM, HNMeOMe, EDC,  -15°C, 1.5h, 
75%; c) Imidazole, DMAP, dry DCM, Ph2tBuSiCl, RT, 24h, 87%; d) VinylMgBr, dry THF, -
15°C, 5h, 65%; e) TBLAH, dry THF/dry EtOH (1:10), -84°C, 4h, 80%; f) 1-pentadecene, 
Grubbs 2nd, dry DCM, reflux, 4 h, 63.5%; g) MOMCl, dry DCM, DIPEA, 0°C then RT, 20h, 
72%; h) TBAF, THF, RT,3h, 88%. 
The cross-metathesis coupling reaction between the vinyl alcohol 205 and 1-pentadecene using 
the Grubbs catalyst second generation in dichloromethane generated the skeleton of the natural 
sphingosine with the primary hydroxyl group and the amino group protected 206 in a moderate 
yield taking in consideration the possible by-products of the E-stereoisomer, homometathesis 
product and the α,β-saturated  ketones198. 
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To avoid any interferences through the secondary hydroxyl group, it was protected using 
Chloromethyl methyl ether in presence of DIPEA to give the fully protected sphingosine 207 
which then was prepared for the next phosphorylation steps by deprotection of the primary 
hydroxyl group using Tetrabutylammonium fluoride (TBAF) to get the target compound of 
this synthetic stage 208. 
3.2.2   Synthesis of the phosphodiesters 
After preparation of the protected sphingosine intermediate 208 as discussed in the last section 
we started with the synthesis of the phosphodiesters of the target sphingomyelin analogs 
(Scheme 8). For the first targeted 2P excitable FRET probe, the same strategy established for 
the synthesis of the first generation of FRET probes121 was followed. In this reaction the 
asymmetric phosphodiester 211 was synthesized through the reaction between the intermediate 
208 and 2-Phthalimidoethyl phosphorodichloridate 210 which was synthesized according to 
Scheme 7. 
 
Scheme 7. Synthesis of 2-Phthalimidoethyl phosphorodichloridate. a) 2-aminoethanol, DMF, 
Reflux, 24 h, 79%; b) POCl3, Dry toluene, Reflux, 4h, 70%. 
The phthalimide protected diphosphate ester 211  was synthesized in good yield with a high 
purity and then the phthalimido protection was cleaved using hydrazine hydrate giving the 
sphingomyelin analogue 212 with the free terminal amino group ready for the coupling of the  
fluorophores.  
To get a sphingomyelin analogue containing a quaternary ammonium group for a higher 
substrate similarity and thus better recognition and rapid cleavage, the reagent  2-chloro-2-oxo-
1,3,2- dioxaphospholane was used for the synthesis of the diphosphate ester. This reagent is 
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Scheme 8. Synthesis of the phosphodiesters of the target sphingomyelin analogs. a) dry DCM, 
0°C, RT, 4 h, H2O, 85 %; b) Hydrazine hydrate 64%, MeOH/CHCl3 (1:1), RT, 4.5 h, 82%; c)  
EtN3, DMAP , 2-chloro-2-oxo-1,3,2- dioxaphospholane, dry toluene, 0°C, 1h, used directly; d) 
N,N-Dimethylpropargylamine,  dry MeCN, 80°C , 24 h, 50%. 
The primary alcohol group of 208 reacted with 2-chloro-2-oxo-1,3,2 dioxaphospholane in the 
presence of triethylamine and a catalytic amount of 4-dimethylaminopyridine (DMAP) in 
toluene to produce the phosphate triester intermediate 213. Compound 213 is sensitive to 
moisture and was used directly in the next reaction without further purification. The five-
membered ring in 213 was then opened by N, N-Dimethylpropargylamine, in a sealed pressure 
tube at 80°C for 24 hours, leading to the sphingomyelin analogue 214. 
Getting out the sphingomyelin analogue 214 in a highly pure form was highly challenging and 
we couldn’t get it in sufficient purity using the chromatography conditions described by 
Sandbhor et al. 200. The high purity of this intermediate is critical because of the excess amount 
of  N, N-Dimethylpropargylamine used during the synthesis which -if remains as an impurity 
with 214- would highly compete with the next alkyne azide click reaction especially with the 
low steric hindrance compared with the target reactant 214. Fortunately, using the reported 
chromatography conditions 201 in which a triple mixture of CHCl3/MeOH/NH4OH with varying 
ratios was used as a mobile phase allowed us to get the target compound 214 in a very pure 
form as confirmed by the mass and NMR data (Figure 45).   
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Figure 45. 1H-NMR-Spectrum of compound 214 in CD3OD. 
With this strategy we preserved the ammonium functionality of the sphingomyelin 
phosphocholine moiety and incorporated an alkyne functionality that serves as a bioorthogonal 
handle for the introduction of a wide range of fluorophores or other labeling agents with 
aqueous phase chemistry. 
3.2.3   Synthesis of the bromo coumarin dye 
Benzyl propiolate 301 was synthesized through the Steglich esterification of propiolic acid with 
benzyl alcohol in the presence of N, N′-dicyclohexylcarbodiimide DCC and a catalytic amount 
of  4-dimethylaminopyridine DMAP202. Using such mild esterification conditions yielded the 
ester in a highly pure yield which is comparable to the highest reported yields for this benzylic 
esterification of the propiolic acid203204. The ester 301 was then reacted with the commercially 
available 6,7-dihydroxy-coumarin in the presence of DMAP to yield the intermediate 302 
(Scheme 9). The cyclic addition of catechols to terminal and internal alkynes is reported205 but 
the first time to be applied to coumarin was reported by Wessig et al.171. This 1,3-
dioxolocoumarin intermediate was synthesized in a nearly quantitative yield. 
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Scheme 9. Synthesis of the intermediate 302 a) DCC, DMAP, DCM,12h, 80%; b) DMAP, dry 
DCM, 7h, 97% 
To synthesize the brominated coumarin dye, the intermediate 302 was brominated using the 
low density and easily handled N-Bromo succinimide NBS which provided the product in a 
quantitative yield. Bromine and dioxane dibromide were reported to be used also for 
bromination of similar coumarins206,207. The brominated coumarin 303 was then catalytically 
hydrogenated to get the free coumarin carboxylic acid 304 which couldn’t be isolated in a pure 
form due to a resistant impurity (Scheme 10). Further investigation of the mass and NMR data 
of the mixture revealed that in addition to the target product 304 another portion of the 
debrominated acid 305 was formed during the hydrogenation reaction. The 1H-NMR of the 
product mixture showed a 1:3 debrominated: brominated product as the arrows in the lower 
spectrum in Figure 46 shows. The aromatic dehalogenation during catalytic hydrogenation is 
reported180,208 and the rate depends on different reaction parameters209,210 from which plays the 
pH a significant role211. 
 
Scheme 10.  Synthesis of the target bromo coumarin 304. a) NBS, NaOAc, dry ACN, 12h, 
Quan. yield ; b) Pd/C, H2 (1 atm) ,dry THF, 12h, 75%; c) Pd/C, H2 (1 atm), dry THF, 12h, 65% 
;d) NBS, NaOAc, dry DMF,12h, 50 %. 
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Figure 46. 1H-NMR spectra (cutted section) comparison  of compounds 302-305 revealing the 
disappearance of the coumarin proton a after bromination and reappearance again after the 
catalytic hydrogenation. 
To avoid this debromination reaction and to get a pure product for the next steps, a new 
synthetic order was followed (steps c and d in Scheme 10). We decided to hydrolyze the benzyl 
ester of 302 to get the free nonbrominated acid 305 then this free acid can be brominated using 
the same previous conditions for bromination to get the target brominated coumarin carboxylic 
acid 304. The challenge with this modified pathway (Scheme 10) was the purification of this 
polar free acid through two consecutive steps. The product was collected in a pure form as 
confirmed with NMR (Figure 47) and mass data. 
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Figure 47. 1H-NMR spectra (cutted section for the surrounded part of structure) comparison 
between the products of the 1st  (upper) and 2nd (lower) pathways in Scheme 10. 
Having the Bromo-coumarin carboxylic acid 304 in pure form, the next step was to couple it 
with a six-carbon atom linker. This six-carbon atom linker should be linked via an amide bond 
between the coumarin carboxylic acid and the amino group of 6-aminohexanoic acid 6-AHA. 
The carboxylic group of 6-AHA is challenging for such a coupling, but it is required for the 
final coupling with the FRET acceptor carrying intermediate. To achieve this reaction and get 
a good yield/ purity balance we tried several pathways according to Scheme 11. 
In the first trial (a &b in Scheme 11), the acid 304 was activated in situ using 
Hydroxybenzotriazole (HOBt)  and coupled directly with the methyl ester of 6-aminohexanoic 
acid in presence of EDC.HCl. The intermediate compound 306 was produced after 24 hours 
reaction time and column purification in a yield of 30%. This yield is relatively low taking into 
consideration the next methyl ester hydrolysis step. This ester alkaline hydrolysis was achieved 
using lithium hydroxide and provided the target free acid 307 in a 30% yield after column 
chromatography purification. 
Results and Discussion    





Scheme 11. Different pathways for the synthesis of the target compound 307. a) Methyl 6-
aminohaxanoate, dry DCM , EDC.HCl , HOBt, RT, 24h, 30%; b) dry THF, LiOH (in H2O), rt, 
3 h, 30%; c) DMAP, NHS, EDC , dry DCM,0°C then RT, 22h, isolated and used without 
purification; d) 6AHA, dry DCM, DIPEA, 0°C then RT, 22h, 45%; e) Thionyl chloride, 2h, 
NaHCO3 in t-BuOH, 2h, 75%; f) 308, dry DCM, EDC.HCl, HOBt, RT, 20h, 75%; g) TFA, dry 
DCM, RT, 3h, 80 %. 
Due to the low yield of the first pathway, we shifted to another pathway (c&d in Scheme 11) 
where the acid 304 was activated using N-Hydroxysuccinimide (NHS) in the presence of 
DMAP and EDC. The complete conversion of the acid to the active ester was confirmed by 
TLC and UPLC-MS. Then the active ester was extracted and dried to be used directly for 
coupling without further purification. Coupling of this active ester with 6AHA in the presence 
of DIPEA revealed the target product 307 after 22 hours reaction in 45% yield over the two 
steps. So, in this alternative pathway, an increase of 36% in yield was accomplished through 
minimizing the purification steps from two columns to only one and avoiding the alkaline ester 
hydrolysis step. 
The purification of the final free acid 307 through column chromatography is the major yield-
reducing step. So, we thought about another pathway in which the final free acid 307 can be 
obtained in a pure form without the need to column chromatography. This can be achieved by 
the coupling with the t- butyl ester of the aminohexanoic acid which can be easily cleaved later 
by trifluoracetic acid. To apply this pathway, the t-butyl ester of 6-aminohexanoic acid was 
synthesized as reported212 by esterification of 6-aminohexanoic with t-butyl alcohol to get the 
ester 308 in 75% yield.  
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Then the ester was coupled to the free acid 304 after in situ activation to get 309 in 75% yield. 
Finally, the t-butyl ester of  309 was hydrolyzed using trifluoracetic acid TFA providing a 60% 
yield of the pure product 307 over the two steps after simple evaporation of the solvent without 
the need to further purification. This product 307 was then activated using N-
hydroxysuccinimide EDC.HCl to get the active ester 310 ready for the final coupling. 
3.2.4   Synthesis of 7-methoxy-coumarin-3-carboxylic acid  
A more economically affordable synthesis of the coumarin fluorophore of the previously 
synthesized probe 121 was targeted for a larger scale synthesis to be used for the high throughput 
screening study. In this project, the commercially available previously used 7-methoxy-
coumarin-3-carboxylic active ester 313 was synthesized starting from commercially available 
cheap starting materials (Scheme 12). Formylation of 3-methoxyphenol was achieved 
selectively at the ortho position of the hydroxy group through the electrophilic aromatic 
substitution reaction using paraformaldehyde in the presence of magnesium chloride and 
triethyl amine as a base. The 4-methoxysalicylaldehyde 311 was obtained in a 98.5 % yield 
which is comparable to the reported yields213,214. 
 
Scheme 12. Synthesis of  7-methoxy-coumarin-3-carboxylic acid based fluorophore. a) MgCl2, 
dry THF, Et3N, Parafomaldehyde, Reflux, 12h, 98.5%; b) Meldrum’s acid, Dist. H2O, NaN3, 
rt, 1h, quantitative yield; c) N-hydroxysuccinimide, dry DMF, 0°C, 1 h, DCC, RT , 2.5 h, 56%; 
d) 6-aminohexanoic acid, dry DMF, DIPEA, rt, 12h, 90%; e) dry DCM, DMAP, N-
hydroxysuccinimide, EDC, RT,12h, used without purification.  
7-Methoxycoumarin-3-carboxylic Acid 312 was then synthesized through Knoevenagel 
condensation and intramolecular cyclization of 4-methoxysalicylaldehyde 311 with Meldrum’s 
acid using sodium azide as a catalyst.  
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This reported method is highly advantageous concerning costs, environmental hazards, ease of 
handle, and efficient also for the large-scale synthesis without the use of toxic solvents and 
tedious column chromatographic purification215. 7-methoxy-coumarin-3-carboxylic active 
ester 313 was obtained in a moderate yield using N-hydroxysuccinimide and DCC according 
to the reported method216. This active ester was then coupled with 6-aminohexanoic acid in the 
presence of DIPEA to get the product 314 in a 90% yield. The coumarin labeled hexanoic acid 
314 was then activated using the N-hydroxysuccinimide and EDC and the active ester 315 was 
isolated and used for the next coupling without further purification. 
3.2.5   Synthesis of the NBD derivatives fluorophores 
For the preparation of the 2P excitable FRET probe, NBD-Cl will be directly coupled with the 
free primary amino group of the phosphodiester sphingomyelin analogue 212 as will be 
discussed in the next steps. For a quaternary ammonium group-containing FRET probes, 
different NBD dye derivatives were prepared as presented in Scheme 13. Our starting goal was 
to synthesize the NBD derivative 316 with the terminal N, N dimethyl group to be used directly 
instead of N, N-Dimethylpropargylamine in Scheme 8. The product 316 was synthesized by 
treating NBD-Cl with N, N-dimethyl ethyl-1,2-diamine under basic condition according to the 
reported procedures217.  
For the azide/alkyne click reaction-based coupling, two different NBD azido derivatives were 
synthesized. The first simple NBD-N3 317 was simply synthesized through the reaction of 
NBD-Cl with sodium azide in a H2O/acetone medium. The product isolated in a highly pure 
good yield comparable to the reported yield218. 
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Scheme 13. Preparation of different NBD based fluorophores. a) NaHCO3, MeCN,   60°C,15 
min, 64%; b) NaN3, H2O/acetone (1:1), RT, 15 min. , 90%; c) NaN3, H2O, 75°C, 12h, 42%; d) 
2-bromoethylamine.HBr, Dry EtOH, 70 °C, 4h, 70%; e) NaN3, DMF, 80 °C for 4 h then RT 
for 15h, 93%. 
The second NBD azido derivative 320 containing a two-carbon linker between the NBD and 
the azide group. It was suggested as an alternative for the NBD-N3 317 in an attempt to exclude 
any possible steric hindrance based unreactivity during the azide/alkyne click reaction. The 
first suggested pathway for the synthesis of 320 was through the preparation of 2-
azidoethanamine 318 from 2-bromoethanamine followed by its coupling with NBD-Cl under 
basic conditions. Due to the extraction challenge and the low yield of 318 and also the reported 
low yield of the next coupling reaction with NBD-Cl219, another pathway220 was selected in 
which NBD-Cl was substituted with 2-bromoethylamine to get the intermediate 319 in a good 
yield which then was reacted with sodium azide to give the target compound 320 in a 93% 
yield. 
3.2.7   Synthesis of the visible light range fluorophores 
For the visible light range excitable FRET probe a Fluorescein /Nile red dye pair was suggested 
according to the excitation/emission wavelengths data. For the azide/alkyne click reaction-
based coupling, a Fluorescein derivative functionalized with an azido group 321 was 
synthesized according to the reported method221.  
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The Fluorescein was converted in situ to the N-hydroxysuccinimidyl (NHS) active ester and 
then coupled with the 2-azidoethanamine 318 to get the N-(2-azidoethyl)-5(6)-fluorescein-
carboxamide 321 in 80%yield (Scheme 14). 
 
Scheme 14. Synthesis of  N-(2-azidoethyl)-5(6)-fluorescein-carboxoamide. a) Et3N, TSTU, 
DMSO, RT, 12h, 80%. 
The previously synthesized Nile red (NR) labeled hexane acid 121 was activated to N-
hydroxysuccinimidyl (NHS) ester derivative 322  (Scheme 15) and used directly for the next 
coupling.  
 
Scheme 15 Synthesis of Nile red labeled Hexanoic acid active ester. a) HOSu, DMAP, EDC, 
dry DCM, 0°C then RT, 4.5h, used without purification. 
3.2.8   Coupling of the fluorescent dyes 
The last stage of our synthetic pathway was the coupling of the previously synthesized dyes 
with the sphingomyelin analogues 212 and 214 to get the target final FRET probes 
3.2.8.1   FRET probes with secondary amino group  
The acceptor dye NBD was coupled to the phosphoryl choline part of the sphingomyelin 
analogue 212 according to the reported methods under basic conditions to get the NBD-labeled 
intermediate 401 in 85% yield according to Scheme 16. For the final coupling of the different 
FRET donor coumarin dyes, both the MOM-protected hydroxyl group and the Boc-protected 
amino group were deprotected using concentrated hydrochloric acid.  
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The active esters 310, 315, and Lauric acid N-hydroxysuccinimide ester could be then coupled 
to the free amino group of 402 under basic condition giving the target final FRET probes ZP-
403 and TP-366 and the NBD-labeled SM analogue TP-367  respectively in reasonable yields.  
 
 Scheme 16. Coupling of the fluorescent dyes and synthesis of the final FRET Probes. a) NBD-
Cl, DIPEA, MeOH/CHCl3 (1:3), RT, 4 h, 85%; b) 4 M HCl (in 1,4-dioxan), MeOH, 70°C, 2 h, 
Used directly without further purification;  c) dry DIPEA,  dry DCM, 310, 315 or Lauric acid 
N-hydroxysuccinimide ester, RT, 24 h, 39%, 24%, and 45% respectively.  
3.2.8.2   FRET probes with a quaternary ammonium group 
Our primary strategy concerning this generation of ASM FRET probes was to keep it as similar 
as possible to the natural substrate. We started our trials of coupling using the N, N 
dimethylamino-functionalized NBD derivative 316 directly to nucleophilically open the five-
membered phosphate triester ring of the intermediate 213. The proposed product is the NBD 
Labeled intermediate 404 with only the dye labeling modification compared to the natural 
substrate (Scheme 17). Unfortunately, this reaction did not work even after different 
optimization trials like Time, Temperature, molar ratios, or catalyst 222 modifications. This 
inactivity is probably due to the increased steric bulk of nucleophile 316 as reported for similar 
reactions200.  
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Scheme 17. Direct coupling trial of NBD for higher substrate similarity. 
The next trial was to couple the FRET donor dye NBD through azide/alkyne click reaction 
between the azido functionalized NBD and the terminal alkyne functionalized intermediate 
214. For a minimized modification from the natural substrate, a direct azido functionalized 
NBD 317 was used for the click reaction with the alkyne intermediate 214 (Scheme 18). The 
reaction did not work even after different optimization trials regarding the solvent, reaction 
time, and molar ratios. Using the  Cu(I) stabilizer Tris[(1-benzyl-1H-1,2,3-triazol-4-
yl)methyl]amine TBTA  for stabilizing the catalytic Cu(I) towards disproportionation and 
oxidation thus enhancing its catalytic effect in the azide-acetylene cycloaddition223 made, 
unfortunately, no difference. Although it did not work with us, conversion of the azide 317 to 
triazoles is already reported but luckily this conversion caused a significant quenching effect 
upon triazole formation224.  
 
Scheme 18. Coupling of NBD through azide/alkyne click reactions; Reagents : t-BuOH/H2O 
(4:1), sodium ascorbate & CuSO4.5H2O, RT, 48h. 
The azide/alkyne click reaction was then repeated using a new azido functionalized NBD 320 
in which the azido group was separated from the NBD nucleus through a 2 carbon linker. In 
our first trials of this pathway, the primary challenge was the purity of the alkyne 214.  
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The primary trials before getting the alkyne 214 completely pure revealed the rapid formation 
of a side product on behave of the target compound 406. Investigation of the mass and NMR 
data of this side product (Figure 48) reveals the click reaction product between the azide 320 
and the N, N-Dimethylpropargylamine which was used in excess in the previous step and was 
not completely removed through the initial purification trials of 214.  
 
 
Figure 48. Structure, mass and 1H-NMR spectrum of the click reaction side product. 
 
After the complete removal of the N, N-Dimethylpropargylamine traces, and repeating the 
click reaction between the azide 320 and the pure alkyne 214, the target triazole 406 could be 
isolated in an  83% yield. The amino and hydroxyl group of   This NBD labeled intermediate 
406 were then deprotected using concentrated hydrochloric acid and finally coupled with the 
coumarin labeled hexanoic acid active ester 315 to give the target FRET probe ZQP-407 in 
30% yield (Scheme 19). 
 
Scheme 19 Synthesis of the final FRET probe ZQP-407. a) 4 M HCl (in 1,4-dioxan), MeOH, 
70°C, 2 h, Used directly without further purification;  b) dry DIPEA,  dry DCM, 315, RT, 48 
h, 30%. 
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3.2.8.3   FRET probes with a quaternary ammonium group and visible light range dyes 
The alkyne functionality of the sphingomyelin analogue 214 serves as a tool for the 
introduction of a wide range of fluorophores or other labeling agents with aqueous phase click 
chemistry. So, we decided to extend our scope of the quaternary ammonium center containing 
probes  to involve a visible light range dyes for either a FRET or simply mono-labeled probes 
(Scheme 20). Encouraged by the interesting results of our fluorescein containing FRET probe 
125, we decided to include it in our target FRET probe aiming to combine the advantages of 
both higher substrate similarity and the cell-friendly visible light excitation ranges. 
Using the established click reaction conditions, we managed to label our sphingomyelin 
analogue 214 with fluorescein and got the triazole intermediate 408 in a 54% yield. For the 
final coupling of the FRET acceptor dye Nile red or the fatty acid only, the intermediate 408 
was deprotected using concentrated Hydrochloric acid and the free amino group was then 
coupled with the active ester of either Nile red -labeled hexanoic acid 322 or the Lauric acid to 
get the final FRET probe ZQ2P-410 or the fluorescein -mono labeled probe ZQ3P-411.  
 
Scheme 20. Synthesis of the Final FRET and mono labeled quaternary probes with Visible 
light  range chromophores. a) DMSO/H2O (3:1), sodium ascorbate & CuSO4.5H2O, RT, 48h, 
54%; b)  4 M HCl (in 1,4-dioxan), MeOH, 70°C, 3 h, Used directly without further purification; 
c) dry DIPEA, 322 or Lauric acid N-hydroxysuccinimide ester,  dry DCM, RT, 72 h or 12h, 
69% or 68% respectively. 
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3.2.8.4   Synthesis of the reference coumarin labeled ceramide analogue  
For the comparative analytical purposes, the acid sphingomyelinase cleavage product of the 
FRET probe ZP-403 was synthesized. This coumarin labeled ceramide analogue 413 was 
obtained starting from the previously synthesized protected sphingosine analogue 208 
according to Scheme 21. After deprotection of the secondary hydroxyl and amino group, the 
active ester of the Bromo coumarin labeled hexanoic acid 310 was coupled with the free amino 




Scheme 21. Synthesis of the coumarin labeled ceramide analogue 413. a)  4 M HCl (in 1,4-
dioxan), MeOH, 70°C, 2 h, Used directly without further purification; b) dry DIPEA, 310, dry 
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3.2.9   Fluorescence spectrophotometric characterization 
3.2.9.1   Characterization of the FRET probe ZP-403 
A FRET probe containing the bromo-coumarin derivative as donor was reported but with 
another acceptor dye171. And a coumarin/NBD FRET system was also reported by our group121 
but with a non-brominated coumarin derivative. So the fluorescence characters of the probe 
ZP-403 with the new coumarin derivative were studied to check the formation of a FRET 
system between the new dye pair NBD and bromo-coumarin combination within the new 
molecule setup (Figure 49).  
 
Figure 49. Fluorescence Emission spectrum for the probe ZP-403 before and after the 
incubation with ASM (0.2 µg/ml) and the emission spectrum of the reference ceramide 
derivative probe 413; Probes concentration= 1µM, ASM buffer, Ex :347 nm, t incubation=17 h. 
Excitation of  the ZP-403 Bromo-coumarin dye at 347 nm wavelength resulted in a main strong 
NBD emission peak at about 536 nm and only a very tiny residual of the coumarin emission at 
430 nm. This means that a FRET system formed between the new bromo-coumarin dye as a 
donor and NBD as an acceptor. This FRET system resulted in a nearly complete transfer of the 
donor dye emission energy to the acceptor dye. 
The next character to be studied was the cleavage of the FRET probe ZP-403 with ASM. 
Enzymatic cleavage is a critical step for the enzymatic assays using artificial substrates because 
the modifications of the natural substrate can lead to either lower recognition or may be a 
complete unrecognized substrate.  
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In our case, although similar FRET probes for the ASM were already reported with similar dye 
pairs, this cannot be a guarantee for the recognition of the new FRET probe by the enzyme 
because some minor structural differences can lead to major enzymatic binding differences. 
Incubation of the new probe with the recombinant enzyme under the established condition 
overnight has revealed a fluorescence intensity change in the form of decreasing fluorescence 
intensity of the FRET acceptor emission peak by about two thirds and increasing the FRET 
donor emission peak by about 10-folds (Figure S 5). This pattern of fluorescence intensity 
change means that the FRET system was destroyed by the enzyme under these conditions and 
thus the new FRET probe ZP-403 is a substrate for the ASM enzyme.  
 
Scheme 22. Enzymatic cleavage of the ZP-403 FRET probe by ASM. 
For more confirmation of the enzymatic cleavage, the fluorescence of the  synthesized cleavage 
product 413 (Scheme 22) was studied under the same condition in order to be used as a 
reference. The newly growing peak through the enzymatic cleavage showed the same maxima 
as the reference cleavage product (Figure 49). 
The real-time enzymatic cleavage in terms of fluorescence change was studied using both the 
specific wavelengths measuring kinetic tool and the full scanning at different time points. Both 
showed a time-dependent change with most of the intensity change in the first two hours as in  
Figure 50. From this kinetic study also, it was reconfirmed that the fluorescence intensity 
change of the donor coumarin dye was higher than that of the acceptor NBD dye. As the 
emission of the new coumarin dye is red-shifted by about 25 nm, better overlap between both 
dyes could be achieved. The lower fluorescence change of the NBD compared to the previously 
reported probe could be explained by this close overlapping in which the increased 
fluorescence of the closely neighboring coumarin peak counteracts the fluorescence decrease 
of NBD.  
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Figure 50. Real time fluorescence intensity changes during the enzymatic reaction; left: 
Intensities at selected wavelengths; right: full spectrum after addition of ASM (0.2 µg/ml) . 
Probe concentration= 1µM, ASM buffer. 
This study also showed the stability of the probe ZP-403 over the time course of the 
experiment. The control experiment in which the probe was incubated in the reaction buffer 
without enzyme showed no change over time. This stability against fluorescence quenching 
excludes the interference with the fluorescence change resulted from the enzymatic cleavage 
and also excludes the concerns regarding the stability of the acetal group of the new coumarin 
in this acidic pH225. 
After the primary characterization of the FRET probe ZP-403 and the confirmation of the 
presence of a FRET system and cleavability by the acid sphingomyelinase, the probe was then 
tested in a more complex environment than the pure recombinant enzyme. For this purpose, a 
Hela cell lysate was used instead of the recombinant enzyme (Figure 51). In the trial where 
the pH was adjusted to 5 (pH optima for the ASM), a significant cleavage was noticed as 
compared to the control experiment with the probe only. While in another trial under a pH 
value of 7 (the pH optima for the neutral sphingomyelinase) no cleavage was detected even 
after a longer time than the presented in Figure 51.  
Full scanning comparison before and after the incubation time revealed also the same results 
with a slight decrease in fluorescence intensity of the FRET peak at 536nm at pH7 which is not 
related to the enzymatic activity when we take in consideration the stability of the FRET donor 
peak at 430nm. From this experiment we could conclude that the probe ZP-403  can be used 
in a complex cellular media and it is specific for the acidic range sphingomyelinase enzyme. 
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Figure 51. FRET probe ZP-403 cleavage using cell lysates at different pH values. Left: kinetic 
study, Ex_347, Em_430, ASM buffer, Inor= I/I0; Right: full spectrum scanning after incubation, 
Ex_347. Probe concentration= 1µM.                                                         
For a further check of the probe selectivity,  another experiment using both ASM knocked out   
MEF cell lysate and recombinant nSMase2 enzyme. The fluorescence intensities at 536nm 
could be presented in Figure 52.  Neither with the ASM knocked out lysate nor with the 
recombinant nSMase 2, a cleavage was detected. Under the same experiment condition, a 
parallel experiment with ASM revealed a significant fluorescence intensity decrease as a result 
of the probe cleavage. 
 
Figure 52. FRET probe ZP-403 cleavage study using ASM Ko MEF lysate and recombinant 
nSMase 2; Ex_347, Em_536, ASM buffer, Inor= I/I0, Probe concentration= 1µM, Concentration 
of ASM (0.2 µg/ml). 
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At this stage, the probe ZP-403 was confirmed as a FRET probe which can be cleaved 
selectively with the acid sphingomyelinase in both recombinant and lysate form in a real time  
manner and this cleavage can be monitored through either the donor , acceptor or both 
fluorescence channels. 
3.2.9.2   Detection of ASM inhibitors using ZP-403 
Enzymes are superior targets for drug discovery research not only because their catalysis is 
essential for all life processes and are commonly modified in various disease states but also, 
the geometry and chemistry of the enzymes’ binding sites are highly well-suited for interactions 
with small, drug-like molecules226. The same attention is paid to the ASM enzyme due to the 
lack of selective, potent, and drug-like inhibitors for it227. 
As the development of new analytical tools is a key route toward the discovery and 
optimization of enzyme inhibitors, our main target during the development of ASM FRET 
probes was to use them for screening for inhibitors. The ability of ZP-403 to detect the 
inhibitors of ASM was primarily studied using a reported phosphoinositide inhibitor121.  
 In the experiment with the ASM inhibitor, a significant decrease was observed in the 
fluorescence change rate compared to the experiment without the inhibitor (Figure 53). This 
means that our setup is suitable for the detection of the inhibitory actions on the enzyme. 
 
Figure 53. The effect of ASM inhibitor on the fluorescence change of ZP-403 during the 
enzymatic cleavage; left: kinetic study, Ex_347, Em_430; Right: full spectrum scanning, 
Ex_347;  ASM buffer, Probe concentration= 1µM, Concentration of ASM (0.2 µg/ml), 
Inhibitor= ASM inhibitor 1‐O‐hexadecylsulfonyl‐myo‐inositol‐3,5‐bisphosphate (500nM). 
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To check the ability of the assay to differentiate between different inhibitor concentrations, a 
new experiment was done where different inhibitor concentrations were tested in parallel 
(Figure 54).    
     
Figure 54. Effect of different inhibitor concentrations on the FRET probe ZP-403 cleavage by 
ASM; Left : kinetic study, Ex_347, Em_430; Right: kinetic study, Ex_347, Em_536. ASM 
buffer, Probe concentration= 1µM, Concentration of ASM (0.2 µg/ml),  Inhibitor= ASM 
inhibitor 1‐O‐hexadecylsulfonyl‐myo‐inositol‐3,5‐bisphosphate. 
In both FRET donor and acceptor channels the action of a 20 nM to 500 nM inhibitor 
concentration range could be detected and differentiated. These results mean that the probe ZP-
403 is a promising screening tool for ASM inhibitors with flexibility regarding the available 
wavelengths filters. Based on the previous results, the effect of the inhibitor was also tested 
using Hella cell lysate instead of the recombinant enzyme as in Figure 55. The assay under 
these conditions was also able to significantly detect the effect of the inhibitor on the activity 
of ASM. 
    
Figure 55. Testing the inhibitory action on ASM in cell lysate mixture; Left: kinetic study, 
Ex_347, Em_430; Right: full spectrum scanning, Ex_347;  ASM buffer, Probe concentration 
= 1µM, Inhibitor = ASM inhibitor: 1‐O‐hexadecylsulfonyl‐myo‐inositol‐3,5‐bisphosphate 
(100nM). 
Results and Discussion    




As the level of an enzyme activity is a critical factor concerning its biological functions and 
the related pathological conditions, the developments of efficient assays for monitoring this 
level/activity is of high need in both diagnostic and drug discovery research areas. Our enzyme 
of interest acid sphingomyelinase is involved in the regulation of cell fate and signaling via 
hydrolysis of sphingomyelin to form ceramide. The increased activity of the lysosomal form 
has been associated with various pathological conditions228 while the severe deficiency in 
sphingomyelinase activity in tissues causes NPD types A and B229. 
Because of the importance of ASM level monitoring, the FRET probe ZP-403 was then used 
to monitor the effect of different ASM concentrations. Using our established setup with these 
different enzyme concentrations revealed different fluorescence change rates which could be 
also monitored through both FRET probe donor and acceptor channels (Figure 56).   
 
 
Figure 56.  Effect of different ASM concentrations on the cleavage rate of the FRET probe 
ZP-403; Left:  kinetic study, Ex_347, Em_430; Right: kinetic study, Ex_347, Em_536. ASM 
buffer, Probe concentration= 1µM. 
With the lowest concentration (0.002µg/ml) used from ASM, a very slight change was 
observed over the experiment time (270 min.). While with the highest concentration used 
(2µg/ml), the reaction plateau was achieved in about 30 minutes. The two other used 
concentrations showed also a concentration-dependent cleavage rate as demonstrated with the 
fluorescence intensity change for both the coumarin donor dye (430 nm) and NBD acceptor 
dye (536nm).  
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3.2.9.3   Two-photon excitation fluorescence microscopy study 
The main target of the ZP-403 probe design and synthesis was to improve the 2P excitability 
through the newly included bromo-coumarin derivative. So after the synthesis and the primary 
characterization, the next step was to practically evaluate the effect of this modification on the 
2P excitability compared to the old version coumarin containing probe TP-366. This 
comparative study was accomplished using a Two-photon excitation fluorescence microscopy 
which will be most probably the future analytical instrument for any live cell application 
studies. 
For this purpose the two FRET probes were loaded on silica gel beads through mixing the 
probe containing freshly prepared liposomes in a 1:1 ratio with defatted Silica Gel 60M (0.04-
0.063 mm) 10mg/ml and then the incubation for 1 hour at room temperature. Afterward, the 
beads were separated from the unbound liposomes by standing for 20 minutes then 
centrifugation for 2 min. The beads were washed with  PBS (0.5 x) two times and resuspended 
in the same amount of  PBS (0.5 x) buffer as the 1:1 mixture of liposomes and beads. The 
resuspended beads were stored at 4°C.  
 
Figure 57. Primary fluorescence microscopy visualization of the FRET probes labeled silica 
beads ZP-403 (left) and TP-366 (right).NBD excitation/emission filter. 
The FRET probes labeled beads act as a cellular lipid membrane but without any enzymatic 
activity which is important for our comparative study to exclude any cellular uptake or 
enzymatic cleavage rate differences. The primary visualization of the FRET probes labeled 
beads through the NBD excitation and emission using epifluorescence microscope (Figure 57) 
showed enough bead coating with a good resolution.  
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All microscopy images and quantifications in the next chapter have been recorded by Dr. 
Cosima Rhein, University of Erlangen. In the first 2P excitability experiment, the silica beads 
coated with ZP-403 were excited at 720 nm which is the 2P excitation wavelength for the 
bromo-coumarin FRET donor dye (1P excitation ~350 nm). At this wavelength, the beads 
could be sufficiently excited and revealed the emission fluorescence of the intact FRET probe 
which could be also got through the direct excitation of the NBD dye. The 2P excitability of 
the FRET probe was proven by merging both the coumarin 2P excitation results with that of 
the direct NBD excitation which were identical (Figure 58). 
                     
 
Figure 58. Fluorescence microscopy graphs of  the lipid beads coated with ZP-403 labeled 
liposomes. from left to right: Coumarin after two-photon excitation 720nm, NBD after two-
photon excitation at 870 nm and the merge of both graphs. The white bar corresponds to 10 
μm. 
From this experiment we could conclude that the new bromo-coumarin dye can be excited 
using 2P excitation wavelengths and the FRET system can be also detected under this setup 
using those static platform beads. In the next step, the FRET probe ZP-403 was applied as  
BSA-complex to Human H4 neuroglioma cells overexpressing ASM for 2 hours at a final 
concentration of 1 µM and then the cells were studied microscopically. Two-photon excitation 
of the bromo-coumarin at 720 nm resulted in the detection of the uncleaved probe that indicates 
sphingomyelin. Direct excitation of NBD revealed also the same emission fluorescence of the 
intact probe and this was further confirmed by merging both shots (Figure 59).  
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Figure 59. FRET substrate ZP-403 in Human H4 neuroglioma cells. from left to right: 
Coumarin after two-photon excitation 720nm, NBD after two-photon excitation at 870 nm and 
the merge of both graphs. 
From this experiment the cellular uptake of the FRET probe ZP-403 as a BSA-complex could 
be confirmed. Also, the 2P excitation of the new coumarin and the detection of the FRET 
emission fluorescence in live cells was confirmed. As the target of the new probe, ZP-403 was 
to improve the 2P excitability compared to the first generation probe TP-366 for a more live-
cell studies suitability, we tried to check the impact of the expected difference between the two 
probes directly in cells in terms of ease of detect, brightness or low beam energy needs. The 
idea was to excite the cells which were previously incubated with the probes with different 
laser powers and check if the expected difference in the 2P excitability will be able to 
compensate the laser power difference or not (Figure 60).   
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Figure 60. Direct comparison of the 2P excitability of ZP-403 and TP-366 FRET probes in 
live cells using different laser powers. OE: Human H4 neuroglioma cells overexpressing ASM; 
Control: Human H4 neuroglioma cells; FRET probes applied as BSA-complex for 2h before 
imaging.   
Assuming a significant difference between the probes, ZP-403 was excited using half of the 
laser power 10 used for TP-366. Under this setup the FRET probe ZP-403 couldn’t be detected 
at all compared to TP-366 as presented in the upper part of Figure 60. To exclude the effect 
of the ASM overexpression in the tested cells, the experiment was repeated using normal  
Human H4 neuroglioma cells. The same results were obtained which excluded our assumption 
of 2P excitability improvement in the >2 fold range. 
For a precise quantification of the difference between the two FRET probes TP-366 and ZP-
403, a new beads model was prepared in which the beads were coated with liposomes 
containing 1:1 mixture of the FRET probe and its coumarin containing cleavage product. The 
selection of the beads and not the cells was to exclude any uptake variations in case of using 
live cells. The use of a mixture of the intact FRET probe and its cleavage product is to get a 
cleavage-mimicking setup. In this setup, we can measure the direct coumarin emission (which 
is mainly quenched in the FRET system) for the free cleavage product in the presence of the 
intact probe. 
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The beads were excited with three different laser powers (3,5,10) and pixel intensities were 
measured for both FRET emissions (350 nm (2P) >> 560 nm and 350 nm (2P) >> 420 nm) and 
the direct NBD (480 nm >> 560 nm) which should be the same for both probes and can be used 
as an internal standard for normalization. Three shots were taken for each laser power and from 
each picture 3 beads were analyzed. Comparing the FRET NBD intensities (350 nm (2P) >> 
560 nm) normalized to the direct NBD of both probes at the different laser powers did not 
reveal any significant difference between them (Figure 61).  
 
Figure 61. Comparative study between the FRET probes ZP-403 and TP-366 using the 
emission of direct NBD excitation as internal standard for normalization. FRET emission: 
Ex_350 nm (2P) >> 560; NBD emission : Ex_480 nm >> 560 nm).   
In an actual cell experiment, the progress of the coumarin signal would be followed as a 
monitor for the cleavage of the probe. In the next experiment, it was checked whether the ZP-
403 probe would be brighter or more intense in the coumarin channel.  Using the same setup 
of the previous experiment,  the coumarin signal (mainly of the cleaved probe portion) was 
measured and normalized to the direct NBD, which should be the same for both probes. 
Interestingly in this experiment a difference between the two beads could be detected and it is 
increasing with the increase of the laser power to reach about 20% difference at laser power 10 
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Figure 62. Comparison study between the beads containing 1:1 ratio ZP-403 to its cleavage 
product 413 with the beads of TP-366 and its cleavage product using the emission of direct 
NBD excitation as internal standard for normalization. Coumarin emission: Ex_350 nm (2P) 
>> 420 nm. 
With these results we concluded that the inclusion of the bromo-coumarin derivative in the 
FRET system for ASM can to an acceptable extent improve the 2P excitability and thus the 
brightness of the probe during the monitoring of the cleavage reaction. This improvement could 
be mainly noticed in the channel of coumarin emission which revealed also in the primary 
characterization experiments about 10-fold intensity change over the course of the reaction 
time.  
3.2.9.4   Live cells study of NBD-labeled SM analogue TP-367  
 
The probe TP-367 was reported by our group and primarily tested in vitro. It revealed a 
fluorescence turn off pattern upon cleavage with ASM. In this study the resynthesized probe 
was tested in vivo using the flow cytometry approach by Dr. Gita Naseri. To test the detection 
ability of this probe; regular HEK293 cells were treated with it and the fluorescence outputs 
were measured at different time points (Figure 63) . The cells treated with the probe TP-367 
for 16 hours showed significant lower green fluorescence (~ 3-fold) compared to cells pre-
treated with the ASM inhibitor ARC39. In contrast to the turn on FAM/BODIPY FRET 
probe125, TP-367 showed maximum fluorescence in its intact form, when ASM activity is low 
thus was confirmed as an in vivo turn off probe. With this results the probe was confirmed as 
an orthogonal probe and a unique ASM assay has been developed. This assay is fast and valid 
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We expect that HEK293 cells carrying mutated SMPD1 will behave like the inhibitor treated 
cells and a facile FACS mediated selection of these cells will thus be possible. 
 
Figure 63. ASM activity assay using the probe TP-367. The data was normalized to the 
fluorescence intensity of cells treated with DMSO. Data are geometric means ± SD of the 
fluorescence intensity obtained from three cultures, each derived from an independent HEK293 
culture and determined in three technical replicates. MFI: mean of fluorescence intensity. 
 
3.2.9.5   Characterization of the quaternary ammonium containing FRET probes  
The first quaternary ammonium group-containing FRET probe ZQP-407 was tested regarding 
the presence of a FRET system although the FRET dye pair is already tested and reported 121. 
As presented in Figure 64, the donor coumarin dye was excited and the emission was scanned 
over a wide range. A neglectable fluorescence was noticed at the emission wavelength of the 
coumarin while the main fluorescence intensity was detected at the emission maxima of the 
acceptor NBD dye. This means that the emission energy was successfully transferred to the 
NBD forming a FRET system with a high efficiency. The stability of the probe in the ASM 
reaction buffer was also studied. It revealed good stability regarding the fluorescence intensity 
after 18 hours of incubation. Thus, a stable FRET probe under the ASM reaction conditions 
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Figure 64. Fluorescence Emission spectrum for the probe ZQP-407 before and after the 
incubation with ASM (0.2 µg/ml); Probes concentration= 1µM, ASM buffer, Ex :347 nm, t 
incubation=18 h. 
Although the target of the design of the probe ZQP-407  was to achieve higher recognition 
through higher substrate similarity, there is still a possibility to be unrecognized and thus 
uncleavable by the enzyme due to the structural modification. Therefore, the recognition and 
cleavage of the probe with the ASM was studied. To figure this out, the probe was incubated 
with the recombinant ASM for 18 hours and the fluorescence behavior was compared with that 
before the addition of the enzyme (Figure 64). The FRET acceptor peak at ~ 536nm was 
significantly decreased while that of the donor emission was also significantly increased. This 
change means that the probe was hydrolyzed by the ASM and accordingly the FRET system 
pattern was cleaved. A time dependent change of both donor and acceptor dyes fluorescence 
with an obviously faster rate compared to the previously studied probes was observed (Figure 
65). Effect of different ASM concentrations on the cleavage rate of the FRET probe ZQP-407 
was also studied and the results are displayed in Figure S 6. 
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Figure 65. Real time fluorescence intensity changes during the enzymatic cleavage of ZQP-
407; ASM (0.2 µg/ml), Probe concentration= 1µM, ASM buffer, Ex :347 nm.  
The second probe ZQ2P-410 containing fluorescein as a donor and Nile red as an acceptor was 
also studied to check the presence of a FRET system and the cleavability with the ASM enzyme 
(Figure 66). Upon exciting the fluorescein, a main emission peak at 624 nm was detected 
which is the emission maxima for the acceptor dye Nile red. This mean that a FRET system 
was formed as expected from the spectral overlap of the dye pair. Then upon incubation of the 
probe with the ASM enzyme, a significant fluorescence intensity increase of the fluorescein 
dye was observed while only a minor decrease was observed with the fluorescence of the Nile 
red dye with the major change occurred at the first one hour as presented in Figure 66. This 
change of fluorescence intensities means that the FRET system can be cleaved by the ASM 
and the only minor change of the Nile red fluorescence can be explained through counteracting 
of the fluorescence decrease by the increasing fluorescence of the closely neighboring 
fluorescein peak as reported in previous probes121,122.  
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Figure 66. Left) Fluorescence Emission spectrum for the probe ZQ2P-410 before and after the 
incubation with ASM; Right) Real time fluorescence intensity changes during the enzymatic 
cleavage. ASM (0.2 µg/ml); Probes concentration= 1µM, ASM buffer, Ex :485 nm, t incubation=4 
h. 
The fluorescein mono-labeled probe ZQ3P-411 was also tested as new a substrate for the ASM 
enzyme and the fluorescence change was monitored over four hours (Figure 67). Due to the 
combination of both quaternary ammonium group and the mono-labelling, the cleavage rate is 
higher than that for the other probes and the plateau was reached after about one hour reaction 
time. About 3.6 fold fluorescence increase was detected revealing that the probe is a 
significantly rapidly cleaved turn on probe.   
 
Figure 67. Real time fluorescence intensity change during the enzymatic cleavage of ZQ3P-
411. ASM (0.2 µg/ml); Probes concentration= 1µM, ASM buffer, Ex :485 nm. 
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3.2.10   Kinetic parameters of the new fluorescent probes as substrates for ASM 
Detailed experiments for the determination of kinetic parameters of the newly synthesized 
probes as a substrate for ASM were carried out (Table 3). According to our driving hypothesis, 
we expected that the novel quaternary ammonium-containing probes would better mimic the 
natural sphingomyelin and thus should be better substrates for ASM. The substrate 
concentration needed for half-maximum catalytic velocity is the Michaelis constant KM and it 
represents the enzyme’s affinity to a given substrate. In contrast, the maximum catalytic 
velocity Vmax is a measure for the enzyme’s ability to cleave a given substrate, assumed that 
all the existing enzyme is saturated by the substrate. Thus, the ideal substrate should have low 
KM and high Vmax values
230. Evaluation of the kinetic parameters of the probes showed that all 
the quaternary probes have higher Vmax values than the non-quaternary ZP-403 while only the 
probe ZQP-407 has a lower KM value than ZP-403. Between the quaternary probes, ASM has 
the highest affinity to  ZQP-407 followed by the mono-labeled one ZQ3P-411. 
Code Structure Vmax KM Kcat kcat/KM 
ZP-403 
 
36,9 8 61,5 7,7 
ZQP-407 
 
74,6 7 373,0 53,3 
ZQ2P-410 
 
59,2 299,7 296,0 0,98 
ZQ3P-411 
 
161,3 22,6 806,5 35,7 
Table 3. kinetic parameters of the new fluorescent Probes as substrates for ASM. Vmax=μmol/ 
(mg. h), KM= μM, Kcat =Vmax/ [ASM], kcat/KM = specificity constant. For the determination of 
kinetic parameters, the substrate concentration was varied from 0.25 to 50 μM at fixed 
concentration of ASM enzyme under standard assay condition (pH 4.5). All the kinetic 
parameters are determined from the Lineweaver-Burk plots and each data point in the plot 
represents Mean from three independent experiments (Figure S 8-Figure S 23). 
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The FRET probe ZQ2P-410 showed the lowest affinity which can be attributed to the large 
size of the labelling dyes (Fluorescein and Nile red) and the longer linker chain length which 
is reported to influence the phosphorylation of sphingosine derivatives by sphingosine 
kinases230. These affinity diminishing factors could not be compensated be the presence of the 
quaternary center or the reported superiority of NR in lipid mediums and membranes231. 
To understand the comparative specificity of the different probes to ASM enzyme active site, 
the specificity constant, the ratio of Kcat to KM, was calculated. the specificity constants of all 
the quaternary probes except ZQ2P-410 were higher than ZP-403 for the hydrolysis by ASM. 
In an agreement with the KM values, ZQ2P-410 showed the lowest value for the specificity 
constant. The unexpected high Vmax value for the ZQ2P-410 can be explained at least in part as 
an inherent result of the fluorescein’s biophysical properties. The kinetic parameters of the 
probe ZQ3P-411-except the value of KM- are in accordance with our expectation as it is only 
mono-labelled in addition to the presence of the quaternary ammonium group which make the 
probe highly mimicking the natural substrate. 
From this study we can conclude that the inclusion of the quaternary centre has a positive 
impact on the recognition and cleavage rate of the probe with the ASM. But the overall 
comparison between the different probes revealed also that the final behaviour is a sum of 
different factors including the intrinsic dye’s characters. 
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3.2.11   Conclusion and outlook 
In the second part of this study, different FRET and mono-labelled ASM probes were designed 
and synthesized in addition to the re-synthesis of the previously reported probes (Figure 68). 
The first goal was to resynthesize the reported probes TP-366 and TP-367 for a high 
throughput screening and a Fluorescence activated cell sorting (FACS) studies. TP-366 was 
resynthesized in a higher scale using a self-prepared more affordable coumarin derivative from 
cheap starting materials. A new FRET probe with a better 2P-excitable coumarin derivative 
was also targeted and synthesized to make a use of the 2P excitation advantages in the 
monitoring of ASM in the biological samples.  
 
Figure 68. Structural elucidation of the ASM probes with a secondary amino group which 
were prepared in this study. 
The new coumarin moiety was synthesized in a high and pure yield after modification of the 
reported method and used for the synthesis of the probe ZP-403. This probe was confirmed as 
an ASM substrate with a 10-fold coumarin fluorescence intensity turnover and could be used 
for the detection of ASM inhibitors. The FRET probe ZP-403 was also confirmed to be a 
specific substrate for only the acid sphingomyelinase and not for the neutral phenotype. 2P-
Fluorescence microscopy study revealed enough cellular labelling and detection. The 
quantification of the 2P excitability difference using a static silica beads labelled with the probe 
showed about 20% enhancement of the coumarin intensity compared to that of TP-366 using 
the direct NBD emission intensity as an internal standard. 
Based on the known importance of the quaternary ammonium for the sphingomyelin 
recognition and cleavage by the sphingomyelinases, we also designed and synthesized a new 
generation of ASM probes containing a quaternary ammonium group which mimics the natural 
substrate (Figure 69). A phosphorylation strategy which allow the insertion of a quaternary 
ammonium in addition to a terminal alkyne group was applied.  
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The terminal alkyne functionality serves as a bioorthogonal handle for the introduction of a 
wide range of fluorophores or other labeling agents with aqueous phase chemistry. With this 
synthetic pathway we synthesized two FRET probes ZQP-407 and ZQ2P-410 which can be 
excited in the ultraviolet and visible light range respectively. Another fluorescein mono-
labelled probe ZQ3P-411 was also synthesized. All the three probes were proven as ASM 
substrates and revealed a varying kinetics parameters. All the new quaternary probes revealed 
higher turnover Kcat values compared to the probe ZP-403. Except ZQ2P-410, all the new 




Figure 69. Structure elucidation of the ASM probes with a quaternary ammonium group which 
were prepared in this study. 
According to the results of the current study, a sphingomyelin-mimicking FRET probe 
containing a quaternary center with a minimum structural deviation from the natural substrate 
would has the best kinetic characters. Applying a synthetic pathway which could allow the 
formation of a quaternary nitrogen with direct attachment to the FRET dye (Figure 70) would 
exclude the possible drawbacks of the extra triazole ring on the recognition and cleavage rate. 
Such a probe could be also recognized by the other sphingomyelinase phenotypes like n-
SMase2 and other comparable sphingomyelinases for which the available analytical tools are 
highly limited. 
 
Figure 70. Proposed Structure for a Future sphingomyelin-mimicking FRET probe. Donor and 
acceptor positions are exchangeable. 
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The in vivo studies are of high importance for addressing the undiscovered issues regarding the 
biology of the ASM in addition to the related pathological disorders. For these in vivo studies, 
the cellular uptake of the chemical probes is a critical factor. Several strategies are applied to 
improve the cellular uptake of the small molecules like the masking of the ionizable groups 
with easily in vivo cleavable protecting groups. Regarding our FRET probes, we hypothesize 
that the temporary masking of the phosphate negatively charged hydroxyl group with an 
enzymatically cleavable protecting group like the acetoxymethyl group (Figure 71) would 





Figure 71. Proposed acetoxymethyl protection of the phosphate hydroxyl group for cellular 
permeation enhancement. D: FRET donor, A: FRET acceptor.
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4   Experimental section 
4.1   General description of chemical reactions methods 
Unless otherwise specified, all reactions were carried out in oven-dried (>120 °C) glassware 
equipped with a magnetic stir bar and a rubber septum under a positive pressure of argon. Air- 
or moisture-sensitive reagents were transferred to the reaction vessel under positive pressure 
of argon via syringe or stainless steel cannula. Reactions were run at room temperature (20-25 
°C) unless otherwise noted in the experimental procedure and reported reaction temperatures 
refer to the external temperatures measured for the bath in which the reaction vessel was 
immersed. Heating was obtained through the use of a silicone oil bath. For reactions run below 
room temperature, the term “0°C” refers to an ice-water bath, “-20 °C” refers to a slurry of 
sodium chloride and ice-water bath and “-78°C” refers to a bath of acetone and dry ice. 
Intermediate temperatures were obtained by the careful addition of dry ice to an acetone bath 
at periodic intervals to maintain the desired temperature. “Concentration” refers to the removal 
of solvent using a rotary evaporator equipped with a vacuum pump. Removal of residual 
solvents was accomplished by evacuation of the container for a period of 10-20 hours using a 
high vacuum line. 
4.2   Reagents and solvents 
Unless otherwise specified, all the commercially available reagents were purchased from 
Sigma-Aldrich, Fluka, Acros or TCI and used without any further purification. Air and/or 
moisture sensitive reactions were carried out in well dried glassware under argon atmosphere 
with dry, freshly distilled solvents using standard syringe-cannula/septa techniques. All the 
solvents were used after distillation by standard methods. The petroleum ether used throughout 
this work had a boiling range of 40–60°C. All corresponding glassware was oven dried and/or 
carefully dried in the line with a flameless heat gun. Reaction progress was monitored with 
analytical normal-phase thin layer chromatography (NP TLC). All synthesized compounds 
were purified to homogeneity as judged by TLC analysis, mass spectrometry (MS) analysis 











4.3   Buffers & media 
Tris-HCl buffer:  (50 mM M Tris/HCl pH 7.4). 
Apyrase Storage buffer : 20 mM MES , 50 mM NaCl ,0.1 mM CaCl2 ,1 mM DTT ,0.1% 
Tween® 20 ,50% Glycerol ,pH 6.5 , 25°C. 
Apyrase Reaction buffer: (50 mM NaCl, 1 mM DTT, 0.05% Tween® 20, 20 mM MES,  
5 mM CaCl2 (pH 6.5). 
ASM buffer: 0.1 M NaOAc, pH 5.0, 150 mM NaCl, 0.1 mM ZnSO4, 0.1% TritonX-100. 
NSM buffer: 50 mM M Tris/HCl pH 7.4, 150 mM NaCl, 0.1% TritonX-100, 5 mM MgCl2. 
Lysis buffer: 0.2 M sucrose, protease inhibitor cocktail w/o EDTA. 
Elution buffer: 50 mM Tris/HCl pH 7.6, 1 M NaCl, 0.1 mM ZnCl2, 0.4% β-octyl 
glucopyranoside (w/v). 
Culture medium: DMEM, 10% FCS, 1% penicillin/streptomycin (Biochrom). 
4.4   Chromatography 
Thin-layer chromatography (TLC) was performed using silica gel 60 F254 (Merck (Darmstadt, 
Germany)) and the compounds were detected with UV light (254 nm/366 nm) and/or by 
spraying the plates with ninhydrin solution (3 w% in EtOH) or KMnO4 solution (2 g of KMnO4 
in 200ml 0.5% K2CO3 aqueous solution) followed by heating. 
Preparative TLC was performed on preparative silica gel 60 plates 20 cm x 20 cm with 
concentrating zone (Merck (Darmstadt, Germany)). After scraping off product bands, the silica 
was removed by extraction with the development solvent followed by 0.45 μm filtration. 
Binder was removed by dissolution of the product in pure MeOH and washing it twice with 
isooctane.  
Flash chromatography was performed manually using glass columns of different size packed 
with Silica Gel 60M (0.04-0.063 mm) as stationary phase. Solvent ratios for chromatography 
and Rf values are reported in v/v% ratios. Solvents were evaporated under reduced pressure 









4.5   Spectroscopic data 
4.5.1   Nuclear magnetic resonance spectroscopy 
NMR spectra (1H, 13C, APT and 31P) were recorded in CDCl3, CD3OD, CD3CN, D2O, 
(CD3)2CO, (CD3)4Si or mixtures of those on Bruker (Rheinstetten, Germany) Avance DPX- 
300, AvanceII-300, Avance400, AvanceIII-500 or Avance600 at 25°C. Chemical shifts are 
given in ppm with respect to TMS as external standard (1H, APT, 13C, δ = 0.00) with calibration 
against the residual solvent signal, internal TMS or 85% H3PO4 (
31P, δ = 0.00) as external 
standard. Compounds were measured as a solution in deuterated methanol (MeOD), deuterated 
chloroform (CDCl3) or deuterated water (D2O), unless otherwise indicated.  Peak multiplicities 
are designed by the following abbreviations: s = singlet; d= doublet; t = triplet; q = quartet; dd 
= doublet of doublets, ddd = doublet of doublet of doublets, dt = doublet of triplets, qd = quartet 
of doublets, m = multiplet; br = broad. The coupling constants (J) are quoted in hertz (Hz). The 
reported chemical shifts are tabulated in the following format: δ (ppm) (multiplicity, coupling 
constant (s), number of protons). The measurements were done by hand or by Mrs. A. Thiesies 
, Mrs. K. Pfaff, J. Hildebrandt or H. Steingräber. 
4.5.2   Mass spectroscopy (MS and HRMS) 
High-resolution mass spectroscopy (HRMS) experiments were recorded on a Hewlett-Packard 
GCMS 5995-A mass spectrometer equipped with standard electrospray ionization (ESI) in the 
positive and negative ion detection modes. The major observable molecular ion and clusters 
have been reported. 
4.5.3   UPLC−MS analyses 
UPLC was performed on a 1290 Infinity series system (Agilent Technologies, Santa Clara, US) 
using Zorbax RRHD C18 Eclipse Plus 2.1x50 mm, 1.8 Micron column, UV/Vis detector and 
either FLD or Agilent 6120 quadrupole LC/MS (ESI+/-). UPLC-MS was carried out using 
mixtures of solvent A (99.9% H2O + 0.1% FA) and B (99.9% MeOH + 0.1% FA) with gradient 










4.5.4   Absorption and fluorescence/luminescence spectroscopy  
Europium complexes: Absorption spectra for the europium complexes were recorded with a 
Specord 210 from Analytik Jena. Luminescence emission spectra (not corrected) and lifetime 
(decay) measurements were carried out in quartz cuvettes with a Edinburgh Instruments 
spectrofluorometer FSP-920 equipped with a µ-flash lamp 920H and a red extended 
photomultiplier tube (R2658P) from Hamamatsu. The delay time between subsequent 
measurement cycles was adjusted to 200 µs. The excitation pulse was 20 µs. 
Time-resolved luminescence intensities (delay time: 100 µs, integration time: 400 µs) in 
presence of anions were recorded with a Tecan Infinite F200 Pro microwell plate reader. The 
excitation wavelength was 345 nm, the detection wavelength 618 nm. All measurements were 
performed 2 min after addition of the anions in 96-microwell plates with transparent flat bottom 
from Greiner Bio One in three replicates. The final sample volume was 100 µL in each well, 
containing 50 µmol L-1 (unless otherwise specified) of the europium complexes and the 
corresponding concentration of anions in 25 mM Tris-HCl buffer (pH 7.4).  
FRET Probes: Fluorescence spectra were recorded with a Cary Eclipse spectrometer (Varian, 
Palo Alto, US) at a constant 37°C in 3 mL 1x1 cm quartz cuvettes. Unless otherwise specified, 
the slot widths were 5 nm and the scan rate 600 nm min -1. The optical density at the wavelength 
used was less than 0.05 in each experiment.  
The data obtained were corrected for background and volume, normalized and plotted using 
OriginLab OriginPro 9.1G software and Microsoft Excel (2007 &2010). 
4.6   Assay Protocols 
 
4.6.1   ASM/ nSMase 2 homogenous assay using Eu complex 
The ASM assay was carried out using Victor 1420 Multilabel counter from Wallac, Perkin–
Elmer Life and Analytical Sciences (Wellesley, MA). By diluting the required amount of 4-
D+/ 5-D+ in ASM / nSMase 2 buffer, to achieve the desired final concentrations. The sequence 
of reagents addition was 4-D+/ 5-D+ (10/5µM), SM (10/5µM) then waiting till reaching stable 
luminescence intensity. Finally, the ASM enzyme (2µgmL-1) / nSMase 2(30, 60 µgmL-1) was 
added to give a final volume of 100 µL per well. The measurement was started after 1 min at 
25°C. The mean intensities from three parallel runs are always displayed. 
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4.6.2   ASM heterogenous assay using 4-D+Eu complex 
After incubation of sphingomyelin (20 μl of 25 μM) with different concentration of ASM ( in 
80μl ASM buffer) at 37 °C for 1 h, the reaction was stopped by adding 1.5 ml of 
chloroform/methanol (1:1). Phases were separated by centrifugation at 2000 × g for 5 min. 
Quantitation of the amount of released phosphocholine was determined by adding 10 μl of the 
upper phase to 90 μl of 4-D+ complex (to give a final 5 μM concentration). The measurement 
was started after 1 min at 25°C. The mean intensities from three parallel runs are always 
displayed. 
4.6.3   Apyrase assay 
Apyrase (recombinant, E. coli) and apyrase reaction buffer were obtained from New England 
Biolabs (NEB). The apyrase assay was carried out using Victor 1420 Multilabel counter from 
Wallac, Perkin–Elmer Life and Analytical Sciences (Wellesley, MA) by diluting the required 
amount of 5-D+ and apyrase in TRIS or apyrase buffer, respectively, to achieve the desired 
final concentrations. The sequence of reagents addition was 5-D+ (50µM), ATP (50µM), 
followed by dilution with apyrase buffer. Finally, the apyrase enzyme was added to give a final 
volume of 100 µL per well. The measurement was started after 1 min at 25°C. The mean 
intensities from three parallel runs are always displayed. 
4.6.4   ASM fluorescence assay (cuvette) 
All spectra were recorded at 37°C with magnetic stirring, all slit widths were 5 nm, PMT 
voltage was 700 V, if not stated otherwise. ASM or NSM buffer (usually 2970 μL) was filled 
into quartz cuvettes (1x1 cm, 3 mL) and blank spectra were recorded. The FRET Probe  (0.5 
mM in DMSO, usually 6 μL giving final 1 μM) was added and initial static spectra were 
recorded. Then, recombinant human ASM from insect cells (usually 24 μL 0.0625μg/μL ASM 
in elution buffer) was added simultaneously to the cuvette(s), which were stoppered tightly and 
placed in a multicell holder. After 30 sec of preincubation, data points (depending on the 
maxima of the tested probe dyes) or complete spectra were recorded in time intervals. After 
reaction completion, final spectra were recorded and the reactions were stopped by addition of 
500 μL MeOH, optionally followed by lipid extraction using the Folch method232. If lysates 
were used, blanks and initial spectra were recorded with 9/10 of total reaction volume, before 
additional buffer and lysates (usually 35-100 μL) were added. Fluorescence data was corrected 
(time, blank, volume), normalized and plotted using OriginLab, OriginPro 9.1G, and Microsoft 
Excel (2007 &2010) software.  
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4.6.5   Fluorescence ASM assay (96 well plate) & Fluorescence  microscopy 
The assay was done in non-binding black clear-bottom 96-well microplate (greiner bio-one) 
using Victor 1420 Multilabel counter from Wallac, Perkin–Elmer Life and Analytical Sciences 
(Wellesley, MA). Recombinant ASM was also diluted using assay buffer to reach the desired 
concentration. The assay is done by adding 20 µl of the FRET probe solution and finally the 
addition of 80 µl of the recombinant enzyme solution. The plate is then sealed using transparent 
plastic cover. Measurements are done at room temperature. Fluorescence is measured from the 
bottom (measurement height: 8 mm) using the suitable excitation and emission filters with 
CW-lamp energy 3096. The device is also set to mix the contents of the assay by 5 mm orbital 
shaking for 1 seconds before each measurement.  
The BSA-complexed FRET probes  were added to the Human H4 neuroglioma cells media for 
2 h at a final concentration of 1μM. ASM overexpression increased ASM activity 5-fold over 
control as measured in a parallel experiment using thin layer chromatography. Cells were 
washed with PBS and live cell microscopy was performed on a Zeiss LSM 880 NLO equipped 
with a 680–1300 nm tunable and fixed 1040 nm 2-photon laser from Newport Spectra Physics 
and the ZEN 2010 software (Carl Zeiss MicroImaging). The same Microscopy set up was used 
for imaging the beads labeled with the probes containing liposomes 56. Liposomes were done 
by Dr. Housam Haj Hamdo and the microscopy imaging was done by Dr. Cosima Rhein. 
4.7   Preparation of recombinant ASM 
Human acid sphingomyelinase (ASM) was expressed in insect Sf9 cells and purified to 
homogeneity similar to method described by LANSMANN et al. 233. The recombinant enzyme 
purified in the presence of Zn2+ (0.1 mM) had an activity of 23 nmol h–1 ml-1 as determined in 











4.8   Cell culture 
Adherent HeLa cells, WT or ASM-KO-MEF cells were cultured in 25 cm 2 culture flasks in 
culture medium (see above, with phenol red) at 37 °C, 5% CO2. For cell splitting, the 
(confluent) cells were washed twice with PBS, covered with 500 μL trypsin / EDTA and 
trypsinized at 37 ° C for 3 min. The cells were knocked off the bottom of the dish and the 
trypsin was inactivated by addition of 2.5 ml of culture medium. The cells were uniformly 
suspended, 1/12 of the volume (250 μL) transferred to a new culture flask, filled with 6 mL of 
new culture medium and further incubated. For microscopy purposes, 1/12 of the cell 
suspension (250 μL) was transfered into 35 mm MatTek glass bottom dishes and completed to 
2 mL of imaging medium or 1/20 of the volume (150 μL) in ibidi μ-slides and the Volume 
completed to 230 μL. The sealed culture vessels were re-incubated. The work was done by 
Mrs. S. Diederich. 
4.9   Cell lysis 
In order to obtain cell lysates for cuvette assays, the content of two 75 cm2 culture flasks was 
washed with 2x PBS, trypsinized for 5 min and 5 mL DMEM with 10% FBS without phenol 
red was added. The cell suspensions were combined in a centrifuge tube and centrifuged with 
4000 rpm for 10 min at 4°C. The supernatant was removed and the pellet was resuspended in 
1 mL PBS. Centrifugation was repeated with 3000 rpm for 5 min at 4°C. The supernatant was 
removed and the pellet was resuspended in 325 μL 0.4 M aq. sucrose and 325 μL 2x 
concentrated protease inhibitor stock solution. The suspension was lyzed for 5-10 min at 4°C 
using ultrasonication. The total protein content was determined using a colorimetric assay 
(Pierce™ BCA Protein Assay Kit, Thermo Fisher Scientific). The lysates were stored on ice or 
















4.10   Chemical Synthesis 
4.10.1   Chemical Synthesis of the 5-dentate europium complex 
Diethyl 4-bromo-2,6-pyridinedicarboxylate (101) 
 
Chelidamic acid monohydrate (1.4 g, 6,9 mmol,1 eq.) and phosphorus pentabromide (15 g, 
34.8 mmol, 5 eq.) were heated to 90 °C under dry condition, Till the solids formed a melt. This 
mixture was stirred at 90 ° C for 2.5 h. After the solution was cooled, 10 mL hloroform was 
added, and the solution was stirred for 5 min and filtered. The filtrate was chilled in an ice bath 
and 60 mL ethanol was slowly added to the solution. The solution was concentrated, and the 
oily residue was triturated with ice water to give a white precipitate. Purification with SiO2 
column chromatography (3:9→5:95 Aceton/Cyclohexan) afforded a white crystalline solid 
(1.9 g, 90%). 
1H-NMR (500 MHz, CDCl3) δ 8.42 (s, 2H, CHar), 4.49 (q, J = 7.1 Hz, 4H, CH2CH3), 1.45 (t, J 
= 7.1 Hz, 6H, CH2CH3). 
13C-NMR (126 MHz, CDCl3) δ 163.68(CO), 149.65(C=N), 135.06(C-Br), 131.21(CH), 
62.87(CH2), 14.33(CH3). 
UPLC-MS (ESI): C11H13BrNO4 [M+H]
+:         m/z Calc.: 304.0;                Found: 304.2 
4-Bromo-2,6-pyridinedimethanol (102) 
 
To a suspension of (1 g, 3.3 mmol, 1eq.) of bromo ester 101 in 50 ml of dry ethanol at ° C was 
added (626 mg, 16.5 mmol, 5 eq.) of NaBH4 under stirring. After 1 h at 0°C and 1 h at room 
temperature, the mixture was heated to reflux for overnight, then 20 ml of acetone was added, 
and the mixture was again heated to reflux for 1 h. The solvents were distilled off, the 
gelatinous residue was mixed with 30 ml of a saturated Na2Co3 solution and the mixture was 
heated to reflux for 45 min. The solvent was distilled off, the white residue was extracted 
continuously with chloroform for one day (Soxhlet extraction). After the solution was cooled 
and concentrated, 505 mg (70% yield) of a white solid 2 precipitated. 
 
Experimental Section 




1H-NMR (500 MHz, CDCl3) δ 7.42 (s, 2H, CHar), 4.76 (s, 4H, CH2), 3.00 ((br. s, 2H, OH). 
13C-NMR (126 MHz, CDCl3/CD3OD) δ 161.30 (C=N), 134.92 (C-Br), 122.75 (CH), 64.27 
(CH2).  
UPLC-MS (ESI): C7H9BrNO2 [M+H]
+:         m/z Calc.: 219.9;                Found: 219.3 
4-Bromo-2, 6-bis (bromomethyl) pyridine (103) 
 
Phosphorous tribromide (176.9 mg, 0.65 mmol, 1.5 eq.) was added in one portion to a 
suspension of 102 (95 mg, 0.44 mmol, 1eq.) in chloroform (5ml). The reaction mixture was 
heated under reflux for 4 h. After cooling, the mixture was neutralized with 5% NaHCO3. The 
aqueous layer was extracted with chloroform (6x). the combined organic phase was dried with 
Na2SO4 and evaporated in vacuo. The resulting residue was purified by flash SiO2 column 
chromatography (5% Acetone in Cyclohexane) to obtain 3 (102 mg, 68%yield) as a white 
crystalline powder. 
1H NMR (500 MHz, CDCl3) δ 7.55 (s, 2H, CHar), 4.48 (s, 4H, CH2). 
13C NMR (126 MHz, CDCl3) δ 157.87 (C=N), 134.49 (C-Br), 126.24 (CH), 32.49 (CH2). 
UPLC-MS (ESI): C7H6Br3NNa [M+Na]
+:         m/z Calc.: 367.8;                Found: 368.2 
diethyl 2,2'-(((4-bromopyridine-2,6-diyl)bis(methylene))bis(methylazanediyl)) diacetate 
(104) 
 
4-Bromo-2,6-bis(bromomethyl)pyridine 103 (1.15 g, 3.34 mmol, 1eq.), ethyl 2-(methylamino) 
acetate.HCl (2.05g, 13.37 mmol, 4 eq.) and K2CO3 (1.85g, 13.37 mmol, 4eq.) were dissolved 
in acetonitrile (50 mL), and the mixture was heated to reflux. The reaction was followed with 
TLC (acetone/cyclohexane, 1:2) and after 4 h the reactant was completely consumed. The 
mixture was filtered and the filtrate was evaporated to dryness. The oily residue was purified 
by column chromatography using (3:97→10:90 aceton/cyclohexane). Pure white powder of 
104 (1 g, 72 %yield) was obtained.  
Experimental Section 




1H NMR (500 MHz, CDCl3) δ 7.59 (s, 2H, CHar), 4.18 (q, J = 7.1 Hz, 4H, CH2CH3), 3.80 (s, 
4H, Pyr-CH2), 3.34 (s, 4H, CH2-Carbonyl), 2.42 (s, 6H, CH3-N), 1.28 (t, J = 7.1 Hz, 6H, 
CH2CH3).  
13C NMR (126 MHz, CDCl3) δ 170.95 (C=O), 160.16 (C=N), 134.49 (C-Br), 124.69 (CH), 
62.21 (Pyr-CH2), 60.55 (CH2-O), 58.32 (CH2-Carbonyl), 42.45 (CH3-N), 14.52(CH3). 
HRMS (ESI):     C17H27BrN3O4 [M+H]
+ :             m/z Calc.: 418.1164,    Found: 418.1165. 
                           C17H26BrN3NaO4[M+Na]
+ :       m/z Calc.: 438.1004,    Found: 438.1005. 
Diethyl 2,2'-(((4-((4-(dimethylamino)phenyl)ethynyl)pyridine-2,6-diyl)bis  (methylene)) 
bis(methylazanediyl))diacetate (105)  
 
Compound 104 (500 mg, 1.2 mmol, 1eq.) was dissolved in dry THF (25ml) under argon 
atmosphere. Then 4-ethynyl-N,N-dimethylaniline (209 mg, 1.44 mmol, 1.2 eq.), Pd(PPh3)2Cl2 
(17 mg, 0.024 mmol, 0.02 eq.), Copper(I) iodide (10 mg, 0.05 mmol, 0.04 eq.), Et3N (7.5 ml) 
were added. The mixture was stirred under Argon until the TLC (acetone/cyclohexane 30%) 
revealed complete consumption of 104 (4h). The reaction was quenched by washing with 1M 
NH4Cl (2 x 30 ml), then with brine (2 x 30ml). The organic layer was collected and evaporated 
and the obtained crude residue was purified by column chromatography (10:90 → 50:50 
acetone/cyclohexane) to yield a yellow crystalline powder of 105 (290 mg, 50 % yield). 
1H NMR (500 MHz, CDCl3) δ 7.43 (s, 2H, CHPyr), 7.40 (d, J = 9.0 Hz, 2H, CHPh), 6.66 (d, J = 
9.0 Hz, 2H, CHPh), 4.19 (q, J = 7.1 Hz, 4H, CH2CH3), 3.82 (s, 4H, Pyr-CH2), 3.35 (s, 4H, CH2-
Carbonyl), 3.00 (s, 6H, N(CH3)2), 2.44 (s, 6H, CH3-N), 1.29 (t, J = 7.1 Hz, 6H, CH2CH3). 
 13C NMR (126 MHz, CDCl3) δ 171.15 (C=O),158.37 (Pyr C=N), 150.69(PhC-N), 133.50 
(PyrC4), 133.32 (PhC3,5), 123.03(PyrC3,5), 111.86 (PhC2,6), 108.97 (PhC1-Ethynyl), 95.56 (Ph-
C≡), 85.96 (Pyr-C≡), 62.74 (Pyr-CH2), 60.62 (CH2-O), 58.43(CH2-Carbonyl), 42.64 (CH3-N), 
40.27 N(CH3)2), 14.43(CH3). 
HRMS (ESI):     C27H37N4O4 [M+H]
+ :               m/z Calc.: 481.2815,    Found: 481.2815      
                           C27H36N4NaO4 [M+Na]
+:          m/z Calc.: 503.2634,    Found: 503.2639 
Experimental Section 





bis(methylazanediyl))diacetic acid (106) 
 
Potassium hydroxide (21mg, 0.37mmol, 3eq.) was added to a solution of Compound 105 (60 
mg, 0.12 mmol, 1eq.) in methanol (2mL) and the solution was heated under reflux conditions 
for 3 h. The reaction was quenched with water (5ml) and the crude product was extracted with 
diethyl ether (3x 5ml). The aqueous portion was acidified with concentrated hydrochloric acid. 
The dicarboxylic acid precipitated on standing, was filtered off, and dried to give product 106 
as a yellow crystalline powder (47 mg, 89 % yield).  
UV-VIS: max = 355 nm ( = 7450 L cm-¹ mol-¹). 
1H NMR (300 MHz, MeOD) δ 7.68 (s, 2H, CHPyr), 7.66 (d, J = 8.9 Hz, 2H, CHPh), 7.37 (d, J = 
8.8 Hz, 2H, CHPh), 4.74 (s, 4H, Pyr-CH2), 4.29 (s, 4H, CH2-Carbonyl), 3.19 (s, 6H, N(CH3)2), 
3.09 (s, 6H, CH3-N).  
13C NMR (75 MHz, MeOD) δ 168.24 (C=O), 152.07 (Pyr C=N), 136.16 (PhC-N), 134.97 
(PhC3,5), 127.17 (PyrC3,5), 118.74 (PhC2,6), 87.09 (Pyr-C≡), 60.44 (Pyr-CH2), 56.70 (CH2-
Carbonyl), 44.32 (CH3-N), 43.06(N(CH3)2). 
HRMS (ESI):     C23H29N4O4 [M+H]
+ :      m/z Calc.: 425.2189,    Found: 425.2188 
                           C23H27N4O4  [M-H]













(methylene)) bis(methylazanediyl))diacetic acid (5-D+) 
 
Saponified ligand 106 (849 µg, 0.0019mmol, 1eq.) was dissolved in water (1 mL), and the 
solution was neutralized with NaHCO3 to pH 6.5. Afterwards, EuCl3·6H2O (732.8 µg, 
0.0019mmol, 1eq. ) dissolved in water (1 mL) was added over 15 minutes while the solution 
was kept at pH 5 - 6.5. Then the mixture was stirred for 2h at RT.  
UV-VIS: max = 365 nm ( = 1790 L cm-¹ mol-¹). 
UPLC-MS (ESI):    C23H27EuN4O4 [M+H]+   :          m/z Calc.: 576.1,         Found:  576.3 
                                C23H27N4O4 [Ligand-H]














4.10.2   Chemical Synthesis of the 4-dentate europium complex 
Ethyl 4-bromo-6-(hydroxymethyl)picolinate (107) 
 
Compound 101 (1.037 g, 3.43 mmol, 1 eq.) was dissolved in dry ethanol (100ml) under argon 
atmosphere. Then, NaBH4 (148 mg, 3.9 mmol, 1.14 eq.) was added and the mixture was stirred 
at RT for 1h. A white precipitate was observed. The solvent was evaporated under reduced 
pressure and then 10 ml water was added to the residue and stirred for 10 minutes. The mixture 
was extracted with dichloromethane till no product was observed in the aqueous layer. The 
organic fractions were collected and evaporated and the resulted residue was purified by SiO2 
column chromatography (0:100 to 2:98 MeOH/DCM). (339.2 mg, 38% yield) of 107 was 
obtained as a colorless oil.  
1H NMR (500 MHz, DMSO) δ  8.07 (m, 1H, CHar), 7.90 (d, J = 1.8 Hz, 1H, CHar), 5.71 (t, J = 
5.9 Hz, 1H, OH), 4.62 (d, J = 5.9 Hz, 2H,CH2OH), 4.35 (q, J = 7.1 Hz, 2H, CH2CH3), 1.33 (t, 
J = 7.1 Hz, 3H, CH3).  
13C NMR (126 MHz, DMSO) δ 164.47 (C=O), 163.61 (PyrC6), 148.24 (PyrC2), 133.62 
(PyrC4), 126.42 (PyrC5), 125.80 (PyrC3), 63.52 (CH2-OH), 61.65 (CH2CH3), 14.09 (CH3). 
UPLC-MS (ESI):   C9H11BrNO3 [M+H]
+:           m/z Calc.:  262.0,           Found: 262.0  
Ethyl 4-bromo-6-(bromomethyl) picolinate (108)  
 
Phosphorous tribromide (952 mg, 3.5 mmol, 1.2 eq.) was dissolved in 5 ml DMF and added 
dropwisely to a solution of 107 (772mg, 2.96 mmol, 1eq.) in 15 ml DMF. A white precipitate 
was formed. The reaction mixture was stirred at room temperature for 3 h and the consumption 
of 107 was monitored by TLC. The mixture was neutralized with NaHCO3 and then extracted 
by petroleum ether. The organic layer was evaporated and the residue was purified by short 
flash chromatography using DCM as eluent. The product was obtained as colorless oil (910 
mg, 95% yield).  
Experimental Section 




1H NMR (300 MHz, CDCl3) δ 8.17 (d, J = 1.7 Hz, 1H, CHar), 7.85 (d, J = 1.7 Hz, 1H, CHar), 
4.59 (s, 2H, CH2Br), 4.48 (q, J = 7.1 Hz, 2H, CH2CH3), 1.43 (t, J = 7.1 Hz, 3H, CH3).  
13C NMR (75 MHz, CDCl3) δ 163.79 (C=O), 158.72 (PyrC6), 148.90 (PyrC2), 134.66 (PyrC4), 
130.17 (PyrC5), 127.88 (PyrC3), 62.64 (CH2CH3), 32.32 (CH2-Br), 14.40 (CH3). 
HRMS (ESI):    C9H10Br2NO2 [M+H]
+ :                     m/z Calc.: 321.9073,    Found: 321.9066. 
                          C18H18Br4N2NaO4[2M+Na]
+:            m/z Calc.: 668.7892,    Found: 668.7905. 
Ethyl 4-bromo-6-(((2-ethoxy-2-oxoethyl)(methyl)amino)methyl)picolinate (109) 
 
Ethyl 4-bromo-6-(bromomethyl)picolinate 108 (484 mg, 1.49 mmol, 1 eq.), ethyl 2-
(methylamino) acetate.HCl (500 mg, 3.25 mmol, 2.2 eq.) and K2CO3 (450 mg, 3.25 mmol, 2.2 
eq.) were dissolved in acetonitrile (50 mL), and the mixture was heated to reflux. The reaction 
was followed with TLC (acetone/cyclohexane 1:2) and after 18 h, the Starting compound 108 
was completely consumed. The mixture was filtered and the filtrate was evaporated to dryness. 
The oily residue was purified by column chromatography using (0:100 to 0.5 :99.5 
MeOH/DCM). Pure colorless oil of 109 (323 g, 60 %yield) was obtained. 
1H NMR (300 MHz, CDCl3) δ 8.13 (d, J = 1.8 Hz, 1H, CHar), 7.99 (d, J = 1.8 Hz, 1H, CHar), 
4.46 (q, J = 7.1 Hz, 2H, CH2CH3), 4.19 (q, J = 7.1 Hz, 2H, CH2CH3), 3.92 (s, 2H, Pyr-CH2), 
3.36 (s, 2H, CH2-CO), 2.42 (s, 3H, N-CH3), 1.42 (t, J = 7.1 Hz, 3H, CH2CH3), 1.28 (t, J = 7.1 
Hz, 3H, CH2CH3).  
13C NMR (75 MHz, CDCl3) δ 171.36 (C=O), 164.72 (Pyr-C=O), 162.30 (PyrC6), 149.13 
(PyrC2), 135.01(PyrC4), 129.55 (PyrC5), 127.60, (PyrC3), 62.82 (Pyr-CH2), 62.74 (CH2CH3), 
61.19 (CH2CH3), 59.05 (CH2-CO), 43.07 (CH3-N), 14.82 (CH3).  
HRMS (ESI):    C14H20BrN2O4 [M+H]
+ :                         m/z Calc.: 359.0606,    Found: 359.0609. 
                          C14H19BrN2NaO4[M+Na]










Ethyl 4-((4-(dimethylamino)phenyl)ethynyl)-6-(((2-ethoxy-2-oxoethyl) (methyl) amino) 
methyl)picolinate (110) 
 
Compound 109 (220 mg, 0.61mmol, 1 eq.) was dissolved in dry THF (10 ml) under argon 
atmosphere. Then, 4-ethynyl-N, N-dimethylaniline (105.6 mg, 0.73 mmol, 1.2 eq.), 
Pd(PPh3)2Cl2 (8.4 mg, 0.01 mmol, 0.02 eq.), Copper(I) iodide (4.8 mg, 0.025 mmol, 0.04 eq.), 
Et3N (4 ml) were added. The mixture was stirred under Argon until the TLC 
(acetone/cyclohexane 30%) revealed complete consumption of 109 (5h). The reaction mixture 
was washed with 1M NH4Cl (2 x 10 ml) and with brine (2 x 10 ml). The organic layer was 
collected and evaporated. The crude residue was purified by SiO2 column chromatography 
(5:95 to 50:50 ethyl acetate/cyclohexane). A yellow crystalline powder of 110 (155 mg, 60 % 
yield) was obtained.  
1H NMR (300 MHz, MeOD) δ 7.94 (d, J = 1.5 Hz, 1H, CHpyr), 7.79 (d, J = 1.5 Hz, 1H, CHpyr), 
7.40 (d, J = 9.0 Hz, 2H, CHph), 6.71 (d, J = 9.1 Hz, 2H, CHph), 4.43 (q, J = 7.1 Hz, 2H, CH2CH3), 
4.17 (q, J = 7.1 Hz, 2H, CH2CH3), 3.86 (s, 2H, Pyr-CH2), 3.39 (s, 2H, CH2-CO), 3.00 (s, 6H, 
N-(CH3)2), 2.40 (s, 3H, CH3-N), 1.42 (t, J = 7.1 Hz, 3H, CH2CH3), 1.27 (t, J = 7.1 Hz, 3H, 
CH2CH3). 
 13C NMR (75 MHz, MeOD) δ 172.48 (C=O), 166.01(Pyr-C=O), 161.30 (PyrC6), 152.59 
(PhC1), 148.61 (PyrC2), 135.91(PyrC4), 134.41 (PhC3,5), 128.72 (PyrC5), 125.91(PyrC3), 
112.90 (PhC2,6), 109.11 (PhC4), 98.93 (Ph-C≡), 85.66 (Pyr-C≡) , 63.05 (Pyr-CH2), 62.73 (CH2-
O), 61.68 (CH2-O), 58.99 (CH2-CO), 42.74 (CH3-N), 40.23 (N-(CH3)2), 14.56 (CH3), 
14.53(CH3). 
HRMS (ESI):     C24H30N3O4 [M+H]
+ :                      m/z Calc.: 424.2231,    Found: 424.2251. 
                           C24H29N3NaO4 [M+Na]
+:               m/z Calc.: 446.2050,    Found: 446.2078. 
Experimental Section 





picolinic acid (111) 
 
Compound 110 (25 mg, 0.059 mmol, 1eq.) was dissolved in methanol (1 mL). Potassium 
hydroxide (10 mg, 0.178 mmol, 3 eq.) was added, and the solution was heated under reflux 
conditions for 3 h. The reaction was quenched with water (2 ml) and extracted with diethyl 
ether (3 x 3 ml). The aqueous portion was acidified to pH = 2 with concentrated hydrochloric 
acid. The carboxylic acid precipitated on standing, was filtered off, and dried under vacuum to 
give product 111 as a yellow crystalline powder (19.5 mg, 90 % yield).  
UV-VIS:  max = 361 nm ( = 5200 L cm-¹ mol-¹).  
1H NMR (300 MHz, DMSO) δ  8.01 (s, 1H, CHpyr), 7.87 (s, 1H, CHpyr), 7.44 (d, J = 8.8 Hz, 
2H, CHph), 6.74 (d, J = 9.0 Hz, 2H, CHph), 4.64 (s, 2H, Pyr-CH2), 4.26 (s, 2H, CH2-CO), 2.97 
(s, 6H, N-(CH3)2), 2.90 (s, 3H, CH3-N).  
13C NMR (75 MHz, DMSO) δ 167.63 (C=O), 165.50 (C=O), 151.56 (PyrC6), 151.39 (PhC1), 
148.53 (PyrC2), 134.32 (PyrC4), 133.78 (PhC3,5),129.18 (PyrC5), 125.73 (PyrC3), 112.36 
(PhC2,6), 106.83 (PhC4), 99.07 (Ph-C≡), 85.21 (Pyr-C≡),58.93 (Pyr-CH2), 55.36 (CH2-CO), 
41.81 (CH3-N), 40.12 (N-(CH3)2). 
HRMS (ESI):     C20H20N3O4 [M-H]














phenyl)ethynyl)picolinic acid (4-D+) 
 
The saponified ligand 111 (848 µg, 0.0023) was dissolved in water (1 mL), and the solution 
was neutralized with NaHCO3 to pH 6.5. Afterwards, EuCl3·6H2O (846 µg, 0.0019mmol, 1 
eq.) dissolved in water (1 mL) was added over 15 minutes while the solution was kept at pH 5 
- 6.5. Then, the mixture was stirred for 2h at room temperature. 
 UV-VIS: max = 378 nm ( = 3050 L cm-¹ mol-¹). 
UPLC-MS (ESI):     C20H20N3O4 [Ligand-H]
-:           m/z Calc.: 366.1,       found: 366.0,  
                                 C20H22N3O4 [Ligand+H]


















4.10.3   Chemical synthesis of Protected sphingosine 
(S)-2-(tert-butoxycarbonyl)-3-hydroxypropanoic acid (201) 
 
At 0°C, L-serine (3.15 g, 29.97 mmol, 1 eq.) was added to a solution of NaOH (1.26 g, 
31.5 mmol, 1.05 eq.) in 35 mL H2O. Di-tert-butyl dicarbonate (7.80 g, 35.74 mmol, 1.2 eq.) 
was dissolved in 30 mL 1,4-dioxane and added dropwise to the serine containing solution over 
120 min keeping the temperature at 0°C.  Stirring was continued for 1h at 0°C and additional 
20 h at rt. Then, the reaction mixture was washed twice with cyclohexane (60 mL each). At 
0°C, the pH was adjusted to 2 using 1 M aq. NaHSO4. The mixture was extracted five times 
with EA (60 mL each). The combined organic layers were washed with 60 mL brine and dried 
over Na2SO4, filtered and evaporated to dryness. After drying in high vacuum, Boc-L-Serine 
201 was obtained as colourless oil (5.60 g, 91% crude). the product was used in the next step 
without further purification. 
(S)-tert-butyl 3-hydroxy-1-(methoxy(methyl)amino)-1-oxopropan-2-yl carbamate (202) 
 
Under argon atmosphere, N-(tert-butoxycarbonyl)-L-serine 201 (5.60 g, 27.29 mmol, 1 eq.) 
was dissolved in dry CH2Cl2 (60 mL). N-Methylmorpholine (3.45 mL, 31.38 mmol, 1.15 eq.) 
and N, O-dimethylhydroxylamine hydrochloride (2.90 g, 30.02 mmol, 1.1 eq.) were added 
at -15°C. the mixture was stirred for 10 min. Then, EDC (6.20 g, 32.74 mmol, 1.2 eq.) was 
added to the mixture in 6 portions over 30 min. Stirring was continued at -15°C for 1.5 h. Then, 
the reaction was quenched by addition of 30 g ice and 80 mL 1 M aq. HCl. The organic layer 
was extracted with 4x 50 mL CHCl3 and the combined organic layers were washed with sat. 
aq. NaHCO3 and brine (50 mL each). The combined organic layers were dried over Na2SO4, 
filtered and evaporated to dryness. The title compound was obtained as a colourless solid 
(5.08 g, 75%). 
 
Experimental Section 




1H NMR (500 MHz, CDCl3) δ 5.61 (s, 1H, NH), 4.79 (s, 1H, CH), 3.81 (s, 2H, CH2), 3.77 (s, 
3H, OCH3), 3.22 (s, 3H, NCH3), 2.72 (s, 1H, OH), 1.44 (s, 9H, C(CH3)3). 
13C NMR (101 MHz, CDCl3) δ 171.00 (CON), 156.08 (COO), 80.24 (C), 63.89 (CH2), 61.75 
(CH3), 52.51 (CH3), 32.15 (CH), 28.45 (C(CH3)3). 
(S)-N-methoxy-N-methyl-3-(tert-butyldiphenylsilyloxy)-2-(N-tert butyloxycarbonyl) 
amino propanamide (203) 
 
Under argon atmosphere, 202 (5.00 g, 20.14 mmol, 1 eq.), imidazole (4.10 g, 60.29 mmol, 
3 eq.) and DMAP (0.123 g, 1 mmol, 0.05 eq.) were dissolved in dry CH2Cl2 (45mL). The 
mixture was cooled to 0°C and tert-butyldiphenylchlorsilane (5.76 mL, 22.15 mmol, 1.1 eq.) 
was added dropwise over 30 min. Stirring was continued at RT for 24 h. Then, the reaction was 
quenched by dropwise addition of 25 mL MeOH and diluted with 200 mL CH2Cl2. The organic 
layer was washed with 2x 0.1 M aq. HCl, sat. aq. NaHCO3 and brine (100 mL each, backwash 
with 20 mL CH2Cl2). The combined organic layers were dried over Na2SO4, filtered and 
evaporated to dryness. Column chromatography (CH:EA  98:2 → 85:15) yielded the target 
compound as a colourless oil that solidified upon standing (8.515 g, 87%). 
1H NMR (500 MHz, CDCl3) δ 7.70 – 7.56 (m, 4H, CHar), 7.49 – 7.31 (m, 6H, CHar), 5.41 (d, 
J = 8.8 Hz, 1H, NH), 4.83 (s, 1H, CH), 3.86 (d, J = 4.7 Hz, 2H, CH2), 3.66 (s, 3H, OCH3), 3.19 
(s, 3H, NCH3), 1.44 (s, 9H O-C(CH3)3), 1.04 (s, 9H, Si-C(CH3)3). 
13C NMR (126 MHz, CDCl3) δ 155.40 (CO), 135.62 (CHar), 133.17 (Car),  129.75 (CHar), 
127.71 (CHar), 79.56 (C(CH3)3), 64.14 (CH2OSi), 61.43 (OCH3), 52.48 (CHCO), 28.39 
















Under argon atmosphere, 203 (8.30 g, 17.05 mmol, 1 eq.) was dissolved in dry THF (57 mL). 
The mixture was cooled to -15°C using ice/NaCl mixture and vinyl magnesium bromide (1 M 
in THF, 57 mL, 56.27 mmol, 3.3 eq.) was added over 2 h so as to keep the reaction temperature 
below -15°C. Stirring was continued at the same temperature for 1 h then warmed to RT and 
stirred till TLC indicates complete conversion (about 2h). The reaction was quenched inversely 
by adding it dropwise into a mixture of ice/1 M HCl (150 g each) over a period of 30 min. The 
obtained aqueous mixture was extracted with EA (3x 100 mL). The combined organic layers 
were washed with sat. aq. NaHCO3 and brine (75 mL each), dried over Na2SO4, filtered and 
evaporated to dryness. Column chromatography (CH:EA = 96:4 → 91:9) yielded the target 
compound as a colourless oil that solidified upon standing (5.04 g, 65%). 
1H NMR (500 MHz, CDCl3) δ 7.65 – 7.53 (m, 4H, Har), 7.46 – 7.40 (m, 2H, Har), 7.37 (ddd, 
J = 8.1, 5.2, 2.1 Hz, 4H, Har), 6.51 (dd, J = 17.5, 10.6 Hz, 1H, =CH), 6.40 – 6.27 (m, 
1H,=CHH), 5.82 (d, J = 10.7 Hz, 1H, =CHH), 5.55 (d, J = 7.69, 1H, NH), 4.67 (dt, J = 7.6, 3.7 
Hz, 1H, CH), 4.00 (dd, J = 10.5, 3.5 Hz, 1H, CHHOSi), 3.93 (dd, J = 10.5, 4.0 Hz, 1H, 
CHHOSi), 1.45 (m, 9H, O-C(CH3)3), 1.01 (m, 9H, , Si-C(CH3)3). 
 
13C NMR (126 MHz, CDCl3) δ 196.86 (CO), 155.14 (COO), 135.60 (CHar), 135.55 (CHar), 
133.10 (CH=CH2), 132.83(Car), 132.74 (Car), 129.86 (CHar), 129.60 (CH2=CH),  127.77 















Under argon atmosphere, 204 (5.036 g, 11.10 mmol, 1 eq.) was dissolved in dry THF (4 mL). 
Dry EtOH (40 mL) was added under vigorous stirring and a white slurry was obtained. The 
mixture was cooled to -84°C using Ethyl acetate/liq. N2 and TBLAH (5.65 g, 22.2 mmol, 2.0 
eq.) was added over 20 min to keep the reaction temperature constant. Stirring was continued 
at the same temperature for 4 h. The reaction was quenched by dropwise addition of 49 mL 1 
M 16 HCl at -84°C. The mixture was warmed to RT and Celite was added under stirring. The 
slurry was filtered and the Celite was washed with EA. The filtrate was extracted with EA. The 
combined organic layers were washed with sat. aq. NaHCO3 and brine (75 mL each), dried 
(Na2SO4), filtered and evaporated to dryness. Column chromatography (CH:EA = 92:8) 
yielded the title compound as a colourless oil (4.04 g , 80%). 
1H NMR (500 MHz, CDCl3) δ 7.73 – 7.59 (m, 4H, CHar), 7.52 – 7.33 (m, 6H, CHar), 5.91 
(ddd, J = 17.2, 10.6, 5.0 Hz, 1H, =CH ), 5.42 (dt, J = 17.2, 1.5 Hz, 1H, =CHH), 5.33 – 5.15 (m, 
2H, =CHH+NH), 4.39 – 4.24 (m, 1H, CHOH), 3.91 (dd, J = 10.5, 3.6 Hz, 1H, CHHOSi), 3.76 
(d, J = 10.5 Hz, 1H, CHHOSi), 3.71 (d, J = 4.0 Hz, 1H, CHNH), 3.34 (d, J = 7.8 Hz, 1H,OH), 
1.43 (s, 9H, O-C(CH3)3), 1.07 (s, 9H, Si-C(CH3)3). 
 
13C NMR (126 MHz, CDCl3) δ 156.02 (NCOO), 137.80 (=CH), 135.67 (CHar), 132.62 (Car),  
132.58 (Car), 130.16 (CHar), 130.14 (CHar), 130.12 (CHar), 128.04 (CHar), 128.01 (CHar), 
116.21 (=CH2), 79.73 (Me3CO), 74.69 (CHOH), 64.32 (CH2O), 54.86 (CHNH),  28.53 
((CH3)3CO), 26.98 ((CH3)3CSi), 19.29 (SiCMe3). 
UPLC-MS (ESI):     C26H37NO4NaSi [M+Na]










(2S,3R,E)-1-(tert-butyldiphenylsilyloxy)-2-(N-tertbutyloxycarbonyl) amino octadic -4-en-
3-ol (206) 
 
Under argon atmosphere, 205 (4.043 g, 8.87 mmol, 1 eq.) was dissolved in dry DCM (40 mL) 
and then 1-pentadecene (10.8 mL, 39.92 mmol, 4.5 eq.) was added. Grubbs 2nd catalyst (0.055 
g, 0.0887 mmol, 0.01 eq.) was dissolved in 20 mL dry DCM and added to the mixture. The 
reaction mixture was heated at reflux for 4 h. Then potassium 2-isocyanoacetate (0.15 g, 1.153 
mmol, 0.13 eq.) was dissolved in 1 mL MeOH and added and stirred for 30 minutes to quench 
the reaction. Celite was added and the volatiles were removed in vacuo. Column 
chromatography (CH:EA = 95:5→ 93:7→92:8→90:10) yielded the title compound as a 
colourless oil (3.6 g, 63.5%). 
1H NMR (500 MHz, CDCl3) δ 7.68 (t, J = 6.9 Hz, 4H, CHar), 7.52 – 7.37 (m, 6H, CHar), 5.89 
– 5.73 (m, 1H, =CHCH2), 5.51 (dd, J = 15.4, 6.0 Hz, 1H, =CHCH), 5.25 (d, J = 8.1 Hz, 1H, 
NH), 4.28 (d, J = 4.4 Hz, 1H, CHOH), 3.94 (dd, J = 10.5, 3.6 Hz, 1H, CHHO), 3.79 (d, J = 10.1 
Hz, 1H, CHHO), 3.69 (s, 1H, CHNH), 3.23 (s, 1H, OH), 2.07 (dd, J = 14.4, 6.9 Hz, 2H, 
CH2CH=), 1.48 (s, 9H, (CH3)3CO), 1.41 – 1.36 (m, 2H, CH2Me), 1.29 (s, 20H, 10x CH2), 
1.10 (s, J = 5.9 Hz, 9H, (CH3)3CSi), 0.91 (t, J = 7.0 Hz, 3H, CH3). 
 
13C NMR (126 MHz, CDCl3) δ 155.99 (COO), 135.68 (CHar),133.96 (=CHCH2), 133.46 (Car), 
132.72 (Car), 130.10 (CHar), 130.08 (CHar), 129.29(=CHCH) 127.99(CHar), 79.58 (OCMe3), 
74.48 (CHOH), 64.27 (CH2OSi), 55.15 (CHNH), 32.26 (CH2CH=), 32.07 (CH2Et), 29.84 
(CH2) , 29.81 (CH2), 29.77 (CH2), 29.67 (CH2), 29.50 (CH2), 29.43 (CH2), 29.31 (CH2), 28.54 















Under argon atmosphere, 206 (3.6 g, 5.64 mmol, 1 eq.) was dissolved in dry DCM (28 mL) 
and cooled to 0°C. At the same temperature, dry DIPEA (2.46 mL, 14.106 mmol, 2.5 eq.) was 
added and MOMCl (1.02 mL, 13.54 mmol, 2.4 eq.) was added dropwise. The reaction mixture 
was stirred at RT for overnight. Then, TLC indicated complete conversion of the starting 
material. The solution was diluted with 100 mL DCM  and washed with 1 M aq. NaHCO3, 1 
M aq. NH4Cl, H2O, and brine (50 mL each). The organic layer was dried (Na2SO4) and 
evaporated to dryness. Column chromatography (CH:EA = 99:1→96:4 ) yielded the title 
compound as a colourless oil (2.75 g, 72%). 
1H NMR (300 MHz, CDCl3) δ 7.76 – 7.55 (m, 4H, CHar), 7.51 – 7.30 (m, 6H, CHar), 5.80 – 
5.59 (m, 1H, =CHCH2), 5.27 (dd, J = 15.4, 8.3 Hz, 1H, =CHCH), 4.74 (d, J = 8.1 Hz, 1H, NH), 
4.66 (d, J = 6.6 Hz, 1H, CHHOMe), 4.49 (d, J = 6.6 Hz, 1H, CHHOMe), 4.22 – 4.11 (m, 1H, 
CHHOSi), 3.94 – 3.82 (m, 1H, CHHOSi), 3.77 (s, J = 8.4 Hz, 2H, OCHCHNH), 3.28 (s, J = 
3.2 Hz, 3H, OCH3), 2.08 – 1.93 (m, 2H, CH2), 1.43 (s, 9H, (CH3)3CO), 1.26 (s, 22H, 11x CH2), 
1.08 (s, J = 3.1 Hz, 9H, (CH3)3CSi), 0.88 (t, J = 6.7 Hz, 3H, CH3). 
 
13C NMR (75 MHz, CDCl3) δ = 155.54 (COO), 136.97 (=CHCH2), 135.79 (CHar),, 133.53 
(Car),, 129.85 (CHar), 127.83 (CHar), 126.61 (=CHCH), 93.85 (OCH2O), 79.12 ((CH3)3CO),  
76.71 (CHO), 62.77 (CH2OSi), 55.67 (OCH3), 55.15 (CHNH), 32.49 (CH2CH=), 32.07 (CH2), 
29.84 (CH2), 29.81 (CH2), 29.76 (CH2), 29.64 (CH2), 29.51 (CH2), 29.39 (CH2), 29.26 (CH2), 
28.55 (C(CH3)3), 27.06 (CH2), 22.84 (CH2CH3), 19.45 ((CH3)3CSi), 14.27 (CH3). 
 
UPLC-MS (ESI):     C41H67NO5NaSi [M+Na]










tert-butyl (2S,3R,E)-1-hydroxy-3-(methoxymethoxy) octadec-4-en-2-ylcarbamate (208) 
 
207 (0.391 g, 0.57 mmol, 1 eq.) was dissolved in 4 mL THF at rt. To the first solution 
tetrabutylammonium fluoride trihydrate (0.363 g, 1.149 mmol, 2 eq.), dissolved in 3 mL THF, 
was added dropwise with stirring. The reaction mixture was stirred at RT until complete 
conversion (3 h). 20 mL DCM were added and the mixture was washed with H2O and 2x brine 
(20 mL each). The organic layer was dried (Na2SO4), filtered and evaporated to dryness. Using 
column chromatography (CH:EA =95:05 → 90:10 →80:20) the title product was obtained as 
a colorless waxy solid (0.224 g, 88%). 
1H NMR (300 MHz, CDCl3) δ 5.82 – 5.68 (m, 1H; =CHCH2), 5.35 (dd, J = 15.5, 7.9 Hz, 1H; 
=CHCH), 5.23 (d, J = 8.2 Hz, 1H, NH), 4.67 (d, J = 6.6 Hz, 1H, OCHHOMe), 4.52 (d, J = 6.6 
Hz, 1H, OCHHOMe), 4.24 (dd, J = 7.7, 4.5 Hz, 1H, CHO), 3.95 (dd, J = 11.3, 3.4 Hz, 1H, 
CHHOH), 3.66 (d, J = 14.0 Hz, 2H, CHHOH+CHNH), 3.38 (s, 3H, OCH3), 2.73 (bs, 1H, OH), 
2.05 (dd, J = 13.6, 6.7 Hz, 2H, CH2), 1.45 (s, 9H, (CH3)3CO), 1.36 (m, 2H, CH2CH3), 1.25 (m, 
20H, 10x CH2), 0.88 (t, J = 6.7 Hz, 3H, CH3). 
 
13C NMR (126 MHz, CDCl3) δ 162.60 (COO), 137.21 (=CHCH2), 126.11 (=CHCH), 94.08 
(OCH2O), 78.83 ((CH3)3CO), 78.79 (CHO),  62.62 (CH2OH), 55.88 (OCH3), 55.14 (CHNH), 
32.47 (CH2), 32.07 (CH2), 29.84 (CH2), 29.82 (CH2), 29.75 (CH2), 29.60 (CH2), 29.51 (CH2), 
29.31 (CH2), 29.17 (CH2), 28.53 (CH2), 22.84 CH2Me), 14.27 (CH3). 
UPLC-MS (ESI):     C25H49NO5Na [M+Na]















4.10.4   Chemical Synthesis of the phosphodiesters 
2-(2-hydroxyethyl)isoindoline-1,3-dione (209) 
 
Phthalic anhydride  (4.220 g, 28.00 mmol, 1 eq.) was dissolved in 30 mL DMF and 2-
aminoethanol (1.70 mL, 28.00 mmol, 1 eq.) was added at rt. The reaction mixture was stirred 
under reflux for 24 h, cooled to RT and dissolved in 200 mL EA and 100 mL 0.1 M aq. HCl. 
The organic layer was separated and washed with brine (200 mL), dried (MgSO4) and 
evaporated to dryness. The obtained raw material was purified by crystallization from hot 
toluene yielding the title compound (4.2 g, 79%) as colourless crystals. 
1H NMR (300 MHz, CDCl3) δ = 7.88 – 7.80 (m, 2H, CHar), 7.77 – 7.66 (m, 2H, CHar), 3.93 – 
3.82 (m, 4H, 2x CH2), 2.35 (s, 1H, OH). 
13C NMR (75 MHz, CDCl3) δ 168.77 (CO), 134.14 (CHar), 132.12 (Car), 123.49 (CHar), 61.11 (CH2), 
40.66 (CH2). 
UPLC-MS (ESI):     C11H9NO3 [M+H]
+:           m/z Calc.: 192.1,       found: 192.1 
O-2-phthalimidoethyl phosphorodichloridate (210) 
 
Under argon atmosphere, well dried 209 (1.800 g, 9.414 mmol, 1 eq.) was dissolved in dry 
toluene (15 mL). POCl3 (2.89 mL, 31.066 mmol, 3.3 eq.) was added dropwise and the mixture 
was heated under reflux for 4 h. At 60°C, the volatiles were distilled off and the oily residue 
was dissolved in dry diethyl ether (10 mL). The material was left to crystallize at -20°C, and 
the supernatant was removed using a filtration cannula. After drying in vacuo, the title 
compound was obtained as an off-white solid (2.03 g, 70%). 
 
1H NMR (300 MHz, CDCl3) δ = 7.92 – 7.82 (m, 2H, CHar), 7.80 – 7.69 (m, 2H, CHar), 4.57 
(dt, J = 10.7, 5.4 Hz, 2H, CH2OP), 4.09 (tt, J = 6.1, 3.0 Hz, 2H, CH2N). 
 
13C NMR (75 MHz, CDCl3) δ = 167.89 (Car), 134.65 (CHar), 131.86 (Car), 123.99 (CHar), 
67.88 (d, J = 8.9 Hz, CH2OP), 37.35 (d, J = 9.4 Hz, CH2N). 
 
31P NMR (121 MHz, CDCl3) δ= 8.64 . 
Experimental Section 







Under argon atmosphere, 210 (555 mg, 1.80 mmol, 4 eq.) was dissolved in dry DCM (20 mL) 
containing 1 mL of dry pyridine. At 0°C, a solution of 208 (200 mg, 0.45 mmol, 1 eq.) in 20 
mL dry DCM was added dropwise over 1h. Stirring was continued at RT until complete 
conversion detected by TLC (CH:EA 1:1) (4 h) . The reaction was quenched by the addition of 
20 mL sat. aq. NaHCO3 and stirred for 20 min.CHCl3 (300 mL), MeOH (150 mL) and H2O 
(300 mL) were added. The organic layer was separated and evaporated to dryness. The crude 
material was purified by column chromatography (MeOH:CHCl3 = 1:10→2:8) to yield the 
target compound as an off-white wax (267 mg, 85 %). 
1H NMR (500 MHz, CDCl3/MeOD) δ =.12 – 8.06 (m, 2H, CHar), 8.05 – 7.98 (m, 2H, CHar), 
6.05 – 5.85 (m, 1H, =CHCH2), 5.53 (dd, J = 15.4, 8.5 Hz, 1H, =CHCH), 4.75 (dd, J = 26.0, 
6.8 Hz, 2H, CH2), 4.32 (dd, J = 12.6, 5.9 Hz, 2H, CH2), 4.29 – 4.24 (m, 1H, CH), 4.17 (t, J = 
5.7 Hz, 4H, 2xCH2), 3.98 (d, J = 6.6 Hz, 1H, CH), 3.57 (s, 3H, CH3), 2.28 (dd, J = 13.9, 7.0 
Hz, 2H, CH2), 2.22 (s, 1H, OH), 1.67 – 1.59 (m, 9H, C(CH3)3), 1.49 (s, 22H, 11x CH2), 1.11 
(t, J = 7.0 Hz, 3H, CH3). 
13C NMR (126 MHz, CDCl3/MeOD) δ 169.19 (CON), 157.06 (COO), 138.24 (=CHCH2), 134.90 
(CHar), 132.47 (Car), 126.60 (=CHCH), 123.84 (CHar), 94.07 (OCH2O), 80.01 (CMe3), 77.12 (CHO), 
65.02 (CH2OP), 62.94 (CH2OP), 55.88 (OCH3), 54.59 (NCH), 39.10 (CH2), 39.04 (CH2), 32.89 (CH2), 
32.43 (CH2), 30.17 (CH2), 30.14 (CH2), 30.11 (CH2), 30.00 (CH2), 29.85 (CH2), 29.76 (CH2), 29.65 
(CH2), 28.64 (C(CH3)3), 23.16, 14.33 (CH3). 
31P NMR (202 MHz, CDCl3/MeOD) δ = -2.13.    
UPLC-MS (ESI):C35H57N2O10P[M+H]













methoxy)octadec-4-en-2-yl)carbamate (212)    
 
Compound 211 (110 mg, 0.16 mmol, 1 eq.) was dissolved in 6 mL MeOH/CHCl3 (1:1). 
Hydrazine hydrate (64%, 30 μL, 0.63 mmol, 4 eq.) was added and the mixture stirred at RT for 
4.5 h when TLC indicated complete consumption of the starting material. The solvent was 
evaporated and the crude material was dried under high vacuum. The material was adsorbed 
on Celite® and purified using short flash column chromatography (CHCl3: MeOH: H2O = 
100:15:1→65:25:3). The title compound was isolated as a colorless solid (73.4 mg, 82%). 
1H NMR (400 MHz, Pyr-d5) δ 7.74 (s, 1H,NH), 5.82 (d, J = 15.1 Hz, 1H, =CHCH2), 5.76 – 
5.61 (m, 1H, =CHCH), 4.94 (d, J = 5.9 Hz, 1H, OCHHO), 4.76 (d, J = 5.9 Hz, 1H, OCHHO), 
4.67 – 4.44 (m, 4H, 2 x CH2OP), 4.39 (s, 1H, CHNH), 3.51 (s, 5H, CH2NH2, OCH3), 2.08 (s, 
2H, CH2), 1.53 (d, J = 37.2 Hz, 9H, OC(CH3)3), 1.36 (d, J = 39.4 Hz, 20H, 10 x CH2), 0.90 (t, 
J = 6.7 Hz,3H, CH3). 
13C NMR (126 MHz, Pyr-d5) δ 157.16 (COO), 137.40 (=CHCH2), 128.15 (=CHCH), 94.38 
(OCH2O), 78.79(OC(CH3)3), 77.44 (CHO), 65.81 (CH2OP), 63.25 (CH2OP), 56.11 (OCH3), 
55.77 (NCHCH2OP), 33.17 (CH2CH=), 32.60 (CH2), 30.47 (CH2), 30.43 (CH2), 30.41 (CH2), 
30.31 (CH2), 30.10 (CH2), 30.06 (CH2), 29.94 (CH2), 29.15 (CH2), 23.42 (CH2), 14.76 (CH3). 
31P NMR (202 MHz, pyr-d5) δ = 2.82 

















-2-ynyl)ammonio)ethyl phosphate (214) 
 
 
Under argon atmosphere, alcohol 208 (50 mg, 0.113 mmol, 1eq.) was dissolved in dry toluene 
(1.5 mL) and triethylamine (47 µL, 0.338 mmol, 3eq.) followed by DMAP (2.8 mg, 0.022 
mmol, 0.2 eq.) were added. The reaction mixture was cooled to 0 °C before the addition of 
phospholane (2-chloro-2-oxo-1,2,3- dioxaphospholane) (32 µL, 0.338 mmol, 3eq.) Stirring at 
0 °C continued till TLC showed disappearance of starting material (1 h). The mixture was 
transferred to a sealed reaction tube via cannula under positive argon pressure. The crude 
solution of intermediate 213 was diluted with dry MeCN (3 mL) before N,N-
dimethylpropargylamine (0.5 mL) was added. The mixture was heated at 80 °C for 24 h. The 
reaction mixture was then concentrated in vacuo and purified by flash chromatography on silica 
(85/14/1 then 80/18/2 then 72/25/3 CHCl3/MeOH/NH4OH). The pure product was obtained as 
a white solid (35 mg, 50%). 
1H NMR (400 MHz, MeOD) δ 5.76 (dt, J = 15.1, 6.7 Hz, 1H), 5.35 (dd, J = 15.4, 8.6 Hz, 1H), 
4.71 (d, J = 6.6 Hz, 1H), 4.54 (d, J = 6.6 Hz, 1H), 4.47 (d, J = 2.4 Hz, 2H), 4.33 (s, 2H), 4.21 
(d, J = 10.3 Hz, 2H), 4.15 – 3.96 (m, 2H), 3.85 – 3.69 (m, 2H), 3.63 – 3.52 (m, 1H), 3.39 (s, 
3H), 3.32 (d, J = 6.4 Hz, 6H), 2.19 – 1.98 (m, 2H), 1.53 – 1.40 (m, 11H), 1.32 (s, 20H), 0.93 
(t, J = 6.9 Hz, 3H). 
13C NMR (101 MHz, MeOD) δ 158.00, 138.50, 127.94, 94.61, 83.24, 80.09, 77.72, 72.43, 
65.91, 65.29, 60.22, 56.46, 56.08, 55.66, 52.03,33.42, 33.06, 30.75, 30.69, 30.59, 30.45, 30.30, 
30.26, 28.88, 23.72, 14.44. 
31P NMR (162 MHz, MeOD) δ -0.04. 










4.10.5   Chemical Synthesis of the bromo coumarin dye 
Benzyl propiolate (301)  
 
A solution of DMAP (30 mg, 0.24 mmol, 0.01 eq.) and DCC (5.16 g, 25 mmol, 1 eq.) in DCM 
(30 mL) was added slowly over 1.5 h to a solution of propiolic acid (1.54 mL, 24.84 mmol, 1 
eq.) and benzyl alcohol (2.8 mL, 27.03 mmol, 1.1 eq.) in DCM (30 mL) at 0 °C. The suspension 
was then stirred for overnight at room temperature, monitoring through by TLC (EtOAc: 
Cyclohexan 1:2). Upon completion, the mixture was filtered through a layer of Celite and the 
filtrate concentrated in vacuo. The product was purified using column chromatography (7 % 
EtOAc in Cyclohexan) to yield a colorless oil (3.17 g, 80%).  
1H NMR (500 MHz, CDCl3) δ : 7.41 – 7.33 (m, 5H, CHar), 5.23 (s, 2H, CH2), 2.89 (s, 1H, CH). 
13C NMR (126 MHz, CDCl3) δ : 152.43 (C=O), 134.35 (Car), 128.74 (CHar), 128.70 (CHar), 
128.59 (CHar), 75.05(≡CH) , 74.56(≡C), 67.93(CH2). 
UPLC-MS (ESI): C10H8O2 Na [M+Na]+:             m/z Calc.: 183.0,                    found: 183.1 
Benzyl 2-(8-methyl-6-oxo-6H-[1,3]dioxolo[4,5-g]chromen-2-yl)acetate (302) 
 
To a solution of 6,7-dihydroxy-coumarin (500 mg, 2.6 mmol, 1eq.) in dry DCM (25 mL), 
benzyl propiolate 301 (500 mg, 3.1 mmol, 1.2 eq.) and  DMAP (507 mg, 4.15 mmol, 1.6 eq.) 
were added under argon atmosphere at room temperature. After being stirred for 7 h, the solvent 
was removed under reduced pressure. The product was purified using column chromatography 
(25 % EtOAc in Cyclohexan) afforded 302 (892 mg, 97%) as a white crystalline solid. 
 
1H NMR (500 MHz, CDCl3) δ : 7.39 – 7.31 (m, 5H, CHph), 6.91 (s, 1H, CHcou), 6.79 (s, 1H, 
CHcou), 6.64 (t, J = 5.1 Hz, 1H, OCH), 6.16 (d, J = 1.2 Hz, 1H, C=CH), 5.19 (s, 2H, CH2), 3.07 
(d, J = 5.1 Hz, 2H, CH2), 2.35 (d, J = 1.2 Hz, 3H, CH3). 
 
Experimental Section 




13C NMR (126 MHz, CDCl3) δ : 167.70 (C=O), 161.32 (C=O), 152.51(C-Me), 150.69(Ccou), 
150.59 (Ccou), 144.63 (Ccou), 135.20 (Cph), 128.77 (CHph), 128.71 (CHph), 128.59 (CHph), 
114.07 (Ccou), 112.48 (C=CH), 109.59 (CHcou), 102.37 (CHcou), 98.61 (OCH), 67.29 (CH2), 
40.22 (CH2), 19.28 (CH3). 
UPLC-MS (ESI): C20H17O6 [M+H]
+:             m/z Calc.: 353.1,                    found: 353.1 
Benzyl 2-(7-bromo-8-methyl-6-oxo-6H-[1,3]dioxolo[4,5-g]chromen-2-yl)acetate (303) 
 
To a solution of 302 (600 mg, 1.70 mmol, 1 eq.) in dry ACN (20 mL) were added  NBS (608 
mg, 3.4 mmol, 2 eq.) and NaOAc (14 mg, 0.17 mmol, 0.1 eq.) under argon atmosphere at room 
temperature. The mixture was stirred till complete conversion of 302 monitored by TLC (30 % 
EtOAc in Cyclohexan). The organic layer was washed with brine solution and was extracted 
three times with DCM. The combined organic layers were dried over MgSO4 and concentrated 
under reduced pressure. The resulting residue was purified by flash column chromatography 
(PE/EE 5:1) yielding 303 (730 mg, quant.) 
1H NMR (500 MHz, CDCl3) δ : 7.51 – 7.30 (m, 5H, CHph), 6.96 (s, 1H, CHcou), 6.79 (s, 1H, 
CHcou), 6.66 (t, J = 5.0 Hz, 1H, OCH), 5.19 (s, 2H, CH2), 3.08 (d, J = 5.0 Hz, 2H, CH2), 2.55 
(s, 3H, CH3). 
13C NMR (126 MHz, CDCl3) δ : 167.59 (C=O), 157.47 (C=O), 151.03 (C-Me), 150.76 (Ccou), 
149.05 (Ccou), 145.20 (Ccou), 135.16 (Cph), 128.78 (CHph), 128.74 (CHph), 128.63 (CHph), 
113.93 (Ccou), 110.57 (C-Br), 109.90 (CHcou), 102.76 (CHcou), 98.42 (OCH), 67.33 (CH2), 
40.21 (CH2), 20.17 (CH3). 













2-(7-Bromo-8-methyl-6-oxo-6H-[1,3]dioxolo[4,5-g]chromen-2-yl)acetic acid (304) / 2-(8-
Methyl-6-oxo-6H-[1,3]dioxolo[4,5-g]chromen-2-yl)acetic acid  (305)  (3:1) 
 
A suspension of 303 (541 mg, 1.25 mmol, 1 eq.) and Pd/C (10%, 13.8 mg, 0.012 mmol, 0.01 
eq.) in dry THF (150 mL) was stirred under hydrogen atmosphere (p (H2) = 1 atm) at room 
temperature overnight. After complete conversion of 303 the mixture was filtered over Celite 
and washed with MeOH. The solvent was removed under reduced pressure and the residue was 
purified by flash silica gel column chromatography (MeOH / DCM 10%) yielding a white solid 
of 304 (324 mg, 75%) as a 3:1 mixture with the debrominated product 305.  
1H NMR (500 MHz, (CD3)2CO δ : 7.69 (s, 1H, CHcou), 7.58 (s, 1/3H, CHcou), 7.34 (s, J = 2.4 
Hz, 1H, CHcou), 7.29 (s, 1/3H, CHcou), 7.14 (t, J = 5.2 Hz, 1H, OCH), 7.11 (t, J = 5.2 Hz, 1/3H, 
OCH), 6.57 (d, J = 1.2 Hz, 1/3H, C=CH), 3.55 (d, J = 5.2 Hz, 2H,CH2), 3.54 (d, J = 5.2 Hz, 
2/3H, CH2), 3.04 (s, 3H, CH3). 
13C NMR (126 MHz, (CD3)2CO) δ 169.24  169.19 (C=O), (C=O), 160.85 (C=O), 157.16 
(C=O), 153.79 (C-Me), 152.38 (C-Me), 151.93 (Ccou), 149.89 (Ccou), 146.12 (Ccou), 114.46 
(Ccou), 112.61 (C=CH), 111.46 (CHcou), 111.13 (CHcou), 110.42 (C-Br) , 104.01 (CHcou), 103.49 
(CHcou), 98.59 (OCH), 98.46 (OCH), 40.04 (CH2), 40.00 (CH2), 20.22 (CH3), 19.03 (CH3). 
UPLC-MS (ESI): C13H10BrO6 [M+H]+:             m/z Calc.: 341.0,                    found: 341.0 
UPLC-MS (ESI): C13H11O6 [M+H]+:                 m/z Calc.: 263.1,                    found: 263.1 
2-(8-Methyl-6-oxo-6H-[1,3]dioxolo[4,5-g]chromen-2-yl)acetic acid (305) 
 
A suspension of 302 (1.1 g, 3.1 mmol, 1 eq.) and Pd/C (10%, 35.9 mg, 0.012 mmol, 0.01 eq.) 
in dry THF (375 mL) was stirred under hydrogen atmosphere (p(H2) = 1 atm) at room 
temperature overnight. After complete conversion TLC (10% MeOH in DCM) of 302 the 
mixture was filtered through Celite and washed with MeOH. The solvent was removed under 
reduced pressure and the residue was purified by column chromatography (gradient from 1.5% 
MeOH to 8% MeOH in DCM) yielding (532 mg, 65%) of 305 as an orange solid.  
Experimental Section 




1H NMR (300 MHz, DMSO-d6) δ 7.25 (s, 1H , CHcou), 7.07 (s, 1H, CHcou), 6.66 (t, J = 5.2 Hz, 
1H, OCH), 6.22 (d, J = 1.1 Hz, 1H, C=CH), 3.04 (d, J = 5.2 Hz, 2H, CH2 ), 2.35 (d, J = 1.1 Hz, 
3H, CH3). 
13C NMR (75 MHz, DMSO) δ 169.75 (C=O), 160.63 (C=O), 154.07 (C-Me), 150.86 (Ccou), 
150.41 (Ccou), 144.74 (Ccou), 113.83 (Ccou), 111.67 (C=CH), 110.64 (CHcou), 103.29 (CHcou), 
98.24 (OCH), 19.11 (CH3). 
UPLC-MS (ESI): C13H11O6 [M+H]+:                 m/z Calc.: 263.1,                    found: 263.1 
 
2-(7-Bromo-8-methyl-6-oxo-6H-[1,3]dioxolo[4,5-g]chromen-2-yl)acetic acid (304) 
 
To a solution of 305 (250 mg, 0.95 mmol, 1 eq.) in dry DMF (10 mL) were added  NBS (508 mg, 2.85 
mmol, 3 eq.) and NaOAc (15.5 mg, 0.19 mmol, 0.1 eq.) under argon atmosphere at room temperature. 
The mixture was stirred (2d) till complete conversion of 305 monitored by TLC (0.5 % MeOH in DCM). 
The mixture was extracted three times with DCM. The combined organic layers were dried over MgSO4 
and concentrated under reduced pressure. The resulting residue was purified by column 
chromatography (gradient from 0.5% MeOH to 5% MeOH in DCM) yielding 304 (163 mg, 50 %.) 
 
1H NMR (500 MHz, (CD3)2CO) δ 7.23 (s, 1H, CHcou), 6.88 (s, 1H, CHcou), 6.68 (t, J = 5.2 Hz, 
1H, OCH), 3.10 (d, J = 5.2 Hz, 2H,CH2), 2.58 (s, 3H, CH3). 
 
13C NMR (126 MHz, (CD3)2CO) δ 169.20 (C=O), 157.15 (C=O), 152.31 (C-Me), 151.87 
(Ccou), 149.87 (Ccou), 146.10 (Ccou), 114.44 (Ccou), 111.44 (CHcou), 110.42 (C-Br), 103.98 
(CHcou), 98.44 (OCH), 40.00 (CH2), 20.21 (CH3). 














Methyl 6-(2-(7-bromo-8-methyl-6-oxo-6H-[1,3]dioxolo[4,5-g]chromen-2-yl)aceta mido) 
hexa noate (306) 
 
To a solution of 304 (380 mg, 1.11 mmol, 1eq.) and Methyl 6-aminohexanoate hydrochloride 
(405 mg, 2.23 mmol, 2 eq.) in dry DCM (50 mL) were added EDC.HCl (257 mg, 1.34 mmol, 
1.2 eq.) and HOBt (175.7 mg, 1.34 mmol, 1.2 eq.) under argon atmosphere at room 
temperature. The reaction was monitored by TLC. After completion of the reaction (24 h), it 
was washed with 1N HCl and saturated NaCl solution, dried over MgSO4 and concentrated 
under reduced pressure. The resulting residue was purified by flash silica gel column 
chromatography (DCM/MeOH 99.5:0.5) yielding 306 (157 mg, 30%) as a white solid. 
 
1H NMR (500 MHz, CDCl3) δ 6.92 (s, 1H, CHcou), 6.71 (s, 1H, CHcou), 6.58 (t, J = 5.2 Hz, 1H, 
OCH), 5.87 (s, 1H, NH), 3.59 (s, 3H, OCH3), 3.33 – 3.17 (m, 2H,CH2), 2.83 (d, J = 5.2 Hz, 
2H, CH2), 2.48 (s, 3H, CH3), 2.25 (t, J = 7.3 Hz, 2H, CH2), 1.58 (dd, J = 15.3, 7.5 Hz, 2H, 
CH2), 1.48 (dt, J = 14.8, 7.2 Hz, 2H, CH2), 1.34 – 1.26 (m, 2H, CH2). 
 
13C NMR (126 MHz, CDCl3) δ 166.25 (C=O) , 157.33 (C=O), 150.96 (C-Me) , 150.74 (Ccou), 
148.84 (Ccou), 145.18 (Ccou), 113.73 (Ccou), 110.93 (CHcou), 110.35 (C-Br), 102.65 
(CHcou), 98.23 (OCH), 51.58 (CH3), 42.11 (CH2), 39.42 (CH2), 33.78 (CH2), 29.01 (CH2), 
26.23 (CH2), 24.32 (CH2), 20.04 (CH3). 



















1st procedure:  
To a solution of 306 (52 mg, 0.11 mmol, 1eq.) in dry THF (3 mL), LiOH (13.3 mg, 0.56 mmol, 
5 eq.) solution in H2O (3 mL) was added and stirred at room temperature. The reaction was 
monitored by TLC. After completion of the reaction (3 h), it was diluted with diethyl ether  (10 
mL) and washed with saturated NaHCO3 solution .The aqueous layer was then acidified with 
10% KHSO4 solution and extracted with diethyl ether (5x ,15mL each), dried over MgSO4 and 
concentrated under reduced pressure. The resulting residue was purified by flash silica gel 
column chromatography (gradient from 0.5% MeOH to 5% MeOH in DCM) yielding 307 (15 
mg, 30 %) as an off white solid. 
2nd procedure:  
In an argon atmosphere, 304 (0.320 g, 0.938 mmol, 1 eq.) was dissolved in dry DCM (50 mL) 
and DMAP (0.137 g, 1.13 mmol, 1.2 eq.), as well as N-hydroxysuccinimide (0.130 g, 1.13 
mmol, 1.2 eq.) were added. At 0°C, EDC (0.360 g, 1.88 mmol, 2 eq.) was added and stirring 
was continued for 22 h with protection from light and gradual warming to rt. Then, TLC and 
UPLC-MS indicated complete conversion of the starting material. The reaction mixture was 
diluted with DCM (20 mL) and washed with 0.5 M KHSO4 (2x 40 mL) and brine (20 mL). The 
organic layer was dried (Na2SO4), filtered and evaporated to dryness. The obtained material 
was directly used without further purification. 
UPLC-MS (ESI): C17H13BrNO8 [M+H]+:             m/z calc.: 437.9,                      found: 438.0. 
In an argon atmosphere, 6-aminohexanoic acid  (0.136 g,   1.034 mmol, 1.1 eq.) was dissolved 
in dry DCM (20 mL) and dry DIPEA (197.5 μL, 1.13 mmol, 1.2 eq.) was added. At 0°C, the 
freshly prepared  N-succinimidyl ester of 304  was added and stirring was continued 22 h with 
protection from light and gradual warming to rt. Then, TLC and UPLC-MS indicated complete 
conversion of the starting material. the mixture extracted with saturated NaHCO3 solution .The 
aqueous layer was then acidified with Conc. HCl solution and extracted with ethyl acetate, 
dried over MgSO4 and concentrated under reduced pressure.  
Experimental Section 




The resulting residue was purified by silica gel column chromatography (gradient from 0.5% 
MeOH to 5% MeOH in DCM) yielding 307 (192 mg, 45%) as an off white solid. 
3rd procedure: 
To a solution of 309 (279 mg, 0.55mmol, 1 eq.) in dry DCM (3 mL) was added dropwise at RT 
1ml TFA. After stirring (3 h) at RT, TLC and UPLC-MS indicated complete deprotection of 
the t-butyl ester. the solvent and TFA residues were evaporated under reduced pressure to give  
the  free acid 307 as a white pure  solid (198.5 mg, 80 % yield). 
1H NMR (500 MHz, DMSO-d6) δ 8.08 (t, J = 5.6 Hz, 1H, NH), 7.39 (s, 1H, CHcou), 7.13 (s, 
1H, CHcou), 6.67 (t, J = 5.4 Hz, 1H, OCH), 3.06 (dd, J = 12.7, 6.8 Hz, 2H, CH2), 2.85 (d, J = 
5.4 Hz, 2H, CH2), 2.54 (s, 3H, CH3), 2.19 (t, J = 7.4 Hz, 2H, CH2), 1.55 – 1.44 (m, 2H, CH2), 
1.44 – 1.35 (m, 2H, CH2), 1.33 – 1.21 (m, 2H, CH2). 
13C NMR (126 MHz, DMSO-d6) δ 174.43 (C=O), 165.99 (C=O), 156.49 (C=O), 152.04 (C-
Me), 150.67 (Ccou), 148.41 (Ccou), 144.85 (Ccou), 113.20 (Ccou) , 111.46 (CHcou), 108.93 (C-Br), 
103.45 (CHcou), 97.70 (OCH), 40.77 (CH2), 40.02 (CH2), 38.36 (CH2), 33.60 (CH2), 28.70 
(CH2), 25.92 (CH2), 24.18 (CH2), 19.98 (CH3),  
UPLC-MS (ESI): C19H21BrNO7 [M+H]+:             m/z Calc.: 454.1,                    found: 454.1 
 
Tert-butyl 6-aminohexanoate (308) 
 
Aminohexanoic acid (2.0 g, 15.25 mmol, 1 eq.) was dissolved in thionyl chloride (5.0 mL, 68.6 
mmol, 4.5 eq.). This solution was stirred at RT for 2 hours and concentrated in vacuo to dryness. 
To the reddish semi-solid product, a slurry of sodium bicarbonate (2.6 g, 30.4 mmol, 2.0 eq.) 
in t-BuOH (9.0 mL; 86.6 mmol; 5.7 eq.) was added and the slurry was stirred at RT for another 
2 h. The residual  t-BuOH was removed in vacuo at 40 0C. The thick white slurry was diluted 
with ethyl acetate and washed with of 1M NaOH (2x), H2O (2x) and brine (1x). The organic 
layer was dried over Na2SO4 and concentrated to afford 8 (2.14 g, 75%) as a colorless oil.  
1H NMR (500 MHz, CDCl3) δ 2.75 (s, 2H, NH2), 2.20 (t, J = 7.5 Hz, 2H, CH2), 1.58 (dt, J = 
15.2, 7.5 Hz, 2H, CH2), 1.46 (dd, J = 14.4, 7.1 Hz, 2H, CH2), 1.42 (s, 9H, C(CH3)3), 1.33 (ddd, 
J = 15.7, 9.1, 6.1 Hz, 2H, CH2). 
13C NMR (126 MHz, CDCl3) δ 173.28 (C=O), 80.12 (C(Me)3), 35.64 (CH2), 28.24 (CH3), 
26.51 (CH2), 25.03 (CH2). 
UPLC-MS (ESI): C10H21NO2 [M+H]+:             m/z Calc.: 188.2,                    found: 188.2 
Experimental Section 





acetamido) hexanoate (309) 
 
To a solution of 304 (175 mg, 0.51 mmol, 1eq.) and tert-butyl 6-aminohexanoate 308 (192.2 
mg, 1.02 mmol, 2 eq.) in dry DCM (25 mL) were added EDC.HCl (118 mg, 0.61 mmol, 1.2 
eq.) and HOBt (81 mg, 0.61 mmol, 1.2 eq.) under argon atmosphere at room temperature. The 
reaction was monitored by TLC. After completion of the reaction (20 h), it was washed with 
1N HCl and saturated NaCl solution, dried over Na2SO4 and concentrated under reduced 
pressure. The resulting residue was purified by silica gel column chromatography (gradient 
from 0.5% MeOH to 1% MeOH in DCM) yielding 309 (192 mg, 75%) as an off white solid. 
1H NMR (300 MHz, CDCl3) δ 6.90 (s, 1H, CHcou), 6.66 (s, 1H, CHcou), 6.62 (t, J = 5.3 Hz, 1H, 
OCH), 6.43 (t, J = 5.5 Hz, 1H, NH), 3.28 (dd, J = 13.1, 6.7 Hz, 2H, CH2), 2.90 (d, J = 5.3 Hz, 
2H, CH2), 2.48 (s, 3H, CH3), 2.20 (t, J = 7.3 Hz, 2H, CH2), 1.66 – 1.47 (m, 4H, 2x CH2), 1.40 
(s, 9H, C(CH3)3), 1.38 – 1.28 (m, 2H, CH2). 
13C NMR (75 MHz, CDCl3) δ 173.08 (C=O), 166.45 (C=O), 157.26 (C=O), 151.10 (C-Me), 
150.82 (Ccou), 148.62 (Ccou), 145.23 (Ccou), 113.49 (Ccou), 111.21 (CHcou), 109.98 (C-Br), 
102.49 (CHcou), 97.97 (OCH), 80.18 (C(Me)3) , 42.06 (CH2), 39.43 (CH2), 35.30 (CH2), 28.96 
(CH2), 28.10 (CH3), 26.22 (CH2), 24.49 (CH2), 20.01 (CH3). 




Under argon atmosphere, 307 (0.050 g, 0.11 mmol, 1 eq.) was dissolved in dry DCM (10 mL) 
and DMAP (26.9 mg, 0.22 mmol, 2 eq.), as well as N-hydroxysuccinimide (25.3 mg, 0.22 
mmol, 2 eq) were added. At 0°C, EDC.HCl (46.4 mg, 0.242 mmol, 2.2 eq.) was added and the 
mixture was stirred for 1h at 0°C then at RT for overnight with protection from light. Then, 
TLC and UPLC-MS indicated complete conversion of the starting material.  
Experimental Section 




The reaction mixture was diluted with DCM (25 mL) and washed with 0.5 M KHSO4 (2x 20 
mL) and brine (20 mL). The organic layer was dried (Na2SO4), filtered and evaporated to 
dryness. The obtained material was directly used without further purification. 
UPLC-MS (ESI): C23H23BrN2O9 [M+H]
+:             m/z Calc.: 551.1,                      found: 551.1 
 
4.10.6   Chemical synthesis of 7-methoxy-coumarin-3-carboxylic acid 
2-hydroxy-4-methoxybenzaldehyde (311) 
 
To a solution of 3-methoxyphenol (6.2g 50.0 mmol, 1 eq.), magnesium chloride (7.17 g, 75.0 
mmol, 1.5 eq.) in dry THF (150 mL) was added triethylamine (27.2 µL, 112.5 mmol, 2.25 eq.). 
The mixture was stirred at room temperature for 15 min, and then was added dry 
Parafomaldehyde (7.50 g, 250.0 mmol, 5 eq.) in one portion. The mixture was heated to reflux 
overnight until the starting material consumed as monitored by TLC, cooled to ambient 
temperature, and quenched with diluted HCl (3N) until pH = 2. The resulting solution was 
extracted with ethyl acetate (2 × 50 mL), and the combined organic layers were washed with 
brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The 
residue was purified by flash column chromatography on silica gel eluting with cyclohexane-
ethyl acetate (95:5 to 75:25) to give the desired product as colorless oil (7.5 g, 98.5%). 
 
1H NMR (500 MHz, CDCl3) δ 11.49 (s, 1H), 9.72 (s, 1H), 7.43 (d, J = 8.7 Hz, 1H), 6.54 (dd, J 
= 8.7, 2.4 Hz, 1H), 6.43 (d, J = 2.3 Hz, 1H), 3.86 (s, 3H). 
 
13C NMR (126 MHz, CDCl3) δ 194.35, 166.89, 164.20, 135.05, 115.20, 108.34, 100.46, 55.26. 
UPLC-MS (ESI): C8H9O3 [M+H]











7-methoxy-2-oxo-2H-chromene-3-carboxylic acid (312) 
 
An oven-dried screw cap test tube was first charged with a magnetic stir bar, 2-hydroxy-4-
methoxybenzaldehyde 311 (2.7g, 17.7 mmol, 1eq.), Meldrum’s acid (2.6 g, 17.7 mmol 1eq.), 
distilled water (100 mL), and sodium azide (576.6 mg, 8.8mol, 0.5 eq.). The whole mixture 
was then stirred vigorously at room temperature for 1 h to complete the conversion. Upon 
completion, the resulting solution was acidified with chilled acid−water, when solid mass 
precipitated out, filtered off, and thoroughly washed with water to obtain the target product as 
pale yellow solid (3.9 g, Quantitative yield). 
1H NMR (500 MHz, DMSO) δ 8.71 (s, 1H), 7.82 (d, J = 8.7 Hz, 1H), 7.05 – 6.95 (m, 2H), 3.89 
(s, 3H). 
13C NMR (126 MHz, DMSO) δ 164.18, 157.25, 156.91, 149.11, 131.58, 113.82, 113.32, 
111.68, 100.29, 56.26. 
UPLC-MS (ESI): C11H9O5 [M+H]
+:             m/z Calc.: 221.0,                                found: 221.1 
2,5-dioxopyrrolidin-1-yl 7-methoxy-2-oxo-2H-chromene-3-carboxylate (313) 
 
To a solution of 7-methoxycoumarin-3-carboxylic acid 312 (750 mg, 3.4 mmol, 1eq.) in dry 
DMF (10 ml) N-hydroxysuccinimide (392 mg, 3.4 mmol, 1eq.) was added. After dissolution, 
the reaction mixture was cooled at 0 °C for 1 h. DCC (771.7 mg, 3.74 mmol, 1.1 eq.) was 
added. After stirring for 30 min at this temperature, the reaction mixture was stirred at room 
temperature for 2.5 h. The solution was filtered off to remove dicyclohexylurea. An 
isopropanol–hexane solution (1: 20) was added to the filtrate to give product  as a white solid 
(607 mg, 56%). 
1H NMR (500 MHz, CDCl3) δ 8.70 (s, 1H), 7.50 (d, J = 8.8 Hz, 1H), 6.85 (dd, J = 8.7, 2.4 Hz, 
1H), 6.75 (d, J = 2.3 Hz, 1H), 3.83 (s, 3H), 2.80 (s, 4H). 
13C NMR (126 MHz, CDCl3) δ 169.66, 166.80, 158.23, 156.30, 152.34, 131.88, 114.79, 
111.38, 107.92, 100.46, 56.23, 25.53. 
UPLC-MS (ESI): C15H12NO7 [M+H]+:             m/z Calc.: 318.0,                               found: 318.1 
Experimental Section 




6-(7-methoxy-2-oxo-2H-chromene-3-carboxamido)hexanoic acid (314) 
 
In an argon atmosphere, 6-aminohexanoic acid (82.7 g, 0.63 mmol, 1 eq.) was dissolved in dry 
DMF (6.5 mL) and dry DIPEA (128 μL, 0.757 mmol, 1.2 eq.) was added. At 0°C, 7-
methoxycoumarin-3-carboxylic acid N-succinimidyl ester 313 (200mg, 0.63mmol, 1eq.) was 
added and stirring was continued overnight with protection from light at RT. Then, TLC and 
UPLC-MS indicated complete conversion of the starting material. The reaction mixture was 
diluted with 50 mL EA and washed with 10% acetic acid (3x 10 mL) and then with brine (10 
mL). The organic layer was dried (Na2SO4), filtered and evaporated to dryness. the product 
was purified using column chromatography (DCM:MeOH= 9 :1) which yielded the title 
compound as a colorless solid (189 mg, 90%). 
1H NMR (500 MHz, CDCl3) δ 8.85 (s, 1H), 8.81 (t, J = 5.4 Hz, 1H), 7.58 (d, J = 8.7 Hz, 1H), 
6.93 (dd, J = 8.7, 2.4 Hz, 1H), 6.86 (d, J = 2.4 Hz, 1H), 3.91 (s, 3H), 3.45 (dd, J = 13.0, 7.1 Hz, 
2H), 2.37 (t, J = 7.5 Hz, 2H), 1.67 (ddt, J = 19.5, 15.0, 7.5 Hz, 4H), 1.45 (tt, J = 10.2, 6.4 Hz, 
2H). 
13C NMR (126 MHz, CDCl3) δ 178.39, 164.83, 162.18, 161.92, 156.64, 148.40, 130.99, 
114.72, 114.04, 112.47, 100.29, 56.03, 39.59, 33.76, 29.12, 26.43, 24.35. 
UPLC-MS (ESI): C17H18NO6 [M-H]-:             m/z Calc.: 332.1,                               found: 332.0 
 
2,5-dioxopyrrolidin-1-yl 6-(7-methoxy-2-oxo-2H-chromene-3-carboxamido) hexanoate 
(315) 
 
In an argon atmosphere, 314 (100 mg, 0.3 mmol, 1 eq.) was dissolved in dry DCM (14.5 ml) 
and DMAP (44 mg, 0.36 mmol, 1.2 eq.), as well as N-hydroxysuccinimide (41.5 mg, 0.36 
mmol, 1.2 eq.) were added. At 0°C, EDC (115 mg, 0.6 mmol, 2 eq.) was added and stirring 
was continued for overnight with protection from light and gradual warming to RT. Then, TLC 
and UPLC-MS indicated complete conversion of the starting material. The reaction mixture 
was diluted with 40 mL DCM and washed with 0.5 M KHSO4 (2x 50 mL) and brine (20 mL). 
Experimental Section 




The organic layer was dried (Na2SO4), filtered and evaporated to dryness. The obtained 
material was directly used without further purification assuming complete conversion. 
UPLC-MS (ESI): C21H23N2O8 [M+H]+:             m/z Calc.: 431.1,                             found: 431.1 
 
4.10.7   Chemical synthesis of the NBD derivatives fluorophores 
N-(2-(dimethylamino)ethyl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine (316) 
 
In a 50 mL round-bottom flask, N,N-dimethylethyl-1,2-diamine (0.276 ml, 2.52 mmol, 1.01 
eq.) and NaHCO3 (210 mg, 2.5 mmol, 1 eq.) were dissolved in 10 mL of MeCN. To the stirring 
mixture was added dropwise a solution of 4-chloro-7-nitrobenz-2-oxa-1,3-diazole (NBD) (500 
mg, 2.5 mmol, 1 eq.) in 20 mL of MeCN over 1 h. The color turned dark brown. The mixture 
was heated at 60 °C for 15 min. The reaction mixture was cooled to room temperature, filtered 
to remove particulates, and concentrated in vacuo. The product was purified via 
chromatography on silica gel (1:9 MeOH/DCM) and concentrated in vacuo to yield a brown 
solid (400 mg, 64% yield).  
 
1H NMR (400 MHz, CD3CN) δ 8.48 (d, J = 8.8 Hz, 1H), 6.28 (d, J = 8.8 Hz, 1H), 3.56 (s, 2H), 
2.66 (t, J = 6.1 Hz, 2H), 2.29 (s, 6H). 
13C NMR (126 MHz, DMSO) δ 145.12, 137.92, 136.20, 120.85, 119.16, 99.35, 56.27, 44.89, 
41.09. 
UPLC-MS (ESI): C10H14N5O3 [M+H]













4-azido-7-nitrobenzo[c][1,2,5]oxadiazole ‘’azido-NBD’’ (317) 
 
Sodium azide (486 mg, 7.474 mmol, 3.0 eq.) was dissolved in 50 mL of H2O/acetone (1:1, v/v) 
in a 250 mL round bottom flask. Then a solution of NBD chloride (500 mg, 2.5 mmol, 1.0 eq.) 
in acetone (25 mL) was added into the flask dropwise at room temperature with stirring. The 
reaction mixture turned from light yellow to yellow-brown. After 15 min, TLC (EA: CH 1:2) 
monitoring revealed complete conversion. The reaction mixture was concentrated under 
vacuum to remove acetone. The yellow precipitates were filtered out and washed with water 
(15 mL X 3) and then dried to give 317 as yellow crystals (465 mg, 90%). 
1H NMR (500 MHz, CDCl3) δ 8.50 (d, J = 8.1 Hz, 1H), 7.06 (d, J = 8.1 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 146.04, 143.70, 138.22, 132.22, 115.01. 
UPLC-MS (ESI): C6H3N6O3 [M+H]




A mixture of 2-bromo-ethylamin hydrobromide (700 mg, 3.42 mmol, 1 eq.) and sodium azide 
(666.3 mg, 10.25 mmol, 3 eq.) in water (10 mL) was stirred at 75 °C overnight. Then the 
mixture was poured into 1 N NaOH (5 mL) and the resulting mixture was extracted with diethyl 
ether (20 mL × 3). The combined organic layers were washed with brine, dried over anhydrous 
MgSO4 and concentrated smoothly to give the product as  a light yellow oil (123 mg, 42%). 
 
1H NMR (500 MHz, CDCl3) δ 3.38 – 3.30 (m, 2H), 2.89 – 2.82 (m, 2H), 1.42 (s, 2H). 
 
13C NMR (126 MHz, CDCl3) δ 54.77, 41.46. 
 











The ethanol solution of 2-bromoethylamine prepared by mixing 2-bromoethylamine 
hydrobromide (300 mg, 1.46 mmol, 1 eq.) with NaOH (131.7 mg, 3.29 mmol, 2.25 eq.) in 15 
mL anhydrous ethanol was added dropwise into 15 mL of anhydrous ethanol containing 4-
chloro-7-nitrobenz-2-oxa-1,3-diazole (NBD) (292 mg, 1.46 mmol,1 eq.) with stirring under 
reflux. TLC (EA: CH 1:2) monitoring found the reaction was finished in 4 h and the resulted 
green mixture was cooled to room temperature. The solvent was removed by evaporation in 
vacuo. The resulting residue was purified by column chromatography starting with 2:1 CH/EA 
to wash NBD residuals then 1:1 to get the product (291 mg, 70% yield).  
1H NMR (400 MHz, CDCl3) δ 8.50 (d, J = 8.5 Hz, 1H), 6.43 (s, 1H), 6.26 (d, J = 8.5 Hz, 1H), 
3.98 (q, J = 6.0 Hz, 2H), 3.70 (t, J = 6.0 Hz, 2H). 
13C NMR (101 MHz, CDCl3) δ 144.54, 143.97, 143.11, 136.06, 125.40, 99.22, 45.11, 29.20. 
UPLC-MS (ESI): C8H8BrN4O3 [M+H]+:             m/z Calc.: 287.0,                            found: 287.0 
N-(2-azidoethyl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine (320) 
 
N- (2-Bromoethyl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine 319  (100 mg, 0.35 mmol, 1.0 
eq.) and NaN3 (68 mg, 1.04 mmol, 3.0 eq.) were dissolved in DMF (5 mL). The mixture was 
stirred at 80 °C for 4 h and at RT for 15h. H2O (20 mL) was added, the aqueous phase was 
extracted with Et2O (3 × 50 mL), the combined organic layers were dried over MgSO4 and 
the solvents were removed in vacuo to provided azide 320 as an orange solid (81 mg, 93% 
yield). 
1H NMR (400 MHz, DMSO) δ 9.49 (s, 1H), 8.51 (d, J = 8.9 Hz, 1H), 6.50 (d, J = 8.9 Hz, 1H), 3.67 (s, 
4H). 
UPLC-MS (ESI): C8H8N7O3 [M+H]+:             m/z Calc.: 250.1,                            found: 250.1 
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4.10.8   Chemical synthesis of the visible light range fluorophores 
N-(2-azidoethyl)-5(6)-fluorescein-carboxoamide (321) 
 
5(6)-carboxyfluorescein (50 mg, 0.13 mmol, 1 eq.) and triethylamine (30 μL, 0.2 mmol, 1.5 
eq.) were dissolved in 1 mL of DMSO, followed by addition of TSTU (160 mg, 0.5 mmol, 4 
eq.) The reaction mixture was stirred at RT for 30 min Then 2-azidoethanamine 318 (93.7 μl, 
1.06 mmol, 8 eq.) was added and the mixture was stirred overnight at room temperature. 
Triethylamine and azidoaminoethane were evaporated under reduced pressure. Product was 
purified by column chromatography on silica gel using linear gradient of methanol in 
dichloromethane (3–10%) with the addition of 0.1ml acetic acid /100 ml mobile phase to give 
the product as an orange  solid (47mg, 80%). 
 
1H NMR (500 MHz, MeOD) δ 8.35 (s, 1H), 8.11 (dd, J = 8.0, 1.6 Hz, 1H), 8.05 (dd, J = 8.1, 
1.4 Hz, 1H), 8.00 (d, J = 8.1 Hz, 1H), 7.53 (s, 1H), 7.22 (d, J = 8.1 Hz, 1H), 6.62 (d, J = 1.8 
Hz, 2H), 6.53 (dd, J = 8.6, 3.7 Hz, 2H), 6.46 (d, J = 8.7 Hz, 2H), 3.56 – 3.37 (m, 2H), 3.35 – 
3.22 (m, 2H). 
 
13C NMR (126 MHz, MeOD) δ 168.73, 168.51, 154.30, 137.60, 135.24, 130.39, 130.35, 
130.25, 129.86, 126.52, 126.03, 125.13, 124.33, 114.08, 111.19, 111.04, 103.64, 51.37, 51.16, 
40.78, 40.63, 40.43. 
 
















Under argon atmosphere, Nile red labeled Hexane acid (50 mg, 0.11 mmol, 1 eq.), HOSu (15.5  mg, 
0.13 mmol, 1.2 eq.) and DMAP (15.9 mg, 0.13 mmol, 1.2 eq.) were dissolved in 2 ml dry DCM. 
EDC.HCl (42.2 mg, 0.22 mmol, 2 eq.) was added portionwise to the first mixture at 0°C. After 10 min 
the ice bath was removed and stirring was continued at RT for 4.5 h. Then, the reaction was quenched 
and the mixture was washed twice with 10 mL 0.5 M aq. KHSO4 and 10 mL H2O. The organic layer 
was dried (MgSO4), evaporated to dryness and the crude product was used directly for the next step 
without further purification. 
UPLC-MS (ESI): C30H32N3O7 [M+H]+:             m/z Calc.: 546.2,                            found: 546.2 
 
4.10.9   Chemical synthesis of the labeled sphingomyelin analogs 
4-((2S,3R,E)-2-(tert-butyloxycarbonylamino)-3-(methoxymethoxy)octadec-4-en-1 
phosphoethylamino)-7-nitrobenzo-2-oxa-1,3-diazol (401)         
 
The primary amine 212 (250 g, 0.44 mmol, 1 eq.) was dissolved in 10 mL MeOH/CHCl3 (1:3). 
DIPEA (300 μL, 1.76 mmol, 4 eq.) and. NBDCl (264 mg, 1.32 mmol, 3 eq.) were added and 
stirring was continued at RT away from light. After 4 h, all volatiles were evaporated under a 
stream of air and the residue was dissolved in 20 mL CHCl3. The solution was washed twice 
with 0.1 M aq. HCl (25 mL each) with CHCl3 backwash. The organic fractions were collected 
and evaporated in vacuo. The orange crude obtained was subjected to column chromatography 
(CHCl3:MeOH:H2O = 100:15:1 → 66:10:1 to afford (270 mg , 85%) of the title product as a 
yellowish brown solid. 
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1H NMR (400 MHz, CDCl3) δ 8.23 (d, J = 8.6 Hz, 1H), 6.05 (d, J = 8.0 Hz, 1H), 5.59 – 5.23 
(m, 1H), 5.02 (dd, J = 14.8, 8.0 Hz, 1H), 4.38 (d, J = 6.4 Hz, 1H), 4.30 – 4.18 (m, 6H), 3.94 (s, 
1H), 3.81 – 3.71 (m, 2H), 3.52 (s, 2H), 3.07 (s, J = 6.4 Hz, 3H), 1.77 (d, J = 6.6 Hz, 2H), 1.14 
(s, 9H), 0.99 (s, 22H), 0.62 (t, J = 6.6 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 156.14, 144.12, 137.46, 136.93, 125.58, 98.50, 93.28, 79.24, 
76.35, 64.39, 62.64, 55.09, 53.74, 32.05, 31.58, 29.32, 29.14, 29.01, 28.93, 28.79, 27.83, 22.31, 
13.56. 
31P NMR (162 MHz, CDCl3) δ -1.42. 
UPLC-MS (ESI): C33H55N5O11P [M-H]




oxadiazol-4-yl)amino)ethyl) hydrogen phosphate  (ZP-403) 
 
In an argon atmosphere, 401 (46 mg, 0.063 mmol, 1 eq.) was dissolved in MeOH (6 mL). At 
rt, 4 M HCl in 1,4-dioxan (081.5 µL, 1.56 mmol, 25 eq.) was added and the mixture was stirred 
at 70°C for 2 h with exclusion of light. Then, UPLC-MS and TLC indicated complete 
conversion of the starting material. The mixture was concentrated in a stream of air and dried 
under high vacuum. The orange residue 402 was dissolved in dry DCM (4 mL) and dry DIPEA 
(85 µL, 0.49 mmol, 8 eq.). 310 (0.045g, 0.08 mmol, 1.3 eq.) was dissolved in dry DCM (3 mL) 
and added dropwise to the first solution at 0°C. After 24 h stirring at RT, UPLC-MS and TLC 
showed complete conversion. MeOH (1 mL) was added to quench the reaction and left to stir 
for 1 h. The reaction mixture was diluted with CH2Cl2 (75 mL) and washed twice with 10 mL 
0.1 M aq. HCl. The organic layer was dried (Na2SO4), and the volatiles were removed in vacuo. 
The material obtained was purified using preparative TLC  (CHCl3:MeOH:H2O = 65:25:3) to 








1H NMR (500 MHz, CDCl3+CD3OD+TMS) δ 8.48 (d, J = 8.5 Hz, 1H), 7.44 (s, 1H), 7.03 (d, 
J = 3.8 Hz, 1H), 6.80 (s, 1H), 6.65 (t, J = 4.9 Hz, 1H), 6.25 (s, 1H), 5.77 – 5.59 (m, 1H), 5.43 
(dd, J = 15.3, 7.2 Hz, 1H), 4.20 (d, J = 3.3 Hz, 2H), 4.15 – 4.07 (m, 2H), 3.97 (s, 1H), 3.89 (s, 
1H), 3.69 (s, 1H), 3.36 (s, 1H), 3.24 (s, 2H), 2.93 (d, J = 5.0 Hz, 2H), 2.57 (d, J = 3.6 Hz, 3H), 
2.21 (dd, J = 14.3, 7.1 Hz, 2H), 2.08 – 1.87 (m, 2H), 1.65 – 1.58 (m, 2H), 1.55 – 1.45 (m, 2H), 
1.25 (s, 26H), 0.89 (d, J = 6.6 Hz, 3H). 
13C NMR (126 MHz, CDCl3+CD3OD+TMS) δ 174.67, 167.81, 158.32, 152.23, 151.37, 
149.01, 145.76, 134.63, 129.06, 114.00, 111.54, 109.92, 102.92, 98.19, 71.78, 64.67, 54.30, 
41.66, 39.46, 36.21, 35.94, 32.62, 32.14, 32.08, 29.92, 29.88, 29.79, 29.67, 29.58, 29.54, 29.51, 
28.85, 26.39, 25.89, 25.43, 22.89, 20.16, 14.19.  
31P NMR (202 MHz, CDCl3+CD3OD) δ = 5.64 (s, 1P).  
UPLC-MS (ESI): C45H61BrN6O14P [M-H]
-:            m/z Calc.: 1019.3,                   found: 1019.1 
(2S,3R,E)-3-hydroxy-2-(6-(7-methoxy-2-oxo-2H-chromene-3-carboxamido)hexanamido) 
octadec-4-enyl 2-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl amino) ethyl hydrogen phosphate 
(TP-366) 
 
Under argon atmosphere, 401 (50 mg, 0.068 mmol, 1 eq.) was dissolved in MeOH (7 mL). At 
RT, 4 M HCl in dioxane (427 µL, 1.7 mmol, 25 eq.) was added and the mixture was stirred at 
70°C for 2 h with exclusion of light. Then, UPLC-MS and TLC indicated complete 
deprotection of the starting material. The mixture was concentrated in a stream of air and dried 
under high vacuum. The orange residue 402 was dissolved in dry DCM (7 mL) and dry DIPEA 
(93.2 µL, 0.54 mmol, 8 eq.). The active ester 315 (68 mg, 0.016 mmol, 2.3 eq.) is added portion 
wise to the first solution at 0°C. After 20 h stirring at RT, UPLC-MS and TLC showed complete 
conversion. The reaction was quenched and worked up as reported. The material obtained was 
subjected to preparative TLC (DCM: MeOH: H2O = 100:15:1) to get the title compound as an 
orange solid (15 mg, 24%). NMR spectra as reported121.  
UPLC-MS (ESI): C43H62N6O13P [M+H]+:             m/z Calc.: 901.4,                          found: 901.2 
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(2S,3R,E)-2-dodecanamido-3-hydroxyoctadec-4-en-1-yl (2-((7-nitrobenzo[c][1,2, 5]oxadi 
-azol-4-yl)amino)ethyl) hydrogen phosphate (TP-367) 
 
In an argon atmosphere, 401 (50 mg, 0.068 mmol, 1 eq.) was dissolved in MeOH (4 mL). At 
RT, 4 M HCl in dioxane (427 µL, 1.7 mmol, 25 eq.) was added and the mixture was stirred at 
70°C for 3 h with exclusion of light. Then, UPLC-MS and TLC indicated complete 
deprotection of the starting material. The mixture was concentrated in a stream of air and dried 
under high vacuum. The orange residue 402 was dissolved in dry DCM (3 mL) and dry DIPEA 
(174.75 µL, 1.01 mmol, 15 eq.). Lauric acid N-hydroxysuccinimide ester (68 mg, 0.016 mmol, 
2.3 eq.) was added portion wise to the first solution at 0°C. After 24 h stirring at RT, UPLC-
MS and TLC showed complete conversion. MeOH (1 ml) was added to quench the reaction 
and left to stir for 1 h. The reaction mixture was diluted with DCM (40 mL) and washed twice 
with 10 mL 0.1 M aq. HCl then one time with brine. The organic layer was dried (Na2SO4), 
and the volatiles were removed in vacuo. The crude mixture was purified using column 
chromatography (CHCl3:MeOH:H2O = 100:15:1 →65:25:3) and the product was collected as 
an orange solid (23,8 mg, 45%). 
1H NMR (500 MHz, CDCl3+CD3OD) δ 8.51 (d, J = 8.0 Hz, 1H), 7.73 (dd, J = 5.7, 3.2 Hz, 1H), 
7.59 (dd, J = 5.7, 3.2 Hz, 1H), 6.27 (s, 1H), 5.71 (dd, J = 14.4, 7.4 Hz, 1H), 5.45 (dd, J = 14.7, 
6.8 Hz, 1H), 4.16 (s, 4H), 3.99 (s, 1H), 3.90 (s, 1H), 3.68 (dd, J = 18.2, 11.7 Hz, 2H), 2.18 (t, J 
= 7.5 Hz, 2H), 2.02 (d, J = 6.7 Hz, 2H), 1.58 (s, 2H), 1.27 (s, 39H), 0.91 – 0.88 (m, 6H). 
13C NMR (126 MHz, CDCl3+CD3OD) δ 168.41, 134.87, 131.40, 129.04,  68.46, 57.42, 54.07, 
39.01, 36.67, 32.15, 29.94, 29.59, 29.17, 26.16, 24.04, 23.18, 22.89, 14.18. 
31P NMR (202 MHz, CDCl3+CD3OD) δ 3.95. 










ammonio)ethyl phosphate (406) 
 
Propargyl-sphingomyelin 214 (10 mg, 0.016 mmol, 1eq.) was dissolved in a mixture of t-
BuOH/H2O 4:1 (1.25 ml) before azide 320 (4.7 mg, 0.019 mmol, 1.2eq.), sodium ascorbate 
(0.95 mg, 0.0048 mmol.0.3eq.) and copper sulfate hydrate (0.8 mg, 0.003 mmol,0.2 eq.) were 
successively added. The reaction mixture, covered with foil, was stirred 48 h at room 
temperature, concentrated in vacuo and purified by flash chromatography on silica (85/14/1 
then 80/18/2 then 72/25/3 CHCl3/MeOH/NH4OH) to give the NBD-labeled sphingomyelin as 
a yellow solid (11.5 mg, 83%). 
 
1H NMR (500 MHz, MeOD) δ 8.40 (t, J = 9.0 Hz, 1H), 8.31 (s, 1H), 6.30 (d, J = 8.8 Hz, 1H), 
5.63 (dt, J = 15.2, 6.7 Hz, 1H), 5.21 (dd, J = 15.4, 8.6 Hz, 1H), 4.75 (d, J = 6.0 Hz, 2H), 4.64 
(s, 2H), 4.57 (d, J = 6.6 Hz, 1H), 4.40 (d, J = 6.6 Hz, 1H), 4.23 (s, 2H), 4.08 (d, J = 10.1 Hz, 
4H), 4.04 (s, 2H), 3.95 (t, J = 8.1 Hz, 2H), 3.64 (s, J = 6.8 Hz, 1H), 3.45 (s, 2H), 3.25 (s, 3H), 
3.08 (s, 6H), 1.95 (dd, J = 13.8, 6.8 Hz, 2H), 1.38 – 1.26 (m, 11H), 1.23 – 1.15 (m, 20H), 0.79 
(t, J = 4.5 Hz, 3H). 
 
13C NMR (126 MHz, MeOD) δ 158.29, 158.01, 145.95, 145.47, 138.57, 138.08, 136.93, 
130.53, 127.88, 124.42, 94.57, 80.08, 77.73, 65.91, 64.48, 60.36, 60.17, 56.08, 55.67, 52.11, 
33.43, 33.08, 30.79, 30.77, 30.71, 30.61, 30.47, 30.32, 30.26, 28.85, 23.74, 14.44. 
 
31P NMR (202 MHz, MeOD) δ -0.93. 
 










carboxamido)hexanamido)octadec-4-enyl phosphate (ZQP-407) 
 
In an argon atmosphere, 406 (11.5 mg, 0.013 mmol, 1 eq.) was dissolved in MeOH (3 mL). At 
rt, 4 M HCl in 1,4-dioxan (081.5 µL, 0.325 mmol, 25 eq.) was added and the mixture was 
stirred at 70°C for 2 h with exclusion of light. Then, UPLC-MS and TLC indicated complete 
conversion of the starting material. The mixture was concentrated in a stream of air and dried 
under high vacuum. The orange residue was dissolved in dry CH2Cl2 (2 mL) and dry DIPEA 
(22.5 µL, 0.13 mmol, 10 eq.). 315 (0.0073g, 0.017 mmol, 1.3 eq.) was dissolved in dry CH2Cl2 
(2 mL) and added dropwise to the first solution at 0°C. After 48 h stirring at RT, UPLC-MS 
and TLC showed complete conversion. MeOH (0.5 mL) was added to quench the reaction and 
left to stir for 1 h. The reaction mixture was diluted with CH2Cl2 (40 mL) and washed twice 
with 5 mL 0.1 M aq. HCl. The organic layer was dried (Na2SO4), and the volatiles were 
removed in vacuo. The material obtained was subjected to column chromatography (85/14/1 
then 80/18/2 then 72/25/3 CHCl3/MeOH/NH4OH) to give the NBD/Coumarin-labeled 
sphingomyelin as an orange solid (4.2 mg, 30%). 
1H NMR (500 MHz, MeOD) δ 8.74 (s, 1H), 8.47 (d, J = 8.7 Hz, 1H), 8.41 (s, 1H), 7.71 (d, J = 
8.8 Hz, 1H), 6.99 (dd, J = 8.7, 2.4 Hz, 1H), 6.95 (d, J = 2.3 Hz, 1H), 6.37 (d, J = 8.8 Hz, 1H), 
5.77 – 5.63 (m, 1H), 5.49 (s, 1H), 5.45 (dd, J = 15.3, 7.5 Hz, 1H), 4.84 (d, J = 6.1 Hz, 2H), 4.73 
(d, J = 14.2 Hz, 2H), 4.32 (s, 2H), 4.18 – 4.09 (m, 2H), 4.09 – 4.03 (m, 2H), 4.03 – 3.95 (m, 
2H), 3.93 (s, 3H), 3.55 (t, J = 4.3 Hz, 2H), 3.41 (t, J = 7.1 Hz, 2H), 3.18 (d, J = 3.6 Hz, 6H), 
2.22 (t, J = 7.5 Hz, 2H), 2.01 (dd, J = 14.5, 7.0 Hz, 3H), 1.70 – 1.57 (m, 4H), 1.45 – 1.39 (m, 
2H), 1.35 (d, J = 7.2 Hz, 2H), 1.32 – 1.19 (m, 22H), 0.88 (t, J = 7.0 Hz, 3H). 
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13C NMR (126 MHz, MeOD) δ 175.74, 166.98, 166.81, 164.11, 162.54, 158.10, 149.35, 
138.02, 136.96, 135.17, 132.49, 131.10, 130.55, 115.13, 113.58, 101.28, 72.77, 65.90, 65.85, 
60.37, 60.18, 56.77, 52.16, 49.85, 40.54, 37.15, 33.44, 33.08, 30.83, 30.79, 30.73, 30.49, 30.42, 
30.39, 30.15, 27.68, 26.73, 23.74, 14.44. 
31P NMR (202 MHz, MeOD) δ 0.15.  
UPLC-MS (ESI): C50H74N10O13P [M]
+:             m/z Calc.: 1053.5,                         found: 1053.3 
(2S,3R,E)-2-((tert-butoxycarbonyl)amino)-3-(methoxymethoxy)octadec-4-en-1-yl (2-(((1-
(2-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-5(6)-carboxamido) 
ethyl)-1H-1,2,3-triazol-4-yl)methyl)dimethylammonio) ethyl)phosphate (408) 
 
Propargyl-sphingomyelin 214 (6.5 mg, 0.01 mmol, 1eq.) was dissolved in a mixture of 
DMSO/H2O 3:1 (1ml) before azide 321 (5.8 mg, 0.013 mmol, 1.3eq.), sodium ascorbate (0.6 
mg, 0.003 mmol, 0.3 eq.) and copper sulfate hydrate (0.5 mg, 0.002 mmol,0.2 eq.) were 
successively added. The reaction mixture, covered with foil, was stirred 48 h at room 
temperature, concentrated in vacuo and the product was purified by column chromatography 
on silica gel starting with 5% of methanol in dichloromethane then 10% to elute the excess 
azide. 65/25/3 CHCl3/MeOH/H2O mixture* was used to elute the product which then collected 
as an orange solid (6.5 mg, 54%). 
 *0.1ml acetic acid /100 ml mobile phase used to avoid tailing on the column. 
1H NMR (500 MHz, MeOD) δ 8.49 (s, 0.5H), 8.42 (s, 0.5H), 8.37 (s, 0.5H), 8.13 – 8.06 (m, 
0.5H), 8.01 (d, J = 7.6 Hz, 1H), 7.76 – 7.69 (m, 1H), 7.67 – 7.60 (m, 1H), 7.56 (s, 0.5H), 7.34 
(d, J = 7.9 Hz, 0.5H), 6.94 (t, J = 9.2 Hz, 3H), 6.66 (t, J = 8.1 Hz, 4H), 6.61 (d, J = 9.8 Hz, 3H), 
5.71 (dq, J = 13.0, 6.5 Hz, 1H), 5.37 – 5.24 (m, 1H), 4.79 (s, 2H), 4.77 – 4.74 (m, 12H), 4.72 
(s, 2H), 4.70 – 4.64 (m, 4H), 4.49 (t, J = 6.7 Hz, 2H), 4.41 (s, 2H), 4.35 (s, 2H), 4.24 – 4.21 (m, 
2H), 4.10 – 3.99 (m, 6H), 3.95 (s, 2H), 3.86 (s, 2H), 3.75 (s, 2H), 3.66 (dd, J = 3.2, 1.8 Hz, 3H), 
3.60 – 3.56 (m, 2H), 3.24 (s, 6H), 3.12 (d, J = 3.1 Hz, 3H),  
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2.38 – 2.28 (m, 2H), 2.22 (d, J = 3.4 Hz, 1H),2.04 (dd, J = 13.3, 6.6 Hz, 4H), 1.74 – 1.66 (m, 
2H), 1.65 – 1.57 (m, 4H),  1.30 (s, 9H), 1.29 (s, 22H), 0.96 (t, J = 7.5 Hz, 3H). 
13C NMR (126 MHz, MeOD) δ 138.56, 133.59, 132.41, 129.83, 127.92, 104.09, 94.52, 77.69, 
69.11, 65.91, 56.09, 51.98,40.18, 33.42, 33.07, 31.62, 31.51, 30.78, 30.76, 30.70, 30.60, 30.46, 
30.31, 30.25, 30.14, 28.87, 24.94, 24.03, 23.73, 14.44, 11.40. 
31P NMR (202 MHz, MeOD) δ 19.02. 





ethyl) phosphate (ZQ2P-410) 
 
In an argon atmosphere, 408 (5.4 mg, 0.005 mmol, 1 eq.) was dissolved in MeOH/CHCl3 (1.5 
mL). At rt, 4 M HCl in 1,4-dioxan (31.5 µL, 0.126 mmol, 25 eq.) was added and the mixture 
was stirred at 70°C for 3 h with exclusion of light. Then, UPLC-MS and TLC indicated 
complete conversion of the starting material. The mixture was concentrated in a stream of air 
and dried under high vacuum. The orange residue 409 was dissolved in dry CH2Cl2 (2 mL) and 
dry DIPEA (17.6 µL, 0.1 mmol, 20 eq.). 322 (4.1 mg, 0.0075 mmol, 1.5 eq.) was dissolved in 
dry CH2Cl2 (1 mL) and added dropwise to the first solution at 0°C. After 48 h stirring at RT, 
UPLC-MS and TLC showed complete conversion. MeOH (0.5 mL) was added to quench the 
reaction and left to stir for 1 h. The reaction mixture was diluted with CH2Cl2 (10 mL) and 
washed twice with 5 mL 0.1 M aq. HCl. The organic layer was dried (Na2SO4), and the volatiles 
were removed in vacuo. The crude mixture obtained was subjected to column chromatography 
(CHCl3/MeOH 95/5 to 90/10) to elute the residual active ester then (CHCl3/MeOH/H2O* 
65/25/3) to give the target product as a violet solid (4.7 mg, 69%). 
Rf (CHCl3:MeOH:H2O
* = 65:25:3) = 0.56 
*0.1ml acetic acid /100 ml mobile phase used to avoid tailing on the column or TLC. 
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1H NMR (500 MHz, DMSO) δ 8.79 (s, 0.5H), 8.48 (s, 0.5H), 8.34 (s, 0.5H), 8.29 (s, 0.5H), 
8.06 (d, J = 5.3 Hz, 0.5H), 8.05 – 7.96 (m, 1H), 7.92 (d, J = 2.6 Hz, 0.5H), 7.82 (d, J = 8.7 Hz, 
0.5H), 7.73 – 7.62 (m, 1H), 7.59 (dd, J = 9.0, 3.7 Hz, 0.5H), 7.40 (d, J = 17.4 Hz, 0.5H), 7.30 
– 7.19 (m, 1H), 6.80 (d, J = 9.3 Hz, 1H), 6.63 (d, J = 2.4 Hz, 1H), 6.54 (d, J = 8.2 Hz, 2H), 6.17 
(s, 1H), 5.73 (s, 1H), 5.63 – 5.41 (m, 1H), 5.39 – 5.22 (m, 1H), 4.60 (dd, J = 48.3, 23.7 Hz, 
2H), 4.40 (d, J = 33.3 Hz, 1H), 4.19 (ddd, J = 25.6, 12.7, 8.7 Hz, 2H), 4.14 – 4.01 (m, 3H), 3.82 
(ddd, J = 147.0, 58.9, 25.6 Hz, 6H), 3.56 – 3.43 (m, 6H), 2.15 – 1.92 (m, 2H), 1.88 – 1.70 (m, 
2H), 1.55 (ddd, J = 24.8, 15.8, 6.3 Hz, 2H), 1.43 – 1.30 (m, 2H), 1.30 – 0.96 (m, 22H), 0.91 – 
0.68 (m, 9H). 
31P NMR (202 MHz, DMSO) δ -0.57. 
UPLC-MS (ESI): C74H92N8O15P [M]+:             m/z Calc.: 1363.6,                         found: 1363.3 
2-(((1-(2-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-5(6)-
carboxamido)ethyl)-1H-1,2,3-triazol-4-yl)methyl)dimethylammonio) ethyl ((2S,3R,E)-2-
dodecanamido-3-hydroxyoctadec-4-en-1-yl) phosphate  (ZQ3P-411) 
 
In an argon atmosphere, 408 (5.3 mg, 0.0049 mmol, 1 eq.) was dissolved in MeOH/CHCl3 (1.5 
mL). At rt, 4 M HCl in 1,4-dioxan (32 µL, 0.128 mmol, 25 eq.) was added and the mixture was 
stirred at 70°C for 3 h with exclusion of light. Then, UPLC-MS and TLC indicated complete 
conversion of the starting material. The mixture was concentrated in a stream of air and dried 
under high vacuum. The orange residue was dissolved in dry CH2Cl2 (2 mL) and dry DIPEA 
(18 µL, 0.1 mmol, 20 eq.). Lauric acid N-hydroxysuccinimide ester (4.1 mg, 0.0098 mmol, 2 
eq.) was dissolved in dry DMF (1 mL) and added dropwise to the first solution at 0°C. After 
24 h stirring at RT, UPLC-MS and TLC showed complete conversion. MeOH (0.5 mL) was 
added to quench the reaction and left to stir for 1 h. The reaction mixture was diluted with 
CH2Cl2 (10 mL) and washed twice with 5 mL 0.1 M aq. HCl. The organic layer was dried 
(Na2SO4), and the volatiles were removed in vacuo. The crude mixture obtained was subjected 
to preparative TLC (CH3Cl3: MeOH: H2O* = 65:25:3) to get the title compound as an orange 
solid (3.7 mg, 68%). 
Rf (CHCl3:MeOH:H2O
* = 65:25:3) = 0.57 
Experimental Section 




*0.1ml acetic acid /100 ml mobile phase used to avoid tailing on the column or TLC. 
31P NMR (202 MHz, DMSO) δ 0.52, 0.28. 
UPLC-MS (ESI): C60H88N6O12P [M]+:             m/z Calc.: 1115.6,                         found: 1115.4 
 





The intermediate 208 (0.020 g, 0.045 mmol, 1 eq.) was dissolved in 5 mL MeOH and 4 M HCl 
in 1,4-dioxane (281 μL, 1.13 mmol, 25 eq.) was added dropwise. The mixture was heated at 
70°C for 120 min and then concentrated in a stream of air and dried in vacuo. The residue 412 
was dissolved in 6 mL of dry DCM and dry DIPEA (61 μL, 0.360 mmol, 8 eq.) was added. At 
0°C, 310 (0.030 mg, 0.054 mmol, 1.2 eq.) was added. The reaction was protected from light 
and stirred at RT overnight. Then, MeOH (1 mL) was added and the mixture was stirred for 
another 1 h to quench the active ester. 30 mL DCM were added and the reaction mixture was 
washed with 25 mL 0.5 M KHSO4, dried (Na2SO4), filtered an evaporated to dryness. The 
crude mixture was purified using column chromatography (EA:MeOH=100:0→99:1) yielding 
the title compound (0.030 g, 0.082 mmol, 90% over two steps) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.02 (s, 1H), 6.80 (s, 1H), 6.62 (dd, J = 5.1, 4.4 Hz, 1H), 6.41 
(d, J = 7.6 Hz, 1H), 6.21 (s, 1H), 5.87 – 5.67 (m, 1H), 5.63 – 5.39 (m, 1H), 4.32 (s, 1H), 4.03 
– 3.84 (m, 2H), 3.69 (s, 1H), 3.37 – 3.22 (m, 3H), 3.14 (s, 1H), 2.89 (d, J = 5.1 Hz, 2H), 2.56 
(s, 3H), 2.25 (t, J = 6.9 Hz, 2H), 2.12 – 1.96 (m, 2H), 1.51 (dd, J = 14.3, 7.2 Hz, 2H), 1.45 – 
1.16 (m, 22H), 0.87 (t, J = 6.7 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 166.75, 163.62, 157.46, 139.91, 133.93, 113.79, 110.82, 102.79, 
98.23, 74.71, 54.07, 31.93, 29.70, 29.51, 29.42, 29.37, 28.24, 22.70, 20.07, 14.14. 








5   Appendix 
5.1   Supplementary Tables 
 
Europium Chelate 5-D+ 4-D+ 
Absorption maximum [nm] 365 378 
 [ L cm-¹ mol-¹] 1790 3050 








q (H2O) ** 3.5 4.9 
* 617 nm emission, 345 nm excitation, data were fitted with a biexponential decay, in 
brackets: relative amplitudes (%); ** according to Supkowski-Horrocks equation184 
 
Table S 1. Spectral properties of the europium complexes. 
 
5.2   Supplementary Figures 






























Figure S 1. Normalized luminescence decay profile of 4-D+ (c = 100 μmol L-1) and 
monoexponential fits in H2O (blue) and D2O (red). ex = 345 nm, em= 617 nm, delay time = 
200 µs. Fitting parameter for y = exp (-t/)  see Table S 1. R2 > 0.999.  
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Figure S 2. Normalized luminescence decay profile of 5-D+ (c = 100 μmol L-1) in TRIS buffer 
in absence (red bi-exponential fit) and presence of 75 µmol L-1 of ATP (blue bi-exponential 
fit). ex = 345 nm, em= 617 nm, delay time = 200 µs. Fitting parameter for y = A1 exp (-t/) 
+ A2 exp (-t/) 5-D+ see Table S 1; 5-D+ + ATP:  =  218 µs (A1 = 6.4 %),  =  926 µs (A2 
= 93.6 %); R2 = 0.99993.  
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Figure S 3. Steady state fluorescence spectra of dentate ligands (c = 50 µmol L-1) before (black 
lines) and after complexation of an equimolar amount of Eu3+ (red lines).  (A) Five-dentate 
ligand, (B) four-dentate ligand . λ ex= 345 nm. 
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Figure S 4. Normalized luminescence responses (I/I0) of 5-D+ (c=50 µmol L
-1) to ATP, in 
TRIS buffer (pH 7.4) using two different microwell plate (MWP) readers (MWP 1: Tecan, 
MWP 2: Victor). I0 is the luminescence intensity in the absence of phosphate; λex=345 nm, λ 
em=618 nm; time-resolved measurement, Lag time: 100 ms, signal integration time: 400 ms. 
 
Figure S 5.  Real time normalized fluorescence intensity changes of ZP-403 during the 
enzymatic reaction; left: Bromo-coumarin fluorescence intensity change; right: NBD 
fluorescence intensity change. Probe concentration= 1µM, ASM buffer.  
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Figure S 6. Effect of different ASM concentrations on the cleavage rate of the FRET probe 
ZQP-407; Left:  kinetic study, Ex_347, Em_405; Right: kinetic study, Ex_347, Em_536. 
ASM buffer, Probe concentration= 1µM. 
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Figure S 7. ZQP-407 FRET Probe cleavage study by nSMase 2 enzyme. Left:  Scanning before 
and after incubation; Right: kinetic study. ASM buffer, Probe concentration= 1µM. 
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Figure S 8. FRET probe ZP-403 with 0.6 μg/ml ASM: cleavage kinetics. 
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Figure S 9. Iinitial slopes determination of FRET probe ZP-403 with 0.6 μg/ml ASM 
Appendix 























Figure S 10. Calibration curve for the FRET probe ZP-403, derived from the plateau values 
observed in Figure S 8. 




















Figure S 11. lineweaver burk plot for the FRET probe ZP-403  
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Figure S 12. Cleavage kinetics of the FRET probe ZQP-407 with 0.2 μg/ml ASM. 
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Figure S 13. Initial slopes determination of FRET probe ZQP-407 with 0.2 μg/ml ASM 
Appendix 
























Figure S 14. Calibration curve for the FRET probe ZQP-407, derived from the plateau values 
observed in Figure S 12. 
























Figure S 15. lineweaver burk plot for the FRET probe ZQP-407 
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Figure S 16. Cleavage kinetics of the FRET probe ZQ2P-410 with 0.2 μg/ml ASM. 
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Figure S 17. Initial slopes determination of FRET probe ZQ2P-410 with 0.2 μg/ml ASM. 
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Figure S 18. Calibration curve for the FRET probe ZQ2P-410, derived from the plateau 
values observed in Figure S 16. 




















Figure S 19. lineweaver burk plot for the FRET probe ZQ2P-410. 
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Figure S 20. Cleavage kinetics of the FRET probe ZQ3P-411 with 0.2 μg/ml ASM. 
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Figure S 21. Initial slopes determination of FRET probe ZQ3P-411 with 0.2 μg/ml ASM. 
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Figure S 22. Calibration curve for the FRET probe ZQ3P-411, derived from the plateau values 
observed in Figure S 20. 





















Figure S 23. lineweaver burk plot for the FRET probe ZQ3P-411. 
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5.3   Supplementary NMR spectra 


























diethyl 2,2'-(((4-bromopyridine-2,6-diyl)bis(methylene))bis (methylazanedi -yl)) 









Diethyl 2,2'-(((4-((4-(dimethylamino)phenyl)ethynyl)pyridine-2,6-diyl)bis  
















































Ethyl 4-((4-(dimethylamino)phenyl)ethynyl)-6-(((2-ethoxy-2-oxoethyl) (methyl) 



















carbamate  (202)   (CDCl3) 
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tert-butyl ((2S,3R,E)-1-(((2-(1,3-dioxoisoindolin-2-yl)ethoxy) (hydroxy) 




































































































































(304) / 2-(8-Methyl-6-oxo-6H-[1,3]dioxolo[4,5-g]chromen-2-yl)acetic acid  






































































































N-(2-(dimethylamino)ethyl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine (316)  







































N-(2-azidoethyl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine (320)  (DMSO-d6) 
 
 
N-(2-azidoethyl)-5(6)-fluorescein-carboxoamide (321) (CD3OD) 
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en-1 phosphoethylamino)-7-nitrobenzo-2-oxa-1,3-diazol (401) (CDCl3)        
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2, 5]oxadiazol-4-yl)amino)ethyl) hydrogen phosphate (TP-367) (CDCl3+CD3OD) 
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triazol-4-yl)methyl)dimethylammonio) ethyl) phosphate (ZQ2P-410)(DMSO-d6) 
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